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Silver nanoparticles (Ag-np) are distinctively reported as toxic agent. This potentially 
detrimental toxicity of Ag-np can however be used to our advantage to enhance therapeutic 
efficacy of existing cancer drugs. The utilization of Ag-np is promising to solve the 
limitations of conventional chemotherapeutics. Advancement of chemistry and engineering 
enables surface functionalisation of Ag-np, conferring properties such as high aqueous 
solubility, circulation time and bioavailability, increased specificity and lowered multidrug 
resistance. Likewise, Ag-np functions as a DNA damaging agent which can potentially hinder 
its development as effectual cancer targeting drugs.   
A major obstacle to efficient cancer therapy is the development of resistance to the 
anticancer drugs utilised. Standard chemotherapeutics usually contain genotoxic agents, 
designed to damage DNA of existing tumour cells in order to prevent the DNA synthesis 
during proliferation. Normal cells can either repair DNA damage efficiently or tolerate the 
DNA damage to preserve cellular and organ functionality. The increasing evidences suggest 
that increased repair or tolerance of DNA damages in solid tumours may contribute to the 
ability of the cancer cell to survive under high genotoxic stress afforded by the therapy.  
Inhibition of specific DNA repair pathways might prove efficacious when used in 
combination with DNA-damaging chemotherapeutic drugs. Studies attempt to modulate 
DNA repair such as DNA-dependent protein kinase (DNA-PKcs) and Ataxia telangiectasia 
mutated (ATM) as a therapeutic strategy need to be conducted to determine its therapeutic 
value and ensure its safety.  
In this study, Ag-np treatment resulted in DNA damage and subsequent activation of 
DNA-PKcs and double-strand break (DSB) marker, γ-H2AX, signifying the activation of 
DNA damage/repair responses. Lack of functional DNA-PKcs in cells with inherent DNA-
PKcs deficiency or due to DNA-PKcs inhibition sensitises them to DNA damage and genome 
 IX 
 
instability which eventually leading to greater cell cycle arrest or cell death.  The DNA 
damage and genome instability were persisted or enhanced in DNA-PKcs deficient or 
inhibited cells with lack of recovery from Ag-np-induced stress. Normal human cells were 
less sensitive to genotoxic stress from Ag-np treatment. These results offer support that 
DNA-PKcs repairs DNA lesions in Ag-np treated cancer cells and protect them from massive 
cell death.       
The advantageous features of Ag-np over conventional drugs will go in vain if the 
cancer cells gain resistance to Ag-np due to the activation of DNA repair machinery initiated 
by DNA-PKcs. Thus, a combined strategy using DNA-PKcs inhibitor and Ag-np was adopted 
and tested in an array of human cancer cell types. Ag-np treatment triggered activation of 
DNA-PKcs and JNK pathway, which were anticipated as physiologic responses to DNA 
damage and repair. Following DNA-PKcs inhibition, JNK pathway was insufficiently 
activated, abolishing the signalling events required for DNA repair. Located at ends of 
chromosomes, telomeres are constantly exposed to endogenous and exogenous DNA 
damaging agent. Ag-np down-regulates telomerase expression, disrupts shelterin complex 
protecting the telomeres and results in telomere attrition.  Localisation of activated DNA-
PKcs to damaged telomeres indicates the importance of DNA repair machinery at damaged 
telomeres. However, the genotoxic effect of Ag-np is not limited to telomeres but the entire 
genome as Ag-np induced γ-H2AX foci do co-localise with but not specific to telomeres. 
Furthermore, DNA-PKcs inhibition substantiates the damaging effect of Ag-np at telomeres 
in human cancer cells. Abrogation of JNK mediated DNA repair and extensive damages at 
telomeres following DNA-PKcs inhibition are responsible for the greater sensitivity of the 
cancer cells towards Ag-np cytotoxicity. These results suggest that inhibition of DNA-PKcs 
along with Ag-np treatment could be a better strategy to improve anti-proliferative and 
cytotoxic effects in cancer cells.    
 X 
 
Activation of ATM in Ag-np treated cells in first part of this study implies the 
potential involvement of ATM in Ag-np induced DNA damage responses and repair.  We 
showed the localisation of activated ATM to DSB sites in cancer cells following Ag-np 
treatment. Inhibition of ATM in cancer cells carrying TP53 mutation abolished the capability 
of these cells to undergo cell cycle arrest, producing higher DNA damage and persistent γ-
H2AX activation and finally greater cell death. Thus, the presence of functional ATM is 
required for the survival of TP53 mutated cancer cells. Inhibition of ATM sensitises these 
cancer cells to Ag-np cytotoxicity and genotoxicity.   
Therefore, targeting DNA-PKcs or ATM enhances therapeutic performance of Ag-np 
in cancer cells. Since normal cells are less sensitive to the combination treatment, this 
approach could be selective for tumour cells and have fewer side effects on normal cells and 

















LIST OF TABLES 
 
 Title Page 
   
Table 1 Commercially available Ag-np containing products 21 
   




LIST OF FIGURES 
 
 Title Page 
   
Figure 1.1 Updated inventory of nanotechnology-based consumer products 4 
   
Figure 1.2 Current trends in nanotechnology research (% value) per macro 
subject areas 
5 
   
Figure 1.3 Percent value of main research fields of nanotechnology in 
chemistry and medicine 
5 
   
Figure 1.4 Morphological classification of nanomaterials 7 
   
Figure 1.5 The Lycurgus cup 11 
   
Figure 1.6 Potential route of absorption, distribution, metabolism and 
excretion of nanoparticles 
13 
   
Figure 1.7 Pathways of cellular internalisation of nanoparticles 19 
   
Figure 1.8 Schematic representation of DNA repair pathways and the 
inhibitors under investigation 
29 
   
Figure 1.9 Organization of JNK pathway 34 
   
Figure 1.10 The end-replication problem 34 
   
Figure 1.11 Shelterin complex 39 
   
Figure 1.12 The telomere-telomerase hypothesis 40 
   
Figure 1.13 The structure of telomerase ribonucleoprotein complex 46 
   
Figure 1.14 Hallmarks of cancer 47 
   
 XII 
 
Figure 1.15 Chemical structures of NU7026 52 
   







   
Figure 3.2 Cell viability in mammalian cells following Ag-np treatment 75 
   
Figure 3.3 Induction of DNA damage in Ag-np treated cells 78 
   
Figure 3.4 Induction of micronuclei in cells following Ag-np treatment 80 
   
Figure 3.5 Induction of DNA double strand breaks in response to Ag-np 
treatment 
83 
   
Figure 3.6 Ag-np upregulated and activated DNA-PKcs and ATM in 
mammalian cells 
86 
   
Figure 3.7 Cell cycle analysis by flow-cytometry 89 
   
Figure 4.1 Morphological appearance of cells treated with Ag-np 98 
   
Figure 4.2 Scratch wound-healing assay to determine cell migration  99 
   
Figure 4.3 Ag-np treatment results in massive cell death in human breast 
cancer and brain cancer cells 
100 
   
Figure 4.4 Ag-np treatment decreases proliferative potential of human breast 
cancer and brain cancer cells 
101 
   
Figure 4.5 Ag-np treatment restrains proliferation of human breast cancer and 
brain cancer cells potentially through down-regulating c-Myc 
102 
   
Figure 4.6 Inhibition of DNA-PKcs increases cell death in Ag-np treated cells 104 
   
Figure 4.7 Inhibition of DNA-PKcs induce growth inhibition in Ag-np treated 
brain cancer and breast cancer cells 
105 
   
Figure 4.8 Ag-np treatment induced DNA damage in human cells 106 
   
Figure 4.9 Increase in phosphorylation of H2AX (γ-H2AX) upon DNA 
damage induction in Ag-np treated cells 
108 
   
Figure 4.10 DNA damage induced in Ag-np treated cells activates DNA-PKcs 110 
   
Figure 4.11 DNA damage induced in Ag-np treated cells activates JNK 
pathway 
111 
   
Figure 4.12 JNK1 was insufficiently activated after DNA-PKcs inhibition in 114 
 XIII 
 
Ag-np treated human cancer cells 
   
Figure 4.13 Ag-np causes telomere loss in human brain cancer cells and breast 
cancer cells 
116 
   
Figure 4.14 Loss of shelterin complex integrity and reduction of telomerase 
expression in Ag-np treated human breast cancer and brain cancer 
cells 
117 
   
Figure 4.15 Ag-np induced DNA damage is not telomere-specific and 
recruitment of activated DNA-PKcs to telomeres upon Ag-np 
treatment 
121 
   
Figure 4.16 DNA-PKcs inhibition substantiates the damaging effect of Ag-np at 
telomeres in human cancer cells 
124 
   
Figure 5.1 Recruitment of activated ATM and γ-H2AX to DSB sites in human 
brain cancer cells following Ag-np treatment  
136 
   
Figure 5.2 Inhibition of ATM substantiates DNA damaging effect of Ag-np in 
human brain cancer cells  
138 
   




Figure 5.4 Suppression of ATM inhibits in growth of Ag-np treated brain 
cancer cells 
141 
   
Figure 5.5 Inhibition of ATM forbids cell cycle arrest in TP53 mutated U251 












































































































































































































































LIST OF PUBLICATIONS 
1. Hui Kheng Lim, P.V. Asharani and M. Prakash Hande, Enhanced genotoxicity of silver 
nanoparticles in DNA repair deficient mammalian cells, Front Genet. 2012; 3:104. 
 
2. Hui Kheng Lim, Resham Lal Gurung and M. Prakash Hande, DNA-dependent protein 
kinase alters the anti-cancer properties of silver nanoparticles in human cancer cells 
through JNK and telomerase pathways (Manuscript submitted). 
 
3. P.V. AshaRani, Swaminathan Sethu, Hui Kheng Lim, Ganapathy Balaji, Suresh 
Valiyaveettil and M. Prakash Hande, Differential regulation of intracellular factors 
mediating cell cycle, DNA repair and inflammation following exposure to silver 
nanoparticles in human cells, Genome Integr. 2012; 3: 2. 
 
4. P.V. Asharani, Luxmi Fatimathas, Hui Kheng Lim, Suresh Valiyaveettil and M. Prakash 
Hande 2011  Silver nanomedicine and Cancer In Book: Nanomedicine and Cancer, Ed: R. 
Srirajaskanthan and V. R. Preedy, CRC Press (Taylor and Francis Group), London, UK , 





1. Hui Kheng Lim and Manoor Prakash Hande. DNA-Dependent Protein Kinase Reduces 
Toxicity of Silver Nanoparticles in Mammalian Cells through JNK and Telomerase 
Pathways. Society of Toxicology (SOT) 52nd Annual Meeting, March 10-11, 2013, San 
Antonio, Texas, USA. 
 
2. Hui Kheng Lim and Manoor Prakash Hande. DNA-Dependent Protein Kinase Alters 
Toxicity of Silver Nanoparticles in Mammalian Cells through JNK and Telomerase 
Pathways. Frontiers in Cancer Science, Nov 5-8, 2012, National University of Singapore, 
Singapore.   
 
3. Hui Kheng Lim, P. V.  Asharani and Manoor Prakash Hande. Role of DNA-PKcs on the 
effects of silver nanoparticles in human cancer cells. 70
th
 Annual Meeting of the Japanese 
Cancer Association, Oct 03-05, 2011, Nagoya, Japan.  
 
4. Hui Kheng Lim, P. V.  Asharani and Manoor Prakash Hande. Effects of silver 
nanoparticles on DNA repair deficient mammalian cells. Genome Institute of Singapore 
Personalised Cancer Medicine Conference, Feb 21-23, 2011, Biopolis, Singapore.   
 
5. Hui Kheng Lim, P. V.  Asharani and Manoor Prakash Hande. Effects of silver 
nanoparticles on DNA repair deficient mammalian cells. International Symposium on 
Environmental Exposures to Mutagens and Carcinogens on Human Health, Feb 4-6, 2011, 
Vellore, Tamilnandu, India. 
 
6. Hui Kheng Lim, P. V.  Asharani and Manoor Prakash Hande. Effects of silver 
nanoparticles on DNA repair deficient mammalian cells. The Inaugural Yong Loo Lin 
School of Medicine Graduate Scientific Congress. Jan 25, 2011, National University of 





1.1. Nanotechnology: An overview and current trend 
The term “nano” comes from the Greek word nanos (νάνος) which means dwarf. One 
nanometer (nm) stands for one billionth, or 10
−9
, of a meter. The emergence of 
nanotechnology dates back to the 5
th
 century BC when the ancient Romans unknowingly 
became nanotechnologists when they made red and green stained glass by mixing colloidal 
gold and silver and into molten class. In 1959, Richard Feynman, an American theoretical 
physicist, originated the ideal of nanotechnology with his famous lecture “There’s Plenty of 
Room at the Bottom”.  Nearly fifteen years later, the term nanotechnology was defined by 
Professor Norio Taniguchi as nanotechnology mainly consists of the processing, separation, 
consolidation, and deformation of materials by one atom or one molecule (Taniguchi, 1974). 
However, it is Dr. Eric Drexler, the godfather of nanotechnology, who brought this 
technology to its peak. He explored the basic idea of nanotechnology in much more depth and 
promoted the technological significance of nano-scale phenomena and devices through the 
concern of “bottom up” approach, which building machines/things on the scale of molecules, 
with atomic precision (Drexler and Minsky, 1986). The highly innovative technology has 
since blossomed with the development of quantum dots (QDs), fullerenes and carbon 
nanotubes the following years.  
Due to the technology revolution potential, interest in nanotechnology 
commercialization has increased enormously in the last years. In late 1990s, nanotechnology 
related consumer products started appearing on the market. As of March 10, 2011, the 
nanotechnology consumer products inventory contains 1317 products or product lines across 
30 countries, increased by nearly 521% since it was released in March 2006 (The Project on 
 2 
 
Emerging Nanotechnologies (PEN), 2011). Based on the statistics published in 2011 by 
Nanotechnology Consumer Products Inventory, among the 1317 commercialised nano 
products, 738 of the products fall under health and fitness, 209 in household products, 126 in 
automotive, 105 in food and beverages, 59 in electronics and computers and 30 in goods for 
children. The report revealed that silver is the most common material used in manufacturing 
of nano products (313 products) and silver nanoparticles (Ag-np) currently has the highest 
degree of commercialization (The Project on Emerging Nanotechnologies (PEN), 2011). The 
detailed inventory charts are shown in Figure 1.1. 
Apart from rapid economic growth and industrial developments, nanotechnology has 
fuelled intense research activities around the globe and emerges as an important scientific 
discipline. Figure 1.2 displays the trends of nanotechnology research, from 1996 to 2008, 
across all worldwide geo-economic areas. In particular, nano research in ‘‘Chemistry and 
Medicine’’ has been increasing in the last 15 years with a relative high rate of growth, due to 
the high number of applications (innovations) in Chemical Engineering, Biochemistry, 
Genetics, Pharmaceutics, Toxicology, etc. (Figure 1.3) (Coccia et al., 2012). 
The market for nanoparticles in biotechnology and pharmaceuticals/medicine can be 
broken down into four segments: biotechnology applications, drug development and 
formulation, drug delivery systems, and diagnostic imaging and testing. In the last decade, 
the science of nanoparticles has made major advances in particle type production and in 
nanoparticle application in all areas of the life sciences. The most rapid advances have been 
made in the application of nanoparticles in drug research and development, drug product 
formulation, and development of novel drug delivery systems using nanoparticle carriers. 
Engineered nanoparticles with surface functionalisation, in particular, shed new light into the 
development of specific targeted drug delivery, personalised therapeutics, diagnosis and 
imaging medical devices. For example, gold nanoparticles and nanorods are used for the 
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diagnosis and treatment of pathological conditions such as cancer (Boisselier and Astruc, 
2009). Silver nanoparticles, owing to their broad spectrum of antimicrobial action, are widely 
used in antiseptics and wound dressings (Edwards-Jones, 2009, Rai et al., 2009). Polymeric 
nanoparticles are used as nanocarriers which can transport therapeutic agents directly to the 
target site with high efficiency (Mandal and Kundu, 2009). The global market for 
nanoparticles in biotechnology, drug development and drug delivery was valued at $17.5 
billion in 2011 and nearly $21.6 billion in 2012. Total market value is expected to reach 
$53.5 billion in 2017 after increasing at a five-year compound annual growth rate of 19.9% 
(BCC research, 2012). 
The tremendous development of nanotechnology has triggered calls for increased 
community participation and effective regulatory arrangements. Regulatory bodies such as 
the United States Environmental Protection Agency and the Food and Drug Administration in 
the U.S. or the Health and Consumer Protection Directorate of the European Commission 
have started dealing with the potential risks posed by nanoparticles. So far, neither 
engineered nanoparticles nor the products and materials that contain them are subject to any 
special regulation regarding production, handling or labelling. However, well organised 
network from the nanotechnology regulatory bodies have resulting in good co-ordination of 






Figure 1.1: Updated inventory of nanotechnology-based consumer products. The analysis shows increasing trend of nano products 






Figure 1.2: Current trends in nanotechnology research (% value) per macro subject 







Figure 1.3: Percent value of main research fields of nanotechnology in chemistry and 
medicine (Coccia et al., 2012). 
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1.2. Classification of nanomaterials 
The two main approaches to synthesise nanoparticles are: i) “top down” approach to 
dis-assemble bulk solids into nano-scale via mechanical grinding and electrochemical etching; 
and ii) “bottom up” approach to assemble materials at atomic level into nano-sized through 
sol-gel method, precipitation and etc. (Hallock et al., 2009).   
Nanoparticles or ultrafine particles are particles sized between 1 and 100 nm, which 
are relatively much smaller compared with fine particles (between 100 nm and 2.5 µm) and 
coarse particles (between 2.5 µm and 10 µm). Nanoparticles are broadly classified based on 
their composition, shape, uniformity and agglomeration state.  
Based on their composition, nanoparticles are classified as i) inorganic nanoparticles 
such as metal nanoparticles (e.g. QDs, nanogold, nanosilver and metal oxides), ii) dendrimers 
(e.g. nanosized polymers), iii) carbon based nanostructures (carbon nanotubes), iv) 
nanocomposites (hybrid of nanoparticles with other nanoparticles or with larger, bulk-type 
materials), v) liposomes, and vi) biological nanoparticles such as DNA and proteins. 
Based on their shape, nanoparticles are classified as nanospheres, nanorods, 
nanowires, nanorings, nanopods, nanoprisms, nanocrystals, nanocubes, etc. Different 
morphological variants of nanomaterials are represented in Figure 1.4. 
Based on their chemistry and electro-magnetic properties, nanoparticles can exist as 
dispersed aerosols, as suspensions/colloids, or in an agglomerate state. In an agglomerate 





Figure 1.4: Morphological classification of nanomaterials (Tan et al., 2011).
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1.3. Properties of metal nanoparticles 
The biological impact and the biokinetics of nanoparticles are dependent on size, 
shape, chemical composition, surface functionalisation, solubility, and aggregation. These 
parameters impact and dictate the most fundamental characteristics of nanomaterials and can 
modify cellular uptake, protein binding, translocation of nanoparticles from portal of entry to 
the target site, and the possibility of causing tissue injury (Oberdörster et al., 2005).  
 
1.3.1. Size of the nanoparticle 
It has been proved that nanoparticles are more reactive than micron sized particles due 
to the higher penetrative efficiency because of their small size. The efficiency of 
nanoparticles uptake by mammalian cells was also shown to be higher compared to 
microparticles (Desai et al., 1996). Micron sized particles are relatively less toxic compared 
with nano-sized particles (Jiang et al., 2009, Lin et al., 2009). Studies reported that the 
properties of nanoparticles change with size. Mammalian cells proved to be most sensitive to 
gold particles at 1.4 nm in size and less susceptible to gold particles at 15 nm (Pan et al., 
2007). Nanoparticles within the 2–100 nm size range were found to alter signalling processes 
essential for basic cell functions with 40 and 50 nm nanoparticles demonstrated the greatest 
effect (Jiang et al., 2008). 
 
1.3.2. Shape of the nanoparticle 
Apart from size, shape of nanoparticles influences strongly their uptake, catalytic 
activity and reactivity. Chithrani et al. (Chithrani et al., 2006) showed the uptake of rod-
shaped gold nanoparticles is lower than their spherical counterpart. Haruta et al. (Haruta, 
2004) suggested that the catalytic activity of gold nanoparticles depends strongly on the 
particle's shape. Hemispherical particles were found by this group to perform better than 
 9 
 
spherical particles. Xu et al. (Xu et al., 2006) investigated the oxidation of styrene, cubic, 
truncated triangular nanoplates, and near-spherical Ag-np and found the rate of reaction of 
the nanocube particles to be fourteen times higher than the nanoplates and four times higher 
than the nearly-spherical particles. The authors attributed this finding to the increased number 
of atomic steps and dangling bonds. Truncated triangular silver nanoplates with a {111} 
lattice plane as the basal plane displayed the strongest biocidal action, compared with 
spherical and rod-shaped nanoparticles and with Ag
+
 (in the form of AgNO3) (Pal et al., 
2007). 
 
1.3.3. Quantum confinement and surface to volume ratio 
Through the effect of quantum confinement and the large surface to volume ratio, the 
nanostructures have enhanced electronic, optical, chemical and thermal properties, which 
deviate substantially from those of bulk materials.  
In nano crystals, the electronic energy levels are not continuous as in the bulk but are 
discrete (quantised states), because of the confinement of the electronic wave function to the 
physical dimensions of the particles. This phenomenon is called quantum confinement and 
therefore nano crystals are also referred to as QDs. According to quantum confinement theory, 
electrons in the conduction band and holes in the valence band are spatially confined by the 
potential barrier of the surface. Due to confinement of both electrons and holes, the lowest 
energy optical transition from the valence to conduction band will increase in energy and 
eventually bandgap. This quantum confinement has applications in semiconductors, 
optoelectronics, and non-linear optics. 
The high surface area to volume ratio is a very crucial property of nanoparticles. The 
high surface area to volume ratio results in high reactivity, allowing nanoparticles to actively 
interact with their surroundings. In another words, they are highly penetrative. For example, 
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they can serve as very potent catalysts or be applied in thin films to serve as thermal barriers 
or to improve wear resistance of materials. Therefore, this provides a tremendous driving 
force for diffusion, increasing the potential to cross cell membranes (Farré et al., 2011) and 
determining intrinsic toxicity of the surface of nanoparticles (Donaldson et al., 2004, Das and 
Ansari, 2009). The consequence of these two effects is that many properties of nanomaterials 
which for macroscopic particles are independent of size can be tuned to a very significant 
amount by adjusting the particle quantum confinement and surface to volume ratio.  
 
1.3.4. Surface plasmon resonance 
Surface plasmon resonance (Spring et al.) is the collective oscillation of valence 
electrons in a metal stimulated by incident light. The resonance is established when the 
frequency of light photons matches the natural frequency of surface electrons oscillating 
against the restoring force of positive charged nuclei. SPR in nanometer-sized structures is 
called localised SPR and resulted in characteristic colours to specific nanoparticles (Zeng et 
al., 2011). The SPR of silver nanoparticles that are embedded in the glass give the greenish 
yellow colour in reflected light while gold nanoparticles give ruby red colour in transmitted 
light (Figure 1.5). Localised SPR in nanoparticles shows a great potential for bio-analytical 
sensing application and novel plasmonic detection systems.  
 
1.3.5. Surface functionalisation 
Surface functionalisation gives stability to the nanoparticles against coagulation or 
aggregation by conserving particle charge and by modifying the outermost layer of the 
particle. To expand the biological application scope, surface functionalisation has made 
controlled internalisation and biocompatibility of nanoparticles possible (Villanueva et al., 
2009). For example, the use of organic compounds functionalised iron oxide nanoparticles 
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provides not only the basic magnetism characteristics of magnetic nanoparticles, but also 
possess good biocompatibility and biodegradability of the functional organic materials. 
Moreover, organic molecules can provide the ensemble of functional reactive group, e.g. 
aldehyde groups, hydroxyl groups, carboxyl groups, amino groups, and etc. It is crucial that 
their groups can link to the active biosubstances such as antibody, protein, DNA, enzyme, 
etc., for enhanced uptake efficiency or further application (Neouze and Schubert, 2008). 
Choice of capping agent must complement the application for which they are employed for. 
For example, in drug delivery it is ideal to choose a ligand that facilitate easy receptor 
mediated uptake. Conjugation of colourimetric or immunofluorescence probe to nanoparticles 
assists in visualization or tracing of nanoparticles in various cellular compartments or organs 
in animal models (Villanueva et al., 2009). These properties make surface functionalisation a 
crucial factor in nanotechnology. 
 
 
Figure 1.5: The Lycurgus cup. (A) Greenish yellow colour of the cup is reflected light due 
to the silver nanoparticles and (B) ruby red appearance in transmitted light contributed by 
gold nanoparticles. Department of Prehistory and Europe, the British Museum. © The 





1.4. Route of entry of nanoparticles  
The growing use of nanotechnology expose humans to intentionally generated 
engineered nanoparticles, contributing significantly to adverse health effects.  Inhalation, 
ingestion and therapeutic applications are considered as three major uptake routes of 
nanoparticles to the human body (Oberdörster et al., 2004, Oberdörster et al., 2005). Further 
work has highlighted the fact that the targeted organs and cellular uptake of nanoparticles 
depend on particle size, charge, surface area and chemical composition possessed by the 
nanoparticles (Berry et al., 1977). The respiratory system, blood, central nervous system 
(CNS), gastrointestinal (GI) tract and skin have been shown to be targeted by nanoparticles. 
A picture depicts portals of nanoparticle entry is shown in Figure 1.6 (Hagens et al., 2007). 
 
1.4.1. Respiratory system 
Respiratory tract is reported as the primary target organ for inhaled nanoparticles. 
Micron-sized particles (5–30 µm) usually are deposited in the nasopharyngeal region by the 
inertial impaction mechanism. Smaller micron-sized particles (1–5 µm) that evade the 
nasopharyngeal region will be settled as sediment in the tracheobronchial region, which may 
be further removed by mucociliary clearance. Finally, the remaining submicron particles (<1 
µm) and nanoparticles (<100 nm) with the smallest size distribution will penetrate profoundly 
into the alveolar region where removal mechanisms may be insufficient (Menzel and Amdur, 
1986, Siegmann et al., 1998). 
Retention of particles is considerably longer when the particles are deeply deposited 
in the lung. Longer time is needed for clearance of particles from the organ and higher risk of 
adverse health effects due to particle-tissue and particle-cell interactions (Blank et al., 2009). 
The phagocytosis function of alveolar macrophages to remove inhaled nanoparticles appears 
to be considerably inefficient than for larger particles (Lundborg et al., 2001, Bergeron and 
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Archambault, 2005, Muhlfeld et al., 2008). Inhaled nanoparticles can also impair the ability 
of macrophages to phagocytose and eliminate other particles that may be pro-inflammogenic 
(Donaldson et al., 2002). Insoluble particles may remain in the lung indefinitely (Siegmann et 
al., 1998, Muhlfeld et al., 2008). Prolonged residence of particles in the lung may lead to 




Figure 1.6: Potential route of absorption, distribution, metabolism and excretion of 
nanoparticles (Hagens et al., 2007). 
 
 
1.4.2. Gastrointestinal tract 
The gastrointestinal tract (GI) represents an important route of entry for nanoparticles 
since food products may contain nanoparticles (Lomer et al., 2002, Maynard and Michelson, 
2006). Inhaled particles can also be excreted and ingested into the GI tract. Nanoparticles will 
be translocated into and across the gastrointestinal mucosa via four pathways following 
ingestion. The most documented route of uptake for nanoparticles is via the M-cell rich layer 
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of Peyer's Patches (small intestinal lymphoid aggregates). M-cells are specialised, 
differentiated epithelial cells for the transcytosis of macromolecules and particles (Seifert and 
Sass, 1990, Gebert et al., 1996, Seifert et al., 1996, Beier and Gebert, 1998) and are able to 
pass intact material from the lumen to interlocking mononuclear cells. Epithelial cells, also 
known as enterocytes, which absorb and transport nutrients for systemic dissemination and 
optimal cell function, can also take up nanomaterial via endocytosis (Kalgaonkar and 
Lönnerdal, 2009). Another route for translocation of nanoparticles which has been widely 
described is persorption, the paracellular uptake of particles from the digestive tract into 
lymphatic and blood circulation (Volkheimer et al., 1968, Volkheimer, 1974). Lastly, it was 
reported that nanoparticles could gain access to the gastrointestinal tissue via paracellular 
transcytosis across tight junctions of the epithelial cell layer. However, this remains a 
theoretical route as tight junctions are remarkably efficient at preventing paracellular 
permeation though their integrity can be affected by disease and by epithelial cell metabolism 
(e.g. glucose) and calcium chelators (e.g. citrate) (Powell et al., 1994). Charge appears to be 
an important determinant of gastrointestinal absorption. Positively charged particles seem to 
be absorbed more effectively through the GI tract than neutral and negatively charged 
particles (Florence, 1997, Hussain et al., 2001, Janes et al., 2001, Florence, 2005). In addition, 
the size of the particles determines the extent of absorption. Polystyrene nanoparticles of 50 
and 100 nm were found to be absorbed for 34% and 26%, respectively (Jani et al., 1990).  
 
1.4.3. Skin 
Skin is the largest organ of the body accounting for more than 10% of body mass and 
has an important role of barrier versus the external environment with function of protection, 
homeostasis maintaining, metabolism, synthesis, and deposition (Crosera et al., 2009). Four 
pathways of penetration across the skin have been identified depending on physicochemical 
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properties of particulate matters: intercellular, transcellular, and two transappendageal, 
through hair follicles and sweat glands (Blank et al., 1967). A variety of factors can influence 
the extent of the dermal uptake such as the skin barrier integrity, the contaminate surface, the 
anatomical side, and the presence of skin diseases such as allergic and irritant contact 
dermatitis, atopic eczema, and psoriasis. In the literature, there are studies which suggest that 
the skin is an important route of entry for nanoparticles both in occupational and consumer 
setting. Alvarez-Román et al. (Alvarez-Román et al., 2004) revealed that polystyrene 
nanoparticles accumulated preferentially in the follicular openings and was favoured by the 
smaller particle size . Tinkle et al. (Tinkle et al., 2003) showed that mechanical flexion 
facilitated the penetration of fluorescent dextran micron-sized particles that were observed in 
deeper dermal layers . Seo et al. (Seo et al., 2004) found that nanoparticles administered in 
the dermis migrated to regional lymph nodes, potentially via skin macrophages and 
Langerhans cells, raising potential concern for immunomodulation . Some authors suggested 
an increased dermal penetration of nanosilver associated with damaged skin in in vitro 
experiments (Crosera et al., 2009) or following the use of nanosilver coated dressings in case 
of extensive burns (Trop et al., 2006).  
 
1.4.4. Blood 
After nanoparticles absorption following inhalation, ingestion or dermal exposure, 
these ultrafine particles enter the blood circulation, cross the blood-air tissue barrier, further 
distribute and reach readily to secondary target organs (STO), causing systemic health effects 
(Oberdörster et al., 2005). Radioactivity  of 
99m
technetium-labelled carbon nanoparticles 
(<100 nm) was detected in blood in human already at 1 minute, reached a maximum between 
10 and 20 minutes, and remained at this level up to 60 minutes. Substantial radioactivity was 
also detected over the liver and bladder indicating nanoparticles was able to be translocated to 
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STOs via bloodstream (Nemmar et al., 2002). The inhaled iridium and carbon nanoparticles 
with particle sizes of 2–4 nm and 5–10 nm respectively were found in liver, spleen, kidneys, 
heart, soft tissue and bone of rat after 24 hours. The fractions of carbon nanoparticles retained 
in STOs were significantly lower than iridium nanoparticles suggest size and nature of 
nanoparticles serve as major determinants of nanoparticles translocation (Kreyling et al., 
2009). The potency of nanoparticles increases further when studies proved that inhaled 
fluorescent magnetic nanoparticles and the intravenous injected poly(butylcyanoacrylate) 
nanoparticles could penetrate the blood-brain-barrier (Alyaudtin et al., 2001, Kwon et al., 
2008). The distribution of nanoparticles to STOs are often accompanied with harmful effects 
such as myocardial infarction, anti-coagulation of blood and damaged liver, spleen and kidneys 
(Alfaro-Moreno et al., 2007, Chen et al., 2009, Shrivastava et al., 2009).  
 
1.5. Cellular uptake, biodistribution and clearance of nanoparticles  
Due to their ultra-small size, nanoparticles penetration into cell membranes and its 
concomitant membrane disruptions allow nanoparticles to reach various intracellular 
compartments. Uptake of nanoparticles by cells may also occur via several mechanisms such 
as endocytosis, diffusion and phagocytosis. Till date, specific cellular uptake mechanism that 
caters for all nanoparticles was not documented. It was reported that size of nanoparticles 
affect the choice of uptake mechanisms by the cells. Raynal et al. (Raynal et al., 2004) 
reported that the uptake of 100 nm dextran-coated superparamagnetic iron oxide 
nanoparticles (SPION) by mouse peritoneal macrophages is mediated via scavenger receptor 
class A-dependent endocytosis. Smaller (20 nm) dextran-coated particles are primarily taken 
up by pinocytosis (Fleige et al., 2002). The choice of uptake mechanisms is also largely based 
on shape and the coating agent of nanoparticles. Moore et al. (Moore et al., 2005) reported 
that the cellular uptake of SPION is influenced by plasma proteins which coat the iron oxide 
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nanoparticles . Chithrani and Chan (Chithrani and Chan, 2007) showed that the transferrin-
coated nanoparticles were taken up into the cells via a receptor-mediated clathrin-dependent 
endocytosis and rod-shaped nanoparticles showed a lower uptake in comparison to spherical 
shaped nanoparticles . In another study, it was shown that internalisation of hydrophobically 
modified glycol chitosan nanoparticles is mediated by more than one cellular uptake 
mechanisms (Nam et al., 2009). When both clathrin-mediated endocytosis and caveolae 
formation were inhibited by specific inhibitors, the nanoparticle uptake was reduced by 40% 
and 20% respectively. When macropinocytosis was inhibited, the nanoparticle uptake was 
reduced by 30% compared to the uptake by untreated cells. A graphical representation 
explains the several different pathways implicated in the cellular uptake of nanoparticles is 
shown in Figure 1.7 (Kunzmann et al., 2011).  
Upon entering cells, nanoparticles enter a sorting centre known as the endosome. 
After which, nanoparticles will be distributed to various compartments within the 
intracellular region such as the outer-cell membrane, cytoplasm, mitochondria, lipid vesicles 
and nucleus (Buzea et al., 2007). When nanoparticles localise in organelles, such as 
mitochondria, disruption of mitochondrial architecture occurred (Colvin, 2003). In short, 
depending on their localisation inside the cell, the nanoparticles can damage organelles or 
DNA, or ultimately cause cell death.  
It was documented that nanoparticles can be excreted via liver, spleen, kidney and 
bile. However, urinary and faecal excretions are proven experimentally the two major routes 
of nanoparticles excretion. Portal of entry, composition, size, functionalisation and active 
targeting of nanoparticles are the affecting factors. Yamago et al. (Yamago et al., 1995) 
reported that fullerene when administered orally, systemic uptake via lymph into the 
organism can occur and excreted primarily via faeces and small amount into the urine. When 
injected intravenously, they can distribute rapidly throughout the organism and excretion was 
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slow with most of the material was retained in the body after one week. In vivo real-time 
imaged dominant signal in bladder and urine excretion studies revealed that intravenous-
injected silica nanoparticles with a size of 45 nm were partly excreted through the renal 
excretion route (He et al., 2008). Another study pointed that silica nanoparticles were trapped 
by macrophages in the spleen and liver and remained there until 4 weeks after the single 
injection. Smaller sized silica nanoparticles at 50 nm cleared to urine and bile. The 100 nm 
and 200 nm silica particles existed in urine and faeces (Cho et al., 2009). Souris et al. (Souris 
et al., 2010) demonstrated in their study that highly charged mesoporous silica nanoparticles 
(+34.4 mV at pH 7.4) being quickly excreted from the liver into the gastrointestinal tract, 
while less charged nanoparticles (−17.6 mV at pH 7.4) remained sequestered within the liver . 
Burns et al. (Burns et al., 2008) showed in their study that a neutral organic coating on silica 
nanoparticles facilitated efficient urinary excretion . 
Hence, identification of the size, shape, composition, surface properties as well as 
capping agent that coat the nanoparticles is essential for precise understanding of uptake 







Figure 1.7: Pathways of cellular internalisation of nanoparticles (Kunzmann et al., 2011).  
 
1.6. Silver nanoparticles  
Silver has been widely used for thousands of years in human history. Among silver's 
many applications, those exploiting its biocidal property for hygienic and medicinal purposes 
are deemed most outstanding (Chen and Schluesener, 2008). Vessels made of or coated with 
silver were used in ancient times to preserve beverages and silver powder was used as a 
treatment for ulcers. However, it is mainly silver compounds that offer highest medicinal 
value. Silver compounds were used to effectively treat wound infection in World War I until 
the advent of antibiotics. The very first scientifically documented medical use of silver was 
dated back in 1884, when silver nitrate was introduced as an eye solution for prevention of 
Gonococcal ophthalmia neonatorum (Russell et al., 1994). In addition, silver sulfadiazine 
cream was successfully used as standard topical disinfectant for serious burn wounds and is 
still widely utilised in burn units. Recently, silver nanoparticles (Ag-np) was shown to exhibit 




 However, due to the advancement of antibiotics such as penicillins and 
cephalosporins, the usage of silver compound as anti-infection agent has slowly been 
eliminated by choice. However, the advent of modern science has helped silver renew its lost 
lustre. The emergence of engineering technologies has successfully refined metallic silver 
with extraordinarily novel physico-chemical properties. Metallic silver is engineered into 
particles of nano range, instead of being produced bulky.   
Currently silver is used in the expanding field of nanotechnology and appears in many 
consumer products. The choice of silver over other metallic nanoparticles offers several 
advantages. Silver is relatively inexpensive when compared others in the precious metal 
group such as gold, platinum, palladium, copper and zinc. Silver exhibits higher extinction 
coefficients, sharper extinction bands, higher ratio of scattering to extinction, and extremely 
high field enhancements. Silver nanoparticles have unique optical, electrical, and thermal 
properties and are being incorporated into products that range from photovoltaics to 
biological and chemical sensors. Examples include conductive inks, pastes and fillers which 
utilize silver nanoparticles for their high electrical conductivity, stability, and low sintering 
temperatures. Additional applications include molecular diagnostics and photonic devices, 
which take advantage of the novel optical properties of these nanomaterials (McGinnis and 
Elimelech, 2008, Li et al., 2010). Due to their antimicrobial and antiviral properties, majority 
of nanosilver products are catered for disinfection or medical purpose. Consumer products 
that utilise Ag-np include acne creams, baby pacifiers, clothing, deodorizing sprays, jewellery, 
cosmetics, utensils, monetary currency, dental alloy, photography, explosives and so much 
more. Some of the commercialised Ag-np containing products are listed in Table 1. 
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Table 1: Commercially available Ag-np containing products  
Product name  Usage Manufacturer 
Soothing Silver Gel Contains colloidal silver and plant-based ingredient skin to promote rapid 
healing irritated or damaged skin 
Utopia Silver Supplements, 
USA 
Nano Silver Spray Contains antibacterial silver ions for the purpose of sterilization and 
deodorization 
Songsing Nano Technology 
Co., Ltd., Taiwan 
Oxy Colloidal silver is used in conjunction with hydrogen peroxide to be used as a 
disinfectant, antiseptic, and oxidiser. 
Skybright Natural Health, 
New Zealand 
Silver Nano Refrigerator | 
Side by Side 
 Silver nano coating to the inner surfaces of silver nano refrigerators. As air 
circulates, the coated surfaces allow the Silver ions to control the airborne 
bacteria.  
Samsung Corporation, South 
Korea 
Nano-silver Toothpaste Nanosilver toothpaste for antibacterial, sterilization and prevention of 
periodontitis, halitosis, and other diseases.  
Quan Zhou Hu zheng Nano 
Technology Co., Ltd., China 
SILCRYST™ Silver atoms are condensed to form new high-energy nanocrystalline 
structures high-density polyethylene for non-adherent wound care dressings. 
NUCRYST Pharmaceuticals 
Corp., USA 
Nano Cosil Beauty Soap Nano Silver shows it competence as a disinfectant by eliminating bacteria and 
germs causing common skin troubles such as pimples and acne. 
Natural Korea Co., Ltd, 
South Korea 
Curad® Silver Bandages A polyethylene net is coated with silver nanoparticles. Moisture from a wound 
or gel allows the release and migration of Ag+ into the wound area. 
Medline Industries, Inc., 
USA 
LG® Antibacterial Mobile 
Phone 
A silver nano antibacterial coating is placed on the surface of the phone that 
establishes new cleanliness standards 
LG Electronics Inc., South 
Korea 
NanoSil™  As immune system boosting and enhancing dietary supplement Conseal International, Inc., 
USA 
X-System™ Scent 
Eliminating Boot Socks 
Nano silver are chemically and permanently bonded to the fibers,  




1.7. Literature on toxicity of Ag-np  
1.7.1. Cytotoxicity of Ag-np 
The primary route of Ag-np exposure is through inhalation and skin absorption due to 
occupational exposure and daily usage of nanosilver containing products ranging from food 
container, clothing and burn dressings. Traditionally, silver is relatively non-toxic to 
mammalian but can cause argyria or argyrosis (irreversible bluish-grey pigmentation of the 
skin and/or the eye due to silver deposition) in subjects with chronic exposure (Eturska and 
Obreshkova, 1979, Rosenman et al., 1979, Spencer et al., 1980, Van de Voorde et al., 2005).  
However, recent reports on toxicity of Ag-np indicated significant cytotoxicity in cell 
lines. As addressed previously, the bioreactivity of nanoparticles is influenced by various 
parameters such as stability, size, shape and choice of capping agent. These factors can 
potentially determine the toxicity of Ag-np. The major toxicological concern associated with 
nanomaterials is the fact that some manufactured nanomaterials are redox active, and some 
particles transport across cell membranes, especially into mitochondria. A study with Wistar 
rat liver mitochondria demonstrates mitochondrial toxicity may have a central role in Ag-np 
toxicity. Ag-np of size 40 nm and 80 nm impair mitochondrial function, mainly due to 
decrease of mitochondrial membrane potential, ADP-induced depolarization, and respiratory 
control ratio, which eventually results in uncoupling effect on the oxidative phosphorylation 
system (Teodoro et al., 2011). In line with the study, Asharani et al. (AshaRani et al., 2008b) 
proposed  a possible mechanism of toxicity which involves disruption of the mitochondrial 
respiratory chain by Ag-np leading to production of ROS and interruption of ATP synthesis . 
Findings from various literatures suggest that Ag-np cytotoxicity is primarily the result of 
oxidative stress and is independent of the toxicity of Ag
+ 
ions. Exposure of Ag-np resulted in 
upregulation of many oxidative stress response genes which include glutathione peroxidase 1, 
catalase, superoxide dismutase 1, matrix metalloproteinases, heme oxygenase-
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1, metallothionein-2A and heat shock protein 70 (Carlson et al., 2008, Kim et al., 2009, 
Miura and Shinohara, 2009). Elevation of reactive oxygen species (ROS) production in turn 
mediates cellular apoptosis and necrosis in Ag-np treated cells (Foldbjerg et al., 2009, Miura 
and Shinohara, 2009, Eom and Choi, 2010, Park et al., 2010). However, most studies have 
not progressed to a stage beyond that of oxidative stress. Two recent studies revealed that 
there may be a margin of safety between exposure for antimicrobial application of Ag-np and 
adverse effects observed in human cells as the concentrations inducing cytotoxicity were 
much higher than those reported to have antimicrobial activity (Hackenberg et al., 2011, Park 
et al., 2011). 
 
1.7.2. Genotoxicity of silver nanoparticles 
Genotoxicity is relatively less explored and least understood compared with 
cytotoxicity in field of nanotoxicology.  Most data available focus primarily on toxicological 
end points which is similar to cytotoxicity studies. Furthermore, no detailed studies were 
done in this area to explore DNA damage and repair responses and the associated signalling 
networks involved. Consensus is yet to be reached on how human body get affected by Ag-np 
induced genotoxicity due to the lack of consistency across literatures.  
DNA damage may result either from the effects of the silver nanoparticles themselves, 
or their by-product silver ions. Damage can be induced by both of these species through 
direct binding of DNA or via downstream effects of their toxicity. Current evidence for the 
direct binding of silver nanoparticles to DNA has been shown in bacteria (Yang et al., 2009) 
and viruses (Lu et al., 2008).  
DNA can be damaged in a variety of ways, including alkylation of bases, hydrolysis 
of bases and bulky adduct formation. However the most widely accepted form of 
nanoparticle-induced genotoxicity is oxidative damage. Oxidative stress results in the 
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production of excess ROS, which in turn oxidise DNA bases and generate both single strand 
breaks and more lethal DSBs (Evans et al., 2004).  
An in vitro study conducted by Ahamed et al. (Ahamed et al., 2008) is one of the first 
to disclose that mammalian cells were responsive to DNA damage induced by Ag-np by the 
upregulation of damage response proteins such as RAD50 and BRCA1. Subsequently, it was 
reported that surface chemistry of Ag-np determine the severity of DNA damage as coated 
Ag-np are more monodispersed while uncoated particles tend to agglomerate, limits their 
surface area availability to access to membrane bound organelles (Ahamed et al., 2008). 
Evidences from cytogenetic studies suggest that Ag-np exposure increased total DNA 
damage, frequency of micronucleus formation and chromosomal aberrations in mammalian 
cells (AshaRani et al., 2008b, Kawata et al., 2009, Panda et al., 2011, Li et al., 2012). A 
concentration-dependent increase in DNA-strand breaks in human testicular embryonic 
carcinoma cell line suggests Ag-np can potential affect human reproduction and fertility 
(Asare et al., 2011). DNA damage can be potentially augmented by Ag-np deposition in the 
nucleus, followed by interactions of Ag-np to the DNA leading to cell cycle arrest in the 
G2/M phase, implying the involvement of DNA repair (AshaRani et al., 2008b).  
Oxidation is not the only way silver nanoparticles can induce DNA damage. In a 
study designed for investigating the haemocompatibility of silver nanoparticles, indirect 
DNA damage was recorded as a consequence of massive haemolysis (Asharani et al., 2010), 
indicating that the mechanism of action of silver nanoparticles is multifactorial and complex.  
 Additionally, the ability of Ag-np to bind to or interact with genomic DNA has 
differentially compromised the DNA replication fidelity of rpsL gene codes for rpS12, a 
ribosomal bacterial protein, which ensure that the mRNA properly aligns with the ribosome 
prior to the start of translation (Yang et al., 2009). Moreover, Ag-np were able to induce 
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genotoxic activity via the induction of somatic recombination which affect the phenotypic 
expression of certain genes in in vivo model (Demir et al., 2011).  
A substantial body of both in vitro and in vivo evidence is now building 
demonstrating the genotoxicity of silver nanoparticles. Further studies are needed to 
understand the significance of these findings in a human context and how this can be 
harnessed in a beneficial manner for the treatment of diseases such as cancer. 
 
 1.7.3. Inflammatory response in silver nanoparticles treated cells 
As reviewed previously, nanomaterials interact with the immune system to elevate 
immunotoxicity
 
(Dobrovolskaia and McNeil, 2007). The activation of macrophages can result 
in release of chemokines, cytokines, ROS, and other mediators which initiate inflammation. 
In addition, impairment of the phagocytic function of macrophages leads to retention of 
particles in the organs, building up of toxicity in cells. 
Nitrite oxide (NO) production and resistance to infection (Kun et al., 2001) plays an 
important role in human innate immunity. NO is generated by phagocytes which include 
monocytes, macrophages and neutrophils which results in inflammation in response to 
foreign materials penetrating the human body. A study conducted by Shavandi et al. 
(Shavandi et al., 2011) showed high doses of Ag-np treatment lead to massive macrophage 
death and subsequently, reduction in Ag-np phagocytosis. Therefore, a significant decrease in 
macrophages NO production (44% to 83%) compared with control group.  
A number of studies suggested that cytotoxic effects of Ag-np in macrophages were 
mediated by the generation of ROS (Carlson et al., 2008, Foldbjerg et al., 2009, Park et al., 
2010). Besides damaging effects to macromolecules such as DNA, proteins and lipids, an 
elevated ROS level triggers the pro-inflammatory signalling cascades in the cells, and 
ultimately leading to programmed cell death (Nel et al., 2006). The generation of ROS in 
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macrophages was also reported as an indirect effect of the interaction of Ag-np with cellular 
components as this event occurred only at concentrations above those decreasing metabolic 
activity of macrophages (Park et al., 2011).  
Exposure to Ag-np triggered the release of a number of pro-inflammatory markers as 
well, most markedly tumour necrosis factor alpha, macrophage inhibitory protein, 
granulocyte colony-stimulating factor, interleukin-1 beta (IL-1β), IL-8, IL-6, intercellular 
adhesion molecule-1,  monocyte chemotactic protein-1  and interferon gamma (Carlson et al., 
2008, Park et al., 2010, Nishanth et al., 2011) to enhance release, maturation, chemotactic and 
phagocytic properties for phagocytes in response to injury induced by Ag-np (Driscoll, 1994). 
But, overproduction of cytokines in response to nanoparticles may lead to inflammatory 
diseases and in some occasions, cell death (Carlson et al., 2008, Park et al., 2011, AshaRani 
et al., 2012). 
 
1.7.4. Ecotoxicity of Ag-np  
With the increasing commercial application of engineered nanomaterials, Ag-np are 
likely to enter the aquatic environment, soil and even air. Ag-np induced a concentration-
dependent increase in larval abnormalities, mostly oedema in fathead minnow (Pimephales 
promelas) embryos (Laban et al., 2010). Treatment of Ag-np hinders normal development of 
zebrafish embryos as abnormal body axes, twisted notochord, slow blood flow, pericardial 
oedema and cardiac arrhythmia and hatching delay was observed in Ag-np treated zebrafish 
embryos (Asharani et al., 2008a). Accumulation of Ag-np inside chorion pore canals and the 
inner mass of zebrafish embryos are likely be responsible for deformities and death of 
zebrafish (Lee et al., 2007). Short-term exposure to Ag-np can effectively inhibit 
photosynthesis in Chlamydomonas reinhardtii, single celled green alga distributed in fresh 
water (Navarro et al., 2008). 
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Extended x-ray absorption fine structure spectroscopy analysis of the soils indicated 
that the Ag
+ 
released from destabilised Ag-np in soil, may be responsible for reduced growth 
and development in earthworm Eisenia fetida (Shoults-Wilson et al., 2011). Their findings 
also suggest that soil type is an essential determinant of Ag accumulation from Ag-np than 
particle size as the effects of Ag-np in naturally sandy form are much significant compared 
with those in the artificial soil (Shoults-Wilson et al., 2011). Functional genomics studies 
using mutant analyses suggested that the increase sod-3 and daf-12 gene expressions maybe 
related to the reproductive failure observed in Ag-np treated Caenorhabditis elegans (Roh et 
al., 2009). 
A study using Allium cepa root tip as model suggests Ag-np could penetrate plant 
system and may impair stages of cell division causing chromatin bridges, stickiness, 
disturbed metaphase, multiple chromosomal breaks and cell disintegration (Kumari et al., 
2009). Furthermore, Ag-np induce heat shock stress, oxidative stress, DNA damage and 
apoptosis in Drosophila melanogaster (Ahamed et al., 2010).  
Ultimately, these findings should lead to the identification of characteristics of silver 
nanomaterials that afford minimal or no toxicity and guide more rational designs of materials 
on the nanoscale.  
 
1.8. Silver nanotechnology: A double-edged sword? 
The increasing usage of Ag-np in various applications and their ultra small size and 
unique properties such as high reactivity undeniably raises concern with regards to short and 
long term health risks. Conversely, silver nanomaterials have been reported a promising 
technology in many novel applications such as targeted drug delivery and controlled drug 
release, improved sensors and environmental clean up technologies, and lighter more 
efficient materials. The issue of whether nanotoxicology will outweigh benefits of 
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nanotechnology has been intensely debated. Despite the concerns and uncertainties 
articulated, majority still believed that the benefits within the fields of nanotechnology in 
term of health and environmental sustainability will outweigh the potential risks. This 
optimism arises due to the confidence of general public towards the ability of current 
regulatory frameworks to control the risks once they have been assessed. However, given the 
ubiquitous and ever-changing nature of nanotechnologies, the authorities should give serious 
consideration and discussion in order to best govern the burgeoning family of 
nanotechnology (Bowman and Hodge, 2007).  
 
1.9. DNA damage response pathways 
The genome is constantly exposed to various DNA damaging agents.  These agents 
can either be environmental agent (exogenous) or formed within cells (endogenous). 
Exogenously, environmental DNA-damaging agents include ionizing radiation (x-rays, 
gamma rays and cosmic rays), UV radiation from the sun (UV-A, UV-B), food-borne and 
water-borne genotoxic chemicals or agents. Endogenous damaging agents include 
methylating species and ROS that arise as metabolic byproducts. Endogenous DNA damage 
can also be resulted from stochastic errors during DNA replication (Freidberg et al., 1995, 
Weeda et al., 1998, De Bont and van Larebeke, 2004).  
Depending on the nature and intensity of DNA damage, cells may survive or undergo 
cell cycle arrest, senescence or apoptosis (Hoeijmakers, 2001). When low or moderate levels 
of DNA damage occurs, cell cycle may be halted in order to allow sufficient time for the 
recruitment of DNA repair machinery to repair damaged DNA. If the repair was unsuccessful 
and the cells survive, the cells may enter a state of senescence where it arrests permanently 
while being metabolically functional. In contrast, when the level of DNA damage is too great 
to warrant repair, cells will be eliminated through apoptosis to avoid cellular transformation. 
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Such regulations are to ensure faithful transmission of genetic material to the progeny 
(Harper and Elledge, 2007). Occasionally, cells survive when DNA damage occurs to 
essential genes which regulate apoptosis, cell cycle check-point or DNA repair pathways.  
Under such circumstances, accumulation of mutations may occur, predisposing cells to 
malignancy.  
DNA damage-repair is categorised into five major pathways: direct damage reversal 
(DR), base-excision repair (BER), nucleotide-excision repair (NER), mismatch repair (MMR), 
and double strand break repair (DSBR). Each of these pathways targets specific type of DNA 
lesions, cellular checkpoints and signal transductions with some overlaps between the 







Figure 1.8: Schematic representation of DNA repair pathways and the inhibitors under 
investigation. The five main DNA repair pathways are direct damage reversal (DR), base-
excision repair (BER), nucleotide-excision repair (NER), mismatch repair (MMR), and double 
strand break repair (DSBR) (Damia and D’Incalci, 2007). 
 
 
1.9.1. Non-homologous end joining (NHEJ) 
Double strand breaks (DSBs) are generally considered the most lethal of all DNA 
lesions that can lead to potentially oncogenic genomic rearrangements or cell death. They can 
be induced by ionizing radiation, ROS and many anticancer agents or when the replicative 
fork encounters a single strand break. In eukaryotic systems, DSBs are dealt with by both 
intrinsically error-free repair pathways (homologous recombination repair-HR and single 
strand annealing (SSA) and error-prone pathway (NHEJ). The homologous recombination 
(HR) requires the alignment of homologous sequence on the sister chromatid to repair DSBs 
and is particularly important during late S and G2 phase of the cell cycle. SSA is similar to 
HR and is dependent upon homologous sequences ﬂanking the site of break (Rothkamm et al., 
2003, Damia and D’Incalci, 2007). The NHEJ is the predominant route for the repair of DSBs 
in mammalian cells and is active throughout the cell cycle, and its activity increases as cells 
progress from G1 to G2/M of the cell cycle (Rothkamm et al., 2003, Mao et al., 2008) and it 
involves the alignment of the broken ends without homology requirements. During the repair, 
DNA bases are lost at the site of the DSBs so that NHEJ can be mutagenic (Damia and 
D’Incalci, 2007). 
 
1.9.2. Role of DNA-dependent protein kinase in NHEJ pathway   
DNA-dependent protein kinase (DNA-PK) is a member of phosphatidylinositol 3-
kinases (PI-3 kinases) family. DNA-PK can be fractionated into two components (Dvir et al., 
1992, Gottlieb and Jackson, 1993). One is a large polypeptide corresponding to the DNA-PK 
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catalytic subunit (DNA-PKcs) which shares carboxy terminal amino sequence homology with 
other family members such as Ataxia Telangiectasia Mutated (ATM) and ATM-related (ATR) 
(Hartley et al., 1995, Poltoratsky et al., 1995). The second component is autoimmune antigen 
Ku, comprising polypeptides of approximately 70 kDa and 80 kDa in a heterodimeric 
complex. DNA-PKcs is inactive on its own and  requires Ku70/80 heterodimer to  direct  it to  
the  DNA  DSBs and  trigger  its  kinase  activity (Gottlieb and Jackson, 1993, Morozov et al., 
1994). It was proposed that the binding of Ku70/80 heterodimer to DNA break sites induces 
conformation alterations which in turn facilitate DNA-PKcs–DNA interactions that release 
the catalytic potential of the DNA-PK complex in order to initiate NHEJ repair pathway 
(Lees-Miller et al., 1990, Gottlieb and Jackson, 1993). Following activation of DNA-PK, 
downstream DNA repair factors include Rad50/ Mre11/ Xrs2 complex along with XRCC4, 
DNA ligase IV and other repair factors to facilitate the final ligation step (Featherstone and 
Jackson, 1999). Cells defective in DNA-PK components are hypersensitive to killing by 
ionizing radiation owing to an inability to repair DSBs effectively (Jackson and Jeggo, 1995, 
Roth et al., 1995). The DNA-PK holoenzyme is therefore a crucial component of the DNA 
DSB repair (Hartley et al., 1995).  
 
1.9.3. Role of Ataxia Telangiectasia Mutated in DNA damage repair responses 
ATM is the primary transducer of the DSB signal (Shiloh, 2003, Kurz and Lees-
Miller, 2004). The ATM gene encodes a 370-kDa protein that belongs to the PI-3 kinases 
superfamily (Savitsky et al., 1995), most of which possess a serine/threonine nuclear kinase 
activity (Abraham, 2004). In response to DSB induction, ATM is rapidly activated and 
phosphorylates various substrates, each of which is crucial for the initiation of damage-
response signalling pathways in mammalian cells (Bakkenist and Kastan, 2003, Shiloh, 2006).   
 32 
 
There is great diversity of the ATM-dependent responses to DSBs due to the 
versatility of ATM as a protein kinase with numerous substrates. In addition, the ATM 
signalling network contains protein kinases that are capable of targeting several downstream 
effectors simultaneously, as such, controlling subsets of pathways. A prominent example is 
ATM-mediated activation and stabilization of the p53 protein, an important mediator of cell-
cycle checkpoints and damage-induced apoptosis (Bakkenist and Kastan, 2003, Jayne and 
Geoffrey, 2004, Kurz and Lees-Miller, 2004). A direct link between ATM and a DSB repair 
pathway has been established via a novel substrate – the nuclease Artemis. After its 
phosphorylation by ATM, Artemis engages in processing the ends of some DSBs in 
preparation for ligation in the NHEJ repair pathway. Its lack of phosphorylation by ATM 
might interfere with this process (Riballo et al., 2004, Jeggo and Lobrich, 2005). ATM was 
showed to regulate assembly of Rad51-associated complex in HR repair of DSBs as defective 
assembly of this complex was found in A-T cells in response to DSBs (Morrison et al., 2000). 
Morrison et al. also demonstrated in their study that ATM and the Rad54 protein, another 
member of the HR complex, were operating in the same pathway (Morrison et al., 2000). The 
clinical phenotype associated with loss of ATM activity is ataxia telangiectasia (A-T), a 
prominent genomic instability syndrome which is characterised by neuronal degeneration, 
which leads to severe neuromotor dysfunction, immunodeﬁciency, chromosomal fragility, a 
marked predisposition to cancer, and increased sensitivity to DSB-inducing agents (Crawford 
et al., 2000, Chun and Gatti, 2004). Cells from A-T patients displayed telomere abnormalities, 





1.10. c-Jun N-terminal protein kinase (JNK) pathway and DNA repair 
The JNKs consist of ten isoforms derived from three genes: JNK1, JNK2 
and JNK3 (Waetzig and Herdegen, 2005). Each gene is expressed as either 46 kDa or 54 kDa 
protein kinases, depending upon how the 3' coding region of the corresponding mRNA is 
processed. These kinases are members of mitogen-activated protein kinase family and 
responsive to a variety of environmental stress, inflammatory cytokines, growth factors and 
G-protein-coupled receptor agonists. JNKs have been reported to activate a series of 
transcription factors such as ATF2, c-Myc, Elk-1 and p53 (Karin, 1995, Davis, 2000) as well 
as non-transcription factors such as Bcl-2 and Bcl-xL, implying additional roles of JNK in 
apoptosis (Maundrell et al., 1997, Yamamoto et al., 1999). In particular, JNKs function as 
key regulator of c-Jun, the main and direct downstream target of JNKs in JNK pathway. In 
response to stimuli, JNKs specifically phosphorylates c-Jun on serine 63 and 73 on its N-
terminal transactivation domain, boosting the transcription activation potential of c-Jun (Lin, 
2002).  Figure 1.9 gives an overview of JNK pathway.  
JNKs pathway, also known as stress-activated protein kinases (SAPK) pathway are 
reported responsive to cellular stress from DNA damaging agents and become activated by 
these agents. Dominant negative mutant study of c-Jun revealed that activation of JNK/SAPK 
by cisplatin-induced DNA damage is required for DNA repair and viability following 
cisplatin treatment. These evidences suggest JNK/SAPK pathway might play a normal 
physiological role in the regulation of DNA repair following genotoxic stress (Potapova et al., 
1997). Stable expression of a nonphosphorylatable dominant negative protein c-Jun greatly 
increased the cytotoxic effects of DNA-damaging agents associated with enhanced apoptosis. 
No marked increase in sensitivity to non-DNA-damaging cytotoxic agents observed with the 
same mutant, suggesting JNK dependent activation of c-Jun has a selective role in protecting 
human tumour cells from apoptosis induced by DNA damage (Potapova et al., 2001). DNA-
 34 
 
damaging agents such as cisplatin, actinomycin D and etoposide strongly activate JNK kinase 
activity which mediates stress responses associated with DNA-damaging events. JNK-
dependent phosphorylation of downstream effectors also mediates drug resistance in cancer 
cells by enhancing DNA repair by a p53-independent mechanism (Hayakawa et al., 2003). 
Hence, JNK/SAPK pathway may be a rational target for sensitising tumour cells to DNA-
damaging chemotherapy agents.  
However, JNK signalling has also been reported to be critical for inducing apoptosis 
in response to anticancer therapeutics (Potapova et al., 2001). Thus, JNKs have opposing 
roles in promoting proliferation and survival and inducing apoptosis (Heasley and Han, 2006). 
It was concluded that the pro- or anti-apoptotic functions of JNK are correlated to cell type, 
nature of the DNA damaging agents/death stimulus, duration of its activation and the activity 






Figure 1.9: Organization of JNK pathway. JNKs are member of mitogen-activated protein 
kinase (MAPK) family that are activated by a variety of environmental stresses, 
inflammatory cytokines, growth factors and G-protein-coupled receptor agonists. JNK 
phosphorylated a variety of target proteins including mitochondrial substrates and nuclear 
transcription factors such as c-Jun, ATF2, p53, Elk1, Smad, etc., leading to various cell fates  
(Wang et al., 2004).  
 
1.11. End replication problem  
 As pointed by Alexei Olovnikov (Olovnikov, 1973) in the early 1970s that 
conventional DNA polymerase cannot fully replicate the extreme termini of linear 
chromosomes. During DNA replication, DNA polymerases synthesise DNA molecules from 
5’ to 3’ ends and require DNA or RNA primers. Removal of these primers will leave a gap at 
5’ termini of lagging strand that cannot be filled due to intrinsic properties of DNA 
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polymerase. This leads to loss of nucleotides sequences at ends of linear chromosomes each 
cell division. This problem is known as “end replication problem” as depicted in figure 1.10 
(Harley et al., 1990, Allsopp et al., 1992, Rubin, 2002).   
Normal human cells have limited capacity to divide, after which they become 
senescent and undergo apoptosis following sufficient loss of DNA sequences at chromosome 
ends. This phenomenon is known as the ‘Hayflick limit’. In fact, Leonard Hayflick first 
reported that cells derived from human foetal lung ceased to multiply in vitro after 
approximately 50 serial passages (Hayflick, 1965). The finite numbers of cell division 





Figure 1.10: The end-replication problem. The limited capacity of DNA polymerase to 
duplicate chromosome ends when RNA primers are degraded resulted in gap formation 




1.12. Telomere structure and function 
1.12.1. The DNA component and structure of telomeres 
Telomeres are specialised dynamic DNA structures present at chromosome ends 
consisting of non-coding tandem DNA repeats, TTAGGG, and associated telomere structural 
proteins (Blackburn, 1991). All eukaryotic telomeres end in G strand 3’ overhang with 
approximate few hundred nucleotides in length (Klobutcher et al., 1981, Garvik et al., 1995). 
Electron microscopic observations of human telomeres revealed that the 3’overhang was 
tucked back inside the double-stranded DNA, forming a lariat-like molecule known as 
telomeric loop or t-loop (Griffith et al., 1999). The formation of t-loop is essential to provide 
a general mechanism for protection of telomeres and chromosomal integrity. Due to end 
replication problems, chromosomes with truncated ends are unstable, fusing with other 
chromosomes or becoming lost upon cell division. The presence of these terminal DNA-
protein complexes at chromosome ends is able to prevent adverse side effects arise from end 
replication problems (Rhyu, 1995). They also prevent the recognition of chromosomal ends 
as DSBs (Blackburn, 2001). At birth, human telomeres are about 10 to 15 kilo base pairs (kb) 
in length. However, as mentioned previously, due to the end replication problem, telomeres 
gradually shorten with each cell division (Harley et al., 1990).  
 
1.12.2. The protein component of mammalian telomeres 
The TTAGGG repeats of mammalian chromosome ends associate with the six-protein 
complex called shelterin (de Lange, 2005) (Figure 1.11) is crucial for formation of protective 
cap at the chromosome ends and proper telomere functions. These proteins is abundant and 
present at telomeres throughout the cell cycle implying that their functions is highly specific 
for telomeres (de Lange, 2005).  
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Telomeric repeat binding factor 1 (TRF1) and TRF2 bind the double stranded part of 
telomeres. Whereas, protection of telomeres 1 (POT1) bind the single stranded TTAGGG 
repeats present at the 3′ overhang and in the d-loop of the t-loop configuration. The other 
members of shelterin complex, the TRF2- and TRF1-interacting nuclear protein 2 (TIN2), 
Rap1 (the human orthologue of the yeast Repressor/Activator Protein 1), TPP1 (formerly 
known as TINT1, PTOP, or PIP1), and POT1, are recruited to telomeres by TRF1 and TRF2 
(Palm and de Lange, 2008). The linchpin of shelterin is TIN2, which tethers TPP1/POT1 to 
TRF1 and TRF2. TIN2 also connects TRF1 to TRF2 and this link contributes to the 
stabilisation of TRF2 on telomeres (Liu et al., 2004, Ye et al., 2004b). Mutation or inhibition 
of these components may lead to instability of shelterin complex and telomere dysfunction as 
these proteins are vital for shaping and maintenance of d- and t-loop structures 
(Smogorzewska et al., 2000, Loayza and De Lange, 2003, Ye and de Lange, 2004).  
TRF1 functions primarily as negative regulator of telomere length (Van Steensel and 
De Lange, 1997). The poly (ADP)-ribosylation of TRF1 is regulated by TIN2 and is crucial 
in reducing TRF1 binding to TTAGGG repeats allowing telomerase to bind to add telomere 
repeats (Smogorzewska and de Lange, 2004). TRF2, a second negative regulator of telomere 
length, is also found to be important for telomere capping (Smogorzewska et al., 2000). The 
binding of TRF2 with TIN2 is thought to stabilise TRF2 on the telomeres (Ye et al., 2004a). 
POT1 binds to the telomeric single-stranded DNA in the d-loop and cooperates with TRF2 in 
t-loop maintenance (Yang et al., 2005) and this association is reported critical for telomere 
length homeostasis (Kendellen et al., 2009). Furthermore, the interaction of POT1/TPP1 with 
TRF1 allows communication between the double-stranded telomeres and telomerase at the 3′-
overhang (Wang et al., 2007, Xin et al., 2007).  
The formation of d-loop and t-loop at telomere ends associated with shelterin proteins 
sequester chromosome ends from the DNA damage response pathway and prevent 
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inappropriate DNA repair at these sites (Blackburn, 2001). For instance, TRF2 facilitates the 
recruitment of Rap1 and subsequently binds Rap1. The TRF2/Rap1 complex prevents human 
telomeres from end-to-end fusions by inhibiting NHEJ at telomere ends (van Steensel et al., 
1998, Bae and Baumann, 2007, Bombarde et al., 2010). The sensing step in the ATM 
pathway is thought to involve the interaction of the Mre11 complex with DNA ends. TRF2 
maintains proper t-loop structures which block accessibility of Mre11, averting ATM kinase 
activation at telomere ends (Petrini and Stracker, 2003). Likewise, association of POT1 with 
TPP1 repress the ATR kinase activation (Denchi and De Lange, 2007, Hockemeyer et al., 
2007). A recent report showed that Rap1 was critical for the repression of homology-directed 
repair, which can alter telomere length (Sfeir et al., 2010). Collectively, the shelterin proteins 
are essential for formation of d-loop and t-loop at chromosome ends and maintain genome 





Figure 1.11: Shelterin complex. Schematic representation of telomeres associated with six 
shelterin proteins namely TRF1, TRF2, and POT1 that directly recognise TTAGGG 
telomeric repeats. TIN2, TPP1, and Rap1 interconnect with the first three subunits in order to 
form a complex. All together, they form shelterin complex which is vital for regulation of 
telomere length maintenance, end capping and prevent telomeres from being recognised as 





1.12.3. Telomere loss 
Experimental evidence demonstrates that telomere length serves as a determining 
factor of replicative capacity (Harley et al., 1990, Harley, 1991). The gradual loss of 
telomeric DNA sequences records the finite number of cell divisions. Generally, the mean 
telomere lengths of human somatic cells range from 5 to 11 kb. On average, telomeric DNA 
were lost at 50-150 bp/cell division in vitro and 10-50 bp/year in vivo (Harley et al., 1990, 
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Blasco et al., 1997, Niida et al., 1998). This suggests that chromosome ends are progressively 
degraded and protective caps formed of telomeres at chromosome ends were eroded overtime. 
When the telomeres shorten to a critical length which affects the end capping of telomeres, 
cell cycle checkpoints will be activated to signal cells to exit from cell cycle, triggering 
growth arrest. This series of events will lead to replicative senescence also known as 
Mortality Stage 1 (M1) (Hayflick, 1965, Harley et al., 1990). The M1 phase can be bypassed 
by inactivation of cell cycle checkpoint genes such as p53 and or p16/Rb. Cells then continue 
to divide with further decrease in telomere length. At crisis stage (M2), cells experiences 
massive genomic instability with a consequent mitotic catastrophe, leading to apoptosis. As a 
very rare event, cells can escape M2 due to reactivation of telomerase. This allows the cells to 
maintain stable telomeres, bypass crisis, and acquire unlimited replicative capacity. 
Eventually, this leads to an immortal cell and cancer cell progression (Figure 1.12) (Harley et 










Figure 1.12:  The telomere-telomerase hypothesis. The telomeres in normal cells shorten 
after each cell division due to end replication problem. When the telomere lengths reach the 
Hayflick limit (M1), the cells irreversibly enter replicative senescence. The M1 stage can be 
avoided by inactivation of tumour suppressor genes such as the p53 and pRb. Many of the 
cells proliferate beyond M1 enter apoptosis before they enter crisis (M2). At M2, telomerase 
activity is reactivated to provide unlimited proliferative potential by stabilizing the telomere 
lengths (Harley et al., 1992).  
 
 
1.12.4. Role of DNA repair proteins in telomere maintenance 
Chromosomal stability is physiologically protected by telomeres through the shelterin 
protein complex with high affinity and specificity for telomeric DNA. There is increasing 
evidence pointing towards the extensive functional interactions between telomere 
maintenance and DNA damage response mechanisms. Deficiency or inhibition of the DNA 
damage response proteins lead to telomere dysfunctions. On the other hand, telomere 
dysfunctions trigger DNA damage responses similar to that observed for incidental DNA 
damage such as recruitment of DNA damage response and DNA repair proteins such 
as 53BP1, γ-H2AX, Rad17, ATM, and Mre11 (Takai et al., 2003) to dysfunctional telomeres. 
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This suggests potential involvement of DNA damage and repair proteins in maintenance of 
telomere length, structure and capping (Hande, 2004).   
     
   
Table 2: DNA damage response proteins involve in telomere maintenance. Deficient or 
inhibition of these proteins results in telomere dysfunctions which lead to radio- or 
chemosensitivity. Interaction of these proteins with shelterin proteins is necessary in most 




1.12.5. Role of DNA-PKcs in telomere maintenance  
The DNA-PK heterotrimeric complex first attracted attention because of its 
involvement in variable, diverse, and joining (VDJ) recombination for immunoglobulin and 
T-cell receptor formation and in NHEJ repair of DNA damage. Ironically, it now turns out 
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that all three subunits of the complex, Ku70, Ku80, and DNA-PKcs contribute to the 
maintenance of telomeres (Hande et al., 1999, d'Adda di Fagagna et al., 2001, Hande, 2004).  
One of the first indications of the involvement of DNA-PKcs in telomeres came from 
the study on SCID cells (Slijepcevic et al., 1997, Hande et al., 1999). BALB/c mouse cells 
with DNA-PKcs repair deficient background have significant increase in uncapped telomeres 
which are inappropriately detected and processed as DSBs (Williams et al., 2009). Primary 
mouse embryonic fibroblasts (MEFs) and primary cultured kidney cells from DNA-PKcs 
deficient mice accumulate a large number of telomere fusions and exhibit elevated levels of 
chromosome fragments and breaks correlatively. Yet, the cells still retain wild-type telomere 
length (Gilley et al., 2001). Inhibitions of DNA-PKcs kinase activity with specific inhibitor of 
DNA-PK, IC86621, in mouse cells induced chromosomal end-to-end fusion (Bailey et al., 
2004). Hence, these evidences conclusively suggested that DNA-PKcs plays an important 
capping role at the mammalian telomere and the kinase activity of DNA-PKcs is crucial to re-
establishing a protective terminal structure at chromosome ends. In contrast, an accelerated 
rate of telomere shortening observed in mice deficient in both telomerase and DNA-PKcs 
when compared with telomerase deficient mice controls. This finding suggests a functional 
interaction between DNA-PKcs and telomerase in maintaining telomere length (Espejel et al., 
2002).  
Mouse model with DNA-PKcs deficient associated uncapped/dysfunction telomeres 
are radiosensitive and susceptible to radiogenic mammary cancer (Williams et al., 2009). 
DNA-PKcs defective mice with abnormal telomeres had a shorter life span and showed an 
earlier onset of ageing-related pathologies than the corresponding wild-type littermates 
(Espejel et al., 2004). In addition, DNA-PKcs ablation was associated with a markedly higher 
incidence of T lymphomas and infections.  These data link the dual role of DNA-PKcs in 
DNA repair and telomere length maintenance to ageing and cancer. 
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Similar to the DNA-PKcs deficient cells, mouse fibroblasts from Ku70 and Ku80 
deficient mice also show an increase in chromosome end fusions in metaphase  (Bailey et al., 
1999, Hsu et al., 2000, Samper et al., 2000, d'Adda di Fagagna et al., 2001, Tong et al., 2002). 
The binding of Ku70/80 to telomeres requires an interaction with either TRF1 (Hsu et al., 
2000) or TRF2 (Song et al., 2000). Since Ku70/80 possess DNA end-binding affinity, it is 
also possible that this complex loads directly onto the chromosome end (Bianchi and de 
Lange, 1999, Walker et al., 2001a).  These findings suggest DNA-PKcs has additionally 
functions in telomere end capping and telomere length maintenance apart from DSBs repair 
and genome maintenance.   
 
1.13. Telomere maintenance mechanism: Telomerase holoenzyme 
Telomerase is a multimeric ribonucleoprotein complex responsible for telomere 
length maintenance by addition of repetitive nucleotide sequences to chromosome ends. 
Telomerase function is known to be almost universally conserved in eukaryotes (Morin, 
1989). Telomere shortening is avoided in the presence of telomerase as this enzyme 
eradicates end replication problem and ensure sufficient number of telomeric repeats at 
chromosome ends for proper structural formation of d-loop and t-loop. Telomerase activity is 
exhibited in gametes, stem cells and tumour cells which render them unlimited replicative 
capacity. (Greider and Blackburn, 1985). While in human somatic cells which are mostly 
telomerase deficient, their proliferation potential is strictly limited.  
Human telomerase consists of two core subunits: the telomerase RNA (known as TR, 
TER, or TERC) and TERT (telomerase reverse transcriptase) protein (Feng et al., 1995, 
Nakamura et al., 1997). The hTR contains a short segment, which encodes the cognate 
telomere repeat. This segment serves as the template for reverse transcription by TERT which 
adds telomeric repeats to existing telomeres. The primer for reverse transcription is provided 
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by the 3′-OH group of the terminal nucleotide at telomeres (Nakamura et al., 1997). These 
two components are enough to provide functional activity of telomerase in vitro.  In vivo 
functioning of telomerase requires auxiliary proteins, some of which are included in the 
holoenzyme (Figure 1.13).  
Dyskerin, a nucleolar protein present in small nucleolar ribonucleoprotein particles 
that modify specific uridine residues of rRNA by converting them to pseudouridine, is also a 
component of the telomerase ribonucleoprotein complex (Mochizuki et al., 2004). Dyskerin 
binds the H/ACA box of telomerase hTR and is required for telomerase ribonucleoprotein 
biogenesis and maximal telomerase enzymatic function in vivo (Kannan et al., 2008). It is 
also assumed that dyskerin has a structural role in the telomerase complex (Mochizuki et al., 
2004). The X-linked form of the human disease dyskeratosis congenita (DKC), a rare, usually 
fatal, inherited skin and bone marrow failure syndrome, is caused by mutations in the gene 
encoding dyskerin (Heiss et al., 1998). Mutations in dyskerin affect the telomerase pathways 
(Mochizuki et al., 2004). A mutated/dysfunctional dyskerin could inhibit the stability or 
processing of the telomerase hTR, or the assembly and stability of the telomerase 
ribonucleoprotein (Shay and Wright, 1999). DKC patients have relatively lower level of hTR 
and telomerase activity and progressively shorter telomeres compared with matched normal 
controls (Mitchell et al., 1999, Shay and Wright, 1999, Kannan et al., 2008). The pathology 
of DKC is consistent with compromised telomerase function leading to a defect in telomere 
maintenance, which may limit the proliferative capacity of human somatic cells (Mitchell et 
al., 1999). All in all, hTERT, hTR and dyskerin are crucial components of telomerase 
ribonucleoprotein complex and mutations at genes coding for these proteins will disrupt the 
telomere-telomerase homeostasis and telomere maintenance and implicate cellular 






Figure 1.13: The structure of telomerase ribonucleoprotein complex. The telomerase 
complex is composed of telomerase reverse transcriptase (TERT), the RNA component (TR, 
TER, or TERC), and associated proteins (dyskerin, NOP10, NHP2, GAR). TERT 
enzymatically adds TTAGGG nucleotide repeats to the 3′ end of telomere’s leading strand 
using TERC as a template. Dyskerin, NOP10, NHP2, and GAR bind to TERC and stabilise 




1.14. Hallmarks of cancer 
Cancer is one of the major causes of the death worldwide. The formation of cancer is 
caused by accumulation of multigenic mutations in somatic cells. Mutations arise in cells 
when DNA attacked by free radicals, ionizing radiation, UV radiation, and chemical 
carcinogens. In some cases, mutations or damage to the genome can be caused by errors 
during DNA replication or intrinsic chemical instability of certain DNA bases. Viruses, such 
as human papilloma virus (HPV), contain proteins that bind to and inhibit p53 and RB 
leading to an increase of genomic instability and an increase in mutation (Bertram, 2000). 
When random mutations occurred in the genes which control proliferation or apoptosis, a de-
coupling of biological mechanisms involved in the regulation of normal cell growth, 
differentiation and apoptosis may occur.  Several biological capabilities are acquired to 
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overcome natural anti-neoplastic cellular constraints. They include sustaining proliferative 
signalling, evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, activating invasion and metastasis, genome instability, 
reprogramming of energy metabolism and evading immune destruction (Hanahan and 
Weinberg, 2011). The alteration in normal cellular physiology causing the cells to grow out 
of control, invade other tissues, and eventually driving the transformation of normal human 
cells into highly malignant derivate and form tumours.   
 
Figure 1.14: Hallmarks of cancer. The acquired capabilities necessary for tumour growth 





1.15. Limitations of conventional cancer treatment  
Traditionally, surgical excision, chemotherapy and radiotherapy are the three main 
approaches in cancer treatment. Decision on applying either one of these approaches for 
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treating cancer depends on tumour type and development stage of cancer. Such therapies 
often used alone or in combination with other anticancer modalities in order to enhance their 
effectiveness for treating localised and metastasised tumours (Tester et al., 2004, Roy and 
Prabhakar, 2010). However, these conventional treatments suffer some limitations which 
restrict their efficacy. One of the most crucial and common problems of existing anticancer 
drugs is their limited aqueous solubility. Most chemotherapeutics either extracted from plant 
or synthetic are hydrophobic and requires solvents to reconstitute and formulate proper 
dosage for treatment, which contribute to severe toxicity. Furthermore, most anticancer 
therapeutics though show efficacy but lack selectivity for cancerous cells over normal cells, 
causing severe side effects to normal cells. Lastly, the development of multidrug resistance is 
a significant obstacle to provide effective chemotherapy to many patients. There are three 
major mechanisms of drug resistance in cells. Firstly, decreased uptake of water-soluble 
drugs such as folate antagonists, nucleoside analogues and cisplatin which require 
transporters to facilitate their entrance into the cells. Secondly, changes in cellular responses 
affecting the cytotoxic effect of anticancer drugs on cancer cells, which include alterations in 
cell cycle, increased repair of DNA damage, reduced apoptosis and altered metabolism of 
drugs. Finally, increased efflux of hydrophobic drugs by diffusion through the efflux pumps 
such as P-glycoprotein embedded in plasma membrane (Ueda et al., 1986, Um et al., 2001, 
Thomas and Coley, 2003). Hence, overcoming these limitations of conventional anticancer 
drugs is essential to provide more effective remedy for human cancer. 
 
1.15.1. Silver nanoparticles and cancer therapy  
Nanotherapeutics is rapidly progressing aimed to solve several limitations of 
conventional drug delivery systems (Chidambaram et al., 2011). Poor aqueous solubility and 
low bioavailability due to hydrophobic nature of chemotherapeutics can be solved by 
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incorporating biocompatible and biodegradable materials such as albumin, lipid, polymeric 
micelles and chitosan on nanotherapeutics or nanotherapeutics drug delivery system. 
Nonspecificity of cancer chemotherapy can be overcome through folate and transferrin 
conjugated nanotherapeutics which are intended to target cancerous cells. Multidrug 
resistance can be significantly reversed by solid lipid based-, polymeric based-, carbon based-, 
and metallic based-nanoparticles which response poorly to efflux systems in the cancer cells.  
Furthermore, favourable size and surface characteristics of nanoparticles increases the 
circulation time of the drug. The nanotherapeutics drug delivery system provides also 
controlled release of the anticancer drugs both during the delivery and at the site of action, 
hence, increases the intercellular drug concentration (Gurny et al., 1984, Duchene et al., 
1988).  
  Though nanoparticles are potentially harmful to human, with the advancement of the 
highly innovative nanotechnology, toxicity of Ag-np can be used to our advantage in myriads 
of diligence especially in cancer therapy. Due to their novel physico-chemical properties, Ag-
np can potentially overcome the limitations of conventional anticancer modalities. Numerous 
studies have also provided solid evidences on the ability of Ag-np in treating human tumours. 
Foldbjerg et al. (Foldbjerg et al., 2011) reported dose dependent cytotoxicity and genotoxicity 
of polyvinylpyrrolidone coated Ag-np in human lung cancer cells. A strong correlation 
between the levels of ROS, mitochondrial damage and early apoptosis was observed. DNA 
damage induced by ROS was detected as an increase in bulky DNA adducts by 
32
P post 
labelling after Ag-np exposure, suggesting Ag-np mediates ROS-induced genotoxicity in the 
human lung cancer cells (Foldbjerg et al., 2011). Asharani and colleagues (Asharani et al., 
2009) showed in their study that human glioblastomas are susceptible to DNA damage with 
lack of recovery from Ag-np-induced stress. Ag-np is found affecting homeostasis of 
intracellular calcium transients and inducing chromosomal aberrations, either directly or 
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through activation of catabolic enzymes. These signalling cascades are believed to be 
responsible for the observed cytoskeleton deformations and ultimately to inhibit cancer cell 
proliferation (Asharani et al., 2009). In a study conducted by Sanpui et al. (Sanpui et al., 
2011), the use of significantly low concentration (0.33 µg/mL) of Ag-np impregnated in 
chitosan nanocarrier is reported a much superior approach in comparison to the use of free 
Ag-np in cancer treatment. The observed nuclear and morphological changes, up-regulation 
of caspase 3 expression and the increased production of intracellular ROS due to chitosan 
nanocarrier incorporated Ag-np treatment could augment the induction of apoptosis in human 
colon cancer cells (Sanpui et al., 2011). Gurunathan et al. (Gurunathan et al., 2009) proved in 
their research that Ag-np are anti-angiogenic. Angiogenesis is under normal circumstances 
involved in growth and wound healing. A loss of balance of the growth factors involved in 
angiogenesis causes the acceleration of diseases including malignancy, invasion and 
metastasis of cancer cells. The authors demonstrated that Ag-np could also inhibit vascular 
endothelial growth factor induced cell proliferation, migration, capillary-like tube formation 
of bovine retinal endothelial cells, and formation of new blood microvessels in a similar 
fashion as pigment epithelium-derived factor, a potent anti-angiogenic agent. They also found 
that Ag-np act as an anti-angiogenic agent by preventing the activation of PI3K/Akt 
signalling pathways (Gurunathan et al., 2009). Sriram et al. (Sriram et al., 2010) demonstrates 
the efficacy of biologically synthesised Ag-np as an antitumor agent using Dalton’s 
lymphoma ascites (DLA) cell lines in vivo. Ag-np decreased the volume of ascitic fluid in 
tumour-bearing mice by 65%. White blood cell and platelet counts in ascitic fluid from the 
tumour-bearing mice were brought to near-normal range after treated with Ag-np. DLA cell 
count was significantly reduced in tumour-bearing mice treated with Ag-np (Sriram et al., 
2010). Taken together, the ability of Ag-np to induce cyto- and genotoxicity, trigger ROS 
production, inhibit cancer cell proliferation, induce apoptosis, inhibit angiogenesis in cancer 
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cells and reduce tumour volume has made Ag-np a promising and cost-effective alternative 
for cancer therapy.  
 
1.15.2. Targeting DNA-PKcs repair pathway in cancer 
The function of DNA repair systems is to protect living organisms from the 
mutagenic and toxic lesions caused by DNA-damaging agents. Many current non-surgical 
cancer treatments target the integrity of cellular DNA, which is crucial to cell survival. As 
studies suggested that the balance between DNA damage and repair determines the ﬁnal 
therapeutic consequences, the activation of DNA repair machineries limits the therapeutic 
effectiveness of anticancer therapeutics (Rothenberg et al., 2003, Sharma et al., 2005). 
Furthermore, an elevated DNA repair response in tumour cells leads to chemoresistance or 
radioresistance towards these DNA-damaging agents. The defects in DNA repair pathways 
therefore can result in hypersensitivity to these agents (Zhou and Bartek, 2004, Longley and 
Johnston, 2005). Thus, researchers have focused on DNA repair interference as an adjuvant 
approach in combination therapy against cancer for combating intrinsic or acquired tumour 
radioresistance and chemoresistance.  
The NHEJ pathway, which is initiated by DNA-PK activation, is one of the most 
important DSB repair pathways in mammalian cells (Collis et al., 2004, Sancar et al., 2004). 
As evidenced by the observations that DNA-PK-deﬁcient mice are hypersensitive to ionizing 
radiation and topoisomerase II poisons, such as etoposide and doxorubicin, whereas, over-
expression of DNA-PKcs correlated with increased repair of ionizing radiation-, etoposide- 
and doxorubicin-induced DNA DSBs and with resistance to these agents (Collis et al., 2004, 
Deriano et al., 2005, Shinohara et al., 2005). Several selective DNA-PKcs inhibitors have 
been reported one of which is 2-(morpholin-4-yl)-benzo[h]chromen-4-one (NU7026). 
NU7026 is a competitive and highly selective inhibitor of DNA-PKcs, with a 60-fold greater 
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potency against this enzyme than PI 3-K, and inactive against both ATM and ATR. This 
agent sensitises cells to ionizing radiation and DNA damaging agents by inhibiting DSBs 
repair (Veuger et al., 2003). This indicates that the simultaneous treatment with anticancer 
agent that damage DNA and DNA-PKcs inhibitor that disrupts the NHEJ pathway could 
delay the occurrence of drug resistance and, thus, enhance the curative effectiveness of 
cancer therapeutics (Veuger et al., 2003, Willmore et al., 2004, Ding et al., 2006, Damia and 
D’Incalci, 2007). It is understandable that inhibition of DNA repair enzymes is associated 
with a high risk to produce damage to normal tissues. For this reason, DNA repair inhibitor 
strategy have been directed to enzymes/pathways activated in anticancer therapeutic treated 




Figure 1.15: Chemical structures of NU7026, a potent inhibitor of DNA-PKcs activity 




1.15.3. Targeting ATM repair pathway in cancer 
ATM is critical for cell cycle checkpoints, DNA repair and genome maintenance. 
Loss of function of ATM has been shown to result in increased cellular sensitivity to DNA-
damaging agents. Pharmacological inhibition of ATM effectively blocks radiation-induced 
phosphorylation of key ATM targets in human cancer cells, sensitising human cancer cells to 
ionizing radiation (Asare et al., 2011). Study showed transient inhibition of ATM kinase for 1 
hour, initiated 15 minutes after cellular irradiation, resulted in an accumulation of persistent 
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chromosome aberrations and increased cell death (White et al., 2010). ATM can also resolve 
DNA damage through mechanism involving sister chromatid exchange (SCE). SCE is 
believed to be a recombination-mediated mechanism for the repair of stalled and collapsed 
DNA replication forks, which arise naturally during DNA replication or can occur if cells are 
irradiated in G1 or S phase (Wilson Iii and Thompson, 2007). Transient inhibition of ATM 
activity after ionizing radiation abrogates ionizing radiation-induced SCE (White et al., 2010). 
It was recently reported that ATM kinase activity inhibition reduced basal serine 473 AKT 
phosphorylation, suggesting that the ATM kinase might regulate a protein phosphatase acting 
on AKT. Correspondingly, glioma cell migration and invasion were inhibited in vitro, 
suggesting that glioma growth and motility might be controlled by ATM via AKT (Golding 
et al., 2009). Apart from chemical inhibition of ATM activity, silencing of ATM gene can 
effectively radiosensitise human prostate cancer cells compared with nontransfected cells 
(Collis et al., 2003). Hence, ATM can be a prominent target in cancer therapy.  
 
 
Figure 1.16: Chemical structures of KU-60019, a potent inhibitor of ATM activity 




1.15.4. Targeting telomeres and telomerase in cancer  
It is widely accepted that cancer cells require unlimited replicative potential in order 
to generate tumours. This characteristic stands in marked contrast to the behaviour of normal 
somatic cells with finite numbers of cell divisions (Shay and Wright, 2000, Blasco, 
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2005). The most prominent hypothesis is that maintenance of telomere stability is required 
for the long-term proliferation of tumours (Shay, 1995, Shay and Wright, 1996b, a, Holt and 
Shay, 1999, Wright and Shay, 2001) and telomerase is key component of the telomere 
maintenance machinery (Kelland, 2005, Blackburn et al., 2006). Thus, transformed cells 
manage to escape from senescence and becoming immortal by activating telomerase to 
maintain telomeres (Bryan et al., 1995). This mechanism is often acquired in most human 
tumours for their ongoing proliferation.  
Targeting the telomere/telomerase machinery, hence, offers a novel and potentially 
broad-spectrum yet specific anticancer therapeutic strategy since telomerase is constitutively 
overexpressed in the vast majority of human cancers cells but not in adjacent normal cells 
(Kim et al., 1994, Shay and Bacchetti, 1997).  
Strategies that target telomere/telomerase include the direct targeting of telomerase 
components: hTERT or RNA component hTR. Anti-tumour effects have been observed in 
xenografted human tumours in mice treated with small molecule BIBR1532, an hTERT 
inhibitor and GRN163L, a thio-phosphoramidate oligonucleotide which target the template 
region of hTR. Expression of antisense to hTR inhibited telomerase activity, shortened 
telomere length and reduced tumour cell growth rate (Mo et al., 2003, Kelland, 2005).  
Alternatively, targeting telomeric DNA showed promising results in anti-cancer 
therapy. Telomeric DNA targeting agent, AS1410/BRACO19, induce the G-rich single-
stranded overhang of telomeric DNA to fold into 4-stranded G-quadruplex structures which is 
incompatible with telomerase function. This is followed by rapid telomere uncapping and 
senescence in cancer cells (Kelland, 2005). Another telomerase inhibitor, 3′-azido-3′-
deoxythymidine (AZT), is a reverse transcriptase that is preferentially incorporated into 
telomeric DNA, which in turn blocks the addition of nucleotides to the telomere ends by 
telomerase in xenograft human tumours models (Agarwal and A Olivero, 1997, Mo et al., 
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2003). Paclitaxel, a mitotic inhibitor used in cancer chemotherapy, caused telomere erosion 
and apoptosis. The combinational usage of AZT with paclitaxel enhanced the antineoplastic 
activity of paclitaxel in mice bearing xenograft human tumours without enhancing host 
toxicity (Saville et al., 1995, Mo et al., 2003, Ganguly et al., 2010). These findings 
demonstrate that combined use of agents targeting both telomere and telomerase yielded 
synergistic activity selective for tumours that depend on telomerase for telomere maintenance.  
The effectiveness of telomeres and telomerase targeting agents, however, are largely 
dependent upon initial telomere length. Telomeres are critically short in most tumours 
compared to normal tissues. In tumours possess relatively long telomeres, a substantial lag 
time is anticipated before antitumor activity is observed (Kelland, 2005). Germline cells and 
stem cells also possess longer telomeres than cancer cells and would therefore require more 
cycles of replication and cell division before crisis or replicative senescence is reached, as 
compared to cancer cells (Harley, 2008). Therefore, it is likely that treatment with telomerase 
inhibitors and telomeres targeting agents will effectively trigger senescence and apoptosis in 
cancer cells without adversely affecting normal somatic cells, germline cells and stem cells 
(Figure 1.12).  
 
1.16. Rationale  
The increasing application of Ag-np in health care and medical industry is largely 
associated with its antimicrobial activity. The novel properties of Ag-np which are small size, 
long term stability and ease of surface manipulation have made them an excellent candidate 
and alternative for cancer treatment. The emergence of silver nanomedicine is expected to 
circumvent the drawbacks of conventional anticancer therapeutics which include lack 
selectivity for cancerous cells, development of multidrug resistance, unable to cross blood 
brain barrier and limited aqueous solubility and bioavailability. 
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However, like other toxic agents, Ag-np are both cytotoxic and genotoxic. Research 
reports on the adverse effects of Ag-np have focused on cytotoxicity of these particles and the 
findings have mostly limited to oxidative stress induction. Genotoxicity of Ag-np is less 
explored. From toxicological endpoint studies, Ag-np exposure can readily disrupt the 
integrity of the genome with DSBs induction as the most prominent and deleterious DNA 
damage in both normal human cells and cancer cells (Ahamed et al., 2008, AshaRani et al., 
2008b). However, no study has reported the DNA repair responses and the associated 
molecular mechanisms involved following Ag-np treatment. The importance of DNA repair 
proteins in particular DNA-PKcs and ATM, two very important caretakers of genome, in 
DNA repair and genome stability maintenance in the context of silver nanotoxicity has yet to 
be investigated. It has been shown that the activation of DNA repair mechanisms in cancer 
cells confers resistance towards chemotherapeutics and therefore reduces the efficacy of these 
anticancer drugs. Hence, thorough understanding of DNA damage and repair responses of 
Ag-np treatment is essential for fostering the development of silver nanomedicine.     
Here, we have synthesised, characterised and purified nanomaterials used in this 
studies to ensure consistency and reproducibility of results. Three main objectives proposed 
are: 
 
1. To identify and understand the underlying mechanisms in particular DNA damage and 
repair responsible for cytotoxic effect of Ag-np in mammalian cells.  
2. To investigate signalling pathways and mechanisms associated with anti-neoplastic 
activity of silver nanoparticles in human cancer cells. 
3. To examine combinatorial effectiveness of silver nanoparticles treatment and DNA repair 




The importance of DNA repair proteins in particular DNA-PKcs and ATM in altering 
cytotoxicity and genotoxicity of Ag-np were evaluated in vitro using DNA repair deficient cell 
lines and the results were compared with DNA repair proteins inhibition in mammalian cells. 
Mechanistic insight and molecular interplay of these DNA repair factors with other DNA 
damage response pathways such as JNK and telomere-telomerase pathway were studied. 
Combination of Ag-np treatment and DNA repair proteins inhibition for improved anti-
proliferative effects of Ag-np on various tumour cells were investigated.  





















2. Materials and methods  
2.1. Synthesis of Polyvinyl Alcohol (PVA) capped Ag-np 
PVA (150 mg, MW: 16,000 g/mol, Sigma-Aldrich, USA) was dissolved in 15 ml of 
boiling ultrapure water. Ag-np capped with PVA were synthesised by reducing AgNO3 
solution (1.5 mM) with 0.02 g of NaBH4 (Sigma-Aldrich, USA), followed by the addition of 
PVA solution, under constant stirring at 500 rpm at room temperature. A colour change of the 
solution to light brown colour indicated Ag-np formation. Stirring was continued for 2 hours. 
The nanoparticle solution was centrifuged at 25,000 rpm for 1 hour and resuspended in 
ultrapure water to remove traces of reducing agent and unbound PVA. The washing was done 
twice. The final pellet was lyophilised overnight (Labconco, USA). 
 
2.2. Characterization of Ag-np 
The lyophilised Ag-np pellet was resuspended in ultrapure water and sonicated to 
prepare a homogenous nanoparticle suspension. The shape of the nanoparticles was 
determined by transmission electron microscope (JEOLJSM1220, JAPAN) analysis. Presence 
of Ag-np was confirmed by performing Ultraviolet (UV) visible spectroscopy (Agilent, USA). 
Additionally, a size and charge distribution of the pure nanoparticle suspension was recorded 
on Zetasizer NanoZS (Malvern, UK) and analysed with Dispersion Technology Software 
(DTS, Malvern, UK). The elemental composition of nanoparticles synthesised was 





2.3. Cells and culture conditions 
All cells were grown in a humidified 5% CO2 incubator at 37°C and maintained in a 
log phase. All supplements were purchased from GIBCO, USA unless otherwise stated.  
 
2.3.1. Normal human cells 
Primary human diploid foetal lung fibroblasts, IMR-90 and MRC-5 were purchased 
from Coriell Cell Repositories, USA and were maintained in modified eagles medium with 
glutamine (MEM, Gibco, Invitrogen, USA) supplemented with 15% foetal bovine serum 
(FBS), 2% essential amino acids, 1% each of non-essential amino acids, vitamins, and 1% 
(100 U/mL) of penicillin streptomycin.  
 
 
2.3.2. Human cancer cells 
Human glioblastoma cells, M059K (CRL-2365; ATCC, USA), M059J (CRL-2366; 
ATCC, USA) and U251 cells (generously provided by Dr. Masao Suzuki, National Institute 
of Radiological Sciences, Chiba, Japan) were grown in Dulbecco’s modified eagles medium 
(DMEM, Sigma-Aldrich, USA) supplemented with 10% FBS and 1% penicillin-streptomycin. 
MO59K cells express normal level of DNA-PKcs while MO59J cells are deficient in DNA-
PKcs expression and activity (Lees-Miller et al., 1990). Human breast adenocarcinoma cells, 
MDA-MB-231 (HTB-26) and MCF-7 (HTB-22; ATCC, USA) were maintained in Roswell 
Park Memorial Institute 1640 (RPMI 1640) medium supplemented with 10% FBS and 1% 
penicillin-streptomycin.  
 
2.3.3. Chinese hamster ovarian cells 
Chinese hamster ovarian cells, CHO AA8 and CHO V33 (kindly provided by Dr. Paul 
Wilson, Lawrence Livermore National Laboratory, Livermore, CA, USA) were cultured in 
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MEM alpha medium with glutamine, ribonucleosides, and deoxyribonucleosides (MEM α) 
supplemented with 10% FBS and 1% penicillin-streptomycin. CHO AA8 cells are DNA-
PKcs proficient and CHO V33 cells are deficient in DNA-PKcs expression and activity 
(Natarajan et al., 2008).  
 
2.4. Cell treatment conditions 
2.4.1 Ag-np treatment 
Stock solutions of nanoparticles (5 mg/mL) were prepared in autoclaved distilled 
water and diluted to the required concentrations using the complete cell culture medium. 
Appropriate concentrations of Ag-np stock solution were added to the cultures and incubated 
for 48 hours for short-term treatment, 4 days for hTERT, TRF2 expression or 14 days for 
Terminal Restriction Fragment (TRF) assay.  
 
2.4.2. DNA repair inhibitors treatment 
2.4.2.1 DNA-PKcs inhibition treatment 
Stock solution of an organic based ATP-competitive and selective inhibitor of DNA-
PKcs, NU7026 (Calbiochem, USA) were prepared in dimethyl sulfoxide (DMSO, 
AppliChem, Germany). Working concentration at 10 µM were made from the stock solution 
using complete cell culture medium, as this concentration, NU7026 is non-cytotoxic to cells 
(Willmore et al., 2004) while able to completely inhibit DNA-PKcs activity and has no 
specificity for other PI-3 kinase such as ATM and ATR (Willmore et al., 2004, Nutley et al., 






2.4.2.2 ATM inhibition treatment 
Inhibitor of ATM kinase, 2-((2S,6R)-2,6-dimethylmorpholino)-N-(5-(6-morpholino-
4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl)acetamide, KU-60019, is effective at blocking 
ATM-mediated phosphorylation of downstream targets. As reported, KU-60019 is highly 
specific for ATM and has no affinity for DNA-PKcs and ATR.  KU-60019 was dissolved in 
DMSO and working concentration at 10 µM was made from the stock solution using 
complete cell culture medium. Cells were treated with KU-60019 1 hour prior to Ag-np 
treatment. 
 
2.5. Cell viability assays  
2.5.1. Measurement of ATP content  
Following treatment, the viability of the treated cells was measured using CellTiter-
Glo® luminescent cell viability assay (Promega, USA) following manufacturer’s instructions. 
Equal volume of reagent mixture was added to the medium with treated cells. The reagent 
mixture contains lysis buffer to break cell membrane, resulting in ATP release and ATPase 
inhibitors in the reagent mixture stabilise the released ATP in the medium. A luminescence 
signal is generated based on the conversion of beetle luciferin to oxyluciferin by a 
recombinant luciferase in the presence of ATP.  The observed luminescence is proportional to 
the quantity of ATP in the cells. The assay was performed in white opaque walled 96-well 
plates (Corning, Costar, USA) for measurement of luminescence using plate reader (Tecan, 
Switzerland).  
 
2.5.2. Trypan blue exclusion assay 
Cells were harvested after treatment and cell pellets were resuspended in 1 ml of 1 × 
phosphate buffered saline (PBS; 1
st
 Base, Singapore). 1 part of 0.4% trypan blue (Sigma-
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Aldrich, USA) was mixed with 1 part of cell suspension. The mixture was incubated 
approximately 3 minutes at room temperature and 10 µl of the trypan blue/cell mixture was 
applied to a haemocytometer. The number of viable cells on the haemocytometer was then 
scored under the Olympus CK40 inverted light microscope. The viable cells were unstained 
whereas the nonviable cells stained blue. The cell concentration per ml was calculated using 




2.6. Scratch wound healing cell migration assay 
The cells were grown to 80% confluency in 100 mm tissue culture dish (Falcon, 
USA). Cells were washed in 1 × PBS. Several straight lines parallel to each other were 
scratched in one direction on the cell monolayer with a fresh autoclaved 200 µl pipette tip 
across the culture dish. The resulting gap distance therefore equals to the outer diameter of 
the end of the tip. After scratching, the cell monolayer was rinsed twice with 1 × PBS to 
remove the detached cells. Fresh medium with particular doses of Ag-np for various cells 
were then added to the culture dish and incubated for 48 hours. After 48 hours incubation, 
used culture media were removed. Cells were washed twice with 1 × PBS. Images of the cell 
monolayer were captured on Olympus CK40 inverted light microscope (Olympus, USA) 
using Olympus C-7070 camera (Olympus, USA).  
 
2.7. Colony formation assay 
Cells were subjected to treatment for 14 days. To determine the colony formation 
capacity, five thousand treated cells were re-seeded and allowed to grow for another 14 days 
in fresh media without treatment. Cells were then rinsed once with 1 × PBS and incubated 
with crystal violet solution (0.75% crystal violet (Sigma, USA) in 50% ethanol (Merck, 
Germany): distilled water with 1.75% formaldehyde (Merck, USA) and 0.25% NaCl (Merck, 
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USA)), which stains DNA by binding electrostatically to nuclear proteins, for 45 minutes at 
room temperature.  The cells were rinsed thrice with 1 × PBS to remove traces of crystal 
violet solution and air dried overnight at room temperature. Images of the colonies formation 
were captured using Olympus C-7070 camera.     
 
2.8. Fluorescence activated cell sorting (FACS) analysis  
Following treatment, cells were harvested, washed in 1 × PBS and fixed in 3:1 70% 
ethanol:PBS and stored at −20˚C. Fixed cells were then washed with 1 × PBS and stained 
with propidium iodide (PI, Sigma-Aldrich, USA):RNaseA (Roche, USA) solution (2 mg 
propidium iodide and 2 mg RNaseA/100 ml in 1 × PBS). Samples were analysed by flow 
cytometry (FACS Calibur™, USA) at 488 nm excitation λ and 610 nm emission λ. A total of 
10,000 cells were collected and data obtained was analysed using Summit 4.3 software. 
 
2.9. DNA damage assays  
2.9.1. Alkaline single cell gel electrophoresis (SCGE Comet) assay 
DNA damage induced was detected using alkaline single-cell gel electrophoresis. 
Treated cells were harvested by trypsinisation and washed in 1 × PBS and resuspended in 
Hank's Balanced Salt Solution (HBSS) with 10% DMSO with 0.5 M 
ethylenediaminetetraacetic acid (EDTA, 1
st
 Base, Singapore). The cells were then suspended 
in 0.7% low melting point agarose at 37°C (Conda, Spain) and immediately layered onto 
comet slides (Trevigen, USA). The cell-gel mixture were left to solidify at 4°C for 15 
minutes and cells were lysed in lysis solution containing 2.5 M NaCl, 100 mM pH 8.0 EDTA, 
10 mM Tris-HCL, 1% Triton-X at 4°C for 1 hour. The samples were then subjected to 
denaturation in chilled alkaline electrophoresis buffer (pH 13.0 –13.7) for 40 minutes. 
Electrophoresis was subsequently carried out for 20 minutes. Slides were immersed in 
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neutralization buffer (500 mM Tris-HCL, pH 7.4), dehydrated, dried and stained with SYBR 
Green dye (Trevigen, USA). A total of 50 nuclei per sample were randomly selected and 
scored with Comet Analysis Software (Metasystems, Germany). The images were captured 
using Zeiss Axioplan 2 imaging fluorescence microscope (Carl Zeiss, Germany) equipped 
with triple band filter. The tail moments of the nuclei which corresponded to the fraction of 
the DNA in the tail of the comet, were measured as a function of DNA damage.  
 
2.9.2. Cytokinesis blocked micronucleus (CBMN) analysis 
Micronucleus assay, an established method to determine genomic instability was 
carried out to evaluate the susceptibility of cells to Ag-np induced chromosomal damage 
endpoint. The cells were treated with Ag-np for 48 hours and further incubated with 
cytochalasin B (Sigma-Aldrich, USA, 4 μg/ml) for 22 hours in fresh medium. Micronuclei 
originate from either lagging chromosomes or chromosome fragments which excluded from 
daughter nuclei following nuclear division prior to cytokinesis. Cytochalasin B was added to 
stop dividing cells from performing cytokinesis, thus allowing cells that have completed one 
nuclear division to be recognised by their binucleate appearance. Cells were harvested and 
centrifuged at 800 rpm for 8 minutes. The pellet was resuspended in cold 75 mM potassium 
chloride (KCl) for hypotonic swelling and centrifuged at 800 rpm for 8 minutes. Cells were 
then resuspended in Carnoy’s fixative (3:1 methanol: glacial acetic acid) with 6-7 drops of 
formaldehyde to fix the cytoplasm and centrifuged at 800 rpm for 8 minutes. Fresh Carnoy’s 
fixative was added and fixed cells were stored in 4°C. Aged cells were then dragged onto a 
clean, dry and stained with acridine orange (30 μg/ml) that allows differential staining of 
nuclear material (yellow/green) and cytoplasm (orange/red). One thousand binucleated cells 
were scored under Zeiss Axioplan 2 imaging fluorescence microscope equipped under FITC-
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TRITC filter, and the number of micronuclei was recorded. All other reagents are from 
Merck, Germany.  
 
2.9.3. Immunofluorescence staining for γ-H2AX, p-DNA-PKcs, p-ATM and telomere 
dysfunction 
2.9.3.1. γ-H2AX foci assay 
Approximately 2 × 10
4
 cells were seeded on cover slip in 6-well plates (Greiner 
BioOne, USA) 24 hours prior treatment. Following treatment, cells were washed once with 1 
× PBS, fixed with 4% formaldehyde for 15 minutes and permeabilised with 0.2% Triton-X 
for 5 minutes. Cells were blocked in 3% bovine serum albumin (BSA; Sigma-Aldrich, USA) 
for 60 minutes at room temperature. Cells were incubated in monoclonal γ-H2AX antibody 
(anti-phospho-H2A.X (Ser139), Millipore, USA, 1:300 3% BSA) for 60 minutes at room 
temperature. Unbound antibody was removed by washing three times with 1 × PBS and 
further incubated in secondary antibody conjugated with Fluorescein isothiocyanate (FITC, 
Santa Cruz Biotechnology, USA, 1:600 FITC/ 3% BSA) for 60 minutes. Cells were washed 
three times with 1 × PBS and mounted with slow fade DAPI. Fifty cells per sample were 
captured randomly with Zeiss Axioplan 2 imaging fluorescence microscope equipped with 
appropriate filters. Number of foci in each cell was recorded. 
 
2.9.3.2. Protein co-localisation assay  
The cells were washed once with 1 × PBS, fixed with 4% formaldehyde for 15 
minutes and permeabilised with 0.2% Triton-X for 5 minutes. Cells were then blocked in 3% 
BSA for 60 minutes at room temperature. Mixture of monoclonal γ-H2AX (anti-phospho-
H2A.X (Serine 139), Millipore, USA, 1:300 in 3% BSA) and phosphorylated DNA-PKcs or 
phosphorylated ATM antibody (anti-phospho-DNA-PKcs (Serine 2056), Abcam, UK; anti-
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phospho-ATM (Serine 1981), GeneTex, USA, 1:300 in 3% BSA) were added to the cells and 
incubated for 60 minutes at room temperature. Unbound antibody was removed by washing 
the cells three times with 1 × PBS and cells were further incubated in secondary antibody 
conjugated with FITC against γ-H2AX and Texas red (TR) against phospho DNA-PKcs or 
phospho ATM (FITC and TR, Santa Cruz Biotechnology, USA, 1:600 FITC/ 3% BSA) for 
60 minutes. Cells were then washed three times with 1 × PBS and mounted with slow fade 
DAPI. Fifty cells per sample were captured randomly with Zeiss Axioplan 2 imaging 
fluorescence microscope equipped with FITC, TR and DAPI filters. Number of co-localised 
foci on each cell were enumerated.  
 
2.9.3.3. Immunofluorescence in situ hybridisation  
For Immunofluorescence In Situ Hybridisation (Immuno-FISH), immunostaining of 
γ-H2AX was performed as described above and followed by fixation 15 minutes in 4% 
formaldehyde, incubation in 0.2% Triton X at 4°C for 10 minutes and followed by 30 
minutes blocking with TBS-T. Cells were then hybridised with the telomere specific peptide 
nucleic acid (PNA) probes labelled with Cy-3. Cells were then counterstained with slow fade 
DAPI. Fifty cells per sample were captured randomly with Zeiss Axioplan 2 imaging 
fluorescence microscope equipped with FITC, Cy-3 and DAPI filters. The number of co-
localisation of γ-H2AX and Cy-3 signals were scored manually.  
 
2.10. Protein expression studies 
2.10.1. Western blot analysis  
Total cellular protein was extracted by lysing cells in 50-200 µL lysis buffer (10 mM 
Tris-HCl [pH 7.4], 1% sodium dodecyl sulphate (SDS), 1 mM sodium-ortho-vanadate in 
distilled H2O) for 60 minutes at 4°C. The whole cell lysate was recovered by centrifugation at 
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13,200 rpm for 60 minutes at 4°C. The supernatants were collected. Protein concentrations 
were determined using Quick Start™ Bradford Protein Assay (Bio-Rad, USA) with BSA as a 
standard. One hundred micrograms protein from each sample was resolved on SDS 
polyacrylamide gels (p-DNA-PKcs, DNA-PKcs, p-ATM, ATM and h-TERT proteins were 
ran in 7.5% gels; TRF2, JNK, c-jun and c-Myc proteins were ran in 10% gels; γ-H2AX 
protein were ran in 15% gels) and transferred onto nitrocellulose membranes (Bio-Rad, USA). 
Membranes were blocked for 60 minutes with 5% non-fat milk in TBS-T (0.1% Tween-20 
(Sigma-Aldrich, USA) in 1 × TBS (0.1 M NaCl, 0.1 M Tris pH 7.4 in ddH2O) (All purchased 
from NUMI, National University of Singapore). Subsequently, membranes were 
immunoreacted overnight with primary antibodies against γ-H2AX (anti-phospho-H2AX 
(Serine 139), Millipore, Germany, 1:1000), phosphorylated ATM (anti-phospho-ATM 
(Serine 1981), GeneTex, USA, 1:1000) phosphorylated DNA-PKcs (anti-phospho-DNA-
PKcs (Serine 2056) , Abcam, UK, 1:1000), phosphorylated JNK1 (phospho JNK1, Cell 
Signalling Technology, USA, 1:1000), hTERT (Epitomics, USA, 1:1000), ATM (GeneTex, 
USA, 1:1000), c-Myc (1:1000), DNA-PKcs (1:1000), JNK1 (1:1000), c-Jun (1:1000), TRF2 
(1:2000), beta actin (Santa Cruz Biotechnology, USA, 1:5000) at 4°C. The membrane was 
then incubated in secondary antibody conjugated to horseradish peroxidase for 60 minutes at 
room temperature. The protein bands were visualised using chemiluminescence substrate 
(Chemiluminescence Reagent Plus, Perkin Elmer, USA) followed by exposure to X-ray film 
(Pierce, USA). 
 
2.11. Telomere restriction fragment (TRF) length analysis 
DNA extraction was performed using DNeasy Tissue Kit (Qiagen, USA) and 
following protocols provided by the manufacturer. The telomere restriction fragment (TRF) 
length analysis assay was performed using Telo-TAGGG Length Assay Kit (Roche Applied 
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Science, USA). Two micrograms of pure genomic DNA was digested with Hinf1 and Rsa1 
restriction enzymes for 2 hours at 37°C. Whole genomic DNA except the sub-telomeric and 
telomeric regions was digested by these restriction enzymes. Digested DNA fragments were 
separated by gel electrophoresis at 60 V for 3 hours in 0.8% agarose gel, transferred via 
overnight Southern blot onto a nylon membrane and cross-linked onto the membrane using a 
UV cross-linker (Stratagene, USA). Telomere restriction fragments were hybridised with 
telomere-specific digoxigenin (DIG)-labelled probe and incubated with anti-DIG alkaline 
phosphatase and tetramethylbenzidine according to manufacturer’s protocol. The 
chemiluminescence signals were scanned by the Kodak Gel imaging system and analysed by 
the Kodak imaging software to calculate the quantitative measurements of the mean TRF 
length. 
 
2.12. Statistical analysis 
Statistical analyses of the values for all experiments are expressed as mean ± standard 
error of at least three independent experiments. The data were analysed using Student’s t-test 
(Microsoft Excel, Microscoft corporation, USA) where statistical significance was calculated 















3. Enhanced genotoxicity of silver nanoparticles in DNA repair deficient 
mammalian cells  
3.1. Background 
Ag-np currently have the highest degree of commercialization due to their anti-
microbial potential (Ip et al., 2006), which made them component of wound-dressing, 
bandages, catheters, and plenty of other medical devices. Ag-np have also been shown to 
have less chance of drug resistance (Barbu et al., 2009). Ag-np have been the centre of 
attention in nanotechnology development for several other reasons too. Ag-np can be 
synthesised easily through chemical reaction by reducing the silver salt using a reducing 
agent to produce small Ag-np and a surfactant to prevent unwanted agglomeration of Ag-np 
(Wiley et al., 2005). Ag-np display long-term stability at room temperature in aqueous 
medium with small changes in morphology, shape, and size (Pinto et al., 2010). These 
properties are particularly important for Ag-np to control their fate, transport, and 
bioavailability in both in vitro and in vivo models.  
Apart from the ease of synthesis and superior optico-chemical properties, Ag-np 
causes significant cytotoxicity and genotoxicity which are closely associated with resulting 
oxidative stress and inflammatory responses (AshaRani et al., 2008b, Carlson et al., 2008, 
Asharani et al., 2009). The cytotoxicity of Ag-np is an active research topic while 
genotoxicity is comparatively much less explored. Evidence from published reports has 
shown that Ag-np induces DNA damage (DSBs) and chromosomal aberrations such as 
acentric and dicentric chromosomes, chromosomal fusions, and fragments (Ahamed et al., 
2008, AshaRani et al., 2008b, Asharani et al., 2009). Up-regulation of DNA damage-
signalling proteins, RAD51 and γ-H2AX, indicative of DNA damage signalling events, most 
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notably DSBs, were recorded in Ag-np exposure (Ahamed et al., 2008, AshaRani et al., 2012). 
However, these findings were primarily focused only on the toxicological endpoints. The 
complex molecular interplay triggering the onset and downstream signalling cascades in 
response to Ag-np induced DNA damage, in particular, DNA damage repair are largely 
unexplored.  
DNA-PK functions as a notable caretaker of genome (Lees-Miller and Meek, 2003) 
and mediates NHEJ pathway, the main DNA repair pathway responsible for DSB repair in 
mammalian cells (Hefferin and Tomkinson, 2005, Sonoda et al., 2006). In the current study, 
we provide mechanistic insights on Ag-np induced DNA damage and repair in mammalian 

















3.2. Results  
3.2.1. Characterization of Ag-np.   
Characterization of Ag-np was carried out in order to determine the shape, size, state 
of dispersion, absorbance, and charge which are major determinants of nanoparticle bio-
kinetics and toxicity. Transmission electron microscopy analysis revealed that the 
nanoparticles employed in this study were spherical in shape and mono-dispersed (Figure 
3.1A). UV–vis spectroscopy showed an absorption maximum at around 400 nm indicating a 
stable homogenous nanoparticle suspension with narrow size distribution (Figure 3.1B). The 
size distribution analysis showed nanoparticles of size between 12 and 40 nm with an average 
diameter of 20 nm (Figure 3.1C). Zeta potential is a measurement of the charge of the 
synthesised nanoparticles. The Ag-np has zeta potential value of −0.309 ± 0.13mV (Figure 
3.1D). The elemental composition of the nanoparticles synthesised was further confirmed 
through elemental analysis. Data indicated that the Ag-np used in our investigations contain 






























          
 
Figure 3.1: Ag-np characterization. (A)Typical transmission electron microscopy image, 
(B) UV-visible spectrum, (C) size distribution, (D) zeta potential, and (E) elemental analysis 
of Ag-np reconstituted after lyophilisation. TEM images were captured with JEOLJSM 1220. 






3.2.2. Cells lacking functional DNA-PKcs are more sensitive to Ag-np induced reduction 
in cell viability. 
To understand how DNA-PKcs affects viability of cells under the influence of Ag-np, 
luminescence based cell viability assay was performed on Ag-np treated DNA-PKcs 
proficient and deficient cells. To further validate the role(s) of DNA-PKcs, cells were treated 
with DNA-PKcs inhibitor, NU7026, and the results were compared with DNA-PKcs deficient 
cells. Normal human cells, IMR-90, showed less susceptibility to Ag-np induced cell damage 
(Figure 3.2A). Interestingly, the human DNA-PKcs proficient glioblastoma cells, MO59K, 
displayed significant dose-dependent decrease in cell viability after treatment with Ag-np. 
Human DNA-PKcs deficient glioblastoma cells, MO59J, were less sensitive to Ag-np 
exposure and showed no obvious decrease in cell survival with increasing doses (Figure 
3.2B).  DNA-PKcs deficient Chinese hamster cells, CHO V33 cells, showed greater reduction 
in cell viability than DNA-PKcs proficient CHO AA8 cells at all doses (Figure 3.2C). In 
IMR-90, MO59K, and CHO AA8 cells pre-treated with NU7026, there was a significant 
decrease in cell viability compared to their respective proficient cells without NU7026. These 
observations suggest a potential role played by DNA-PKcs in supporting cell survival in 
response to Ag-np treatment. 
In addition, we have observed that MO59K cells are more susceptible to Ag-np as 
compared to IMR-90 cells, which are the representatives of cancer and normal cell population, 
respectively. The difference in survival between the IMR-90 and MO59K cells following Ag-















Figure 3.2: Cell viability in mammalian cells following Ag-np treatment. Cell viability of 
(A) IMR-90 cells, (B) MO59K and MO59J cells, and (C) CHO AA8 and CHO V33 cells 
after 48 hour-treatment with Ag-np at different concentrations is shown. The cell viability 
percentage was normalised against the untreated controls (0 μg/ml) for Ag-np treatment alone 
or DMSO control (0 μM) for each cell type pre-treated with NU7026 (10 μM). The values 
represent the mean ± standard error of three sets of independent experiments.* Denotes p 
<0.05; ** denotes p <0.01; and *** denotes p <0.001 as obtained using Student’s t -test, where 






3.2.3. Lack of functional DNA-PKcs shows compromised repair capacity for Ag-np 
induced DNA damage. 
Earlier reports have demonstrated a critical role for DNA-PKcs in DNA repair via 
NHEJ pathway (Jackson, 2001, Jackson, 2002, Uematsu et al., 2007). We examined whether 
NHEJ pathway is responsible for the repair of the DNA damage induced by Ag-np with 
regards to the status of DNA-PKcs in mammalian cells. Single-cell gel electrophoresis (also 
known as Comet assay) under alkaline condition (pH 13) was used to determine the DNA 
damage induced by Ag-np. DNA damage such as DSBs, single-strand breaks, and alkali 
labile sites were measured using Comet assay. Representative images of comet analysis are 
shown in Figures 3.3Ai, ii. Nuclei with undamaged DNA appear round; nuclei with damaged 
DNA result in DNA fragments which migrate faster during gel electrophoresis and give rise 
to a “tail.” The tail moment (product of tail length and fraction of DNA) was used as a 
measure of DNA damage. As presented in Figure 3.3B, IMR-90 cells are less susceptible to 
Ag-np as data show minimal increase in DNA damage (1.5 μm) after 48 hour-treatment. The 
tail moment in MO59K cells increased from 0.9 to 3.3 μm after treated with Ag-np. To our 
surprise, we observed that MO59J cells did not show severe DNA damage after Ag-np 
exposure. Instead, the DNA damage in MO59J cells (3.3 μm, p <0.05) are comparable to 
MO59K after Ag-np exposure. This observation is in agreement with our cell viability data 
for MO59J cells which showed lesser susceptibility to Ag-np. CHO V33 showed much higher 
total DNA damage induced (21 μm) as compared to CHO AA8 (3.3 μm). Induction of DNA 
damage by Ag-np in IMR-90 cells was increased significantly after pre-treatment of NU7026 
(4 μm, p <0.01; Figure 3.3B). MO59K cells pre-treated with NU7026 showed greater DNA 
damage (5.8 μm, p <0.05) compared to MO59K cells without NU7026 treatment. Pre-
treatment with NU7026 renders higher sensitivity in CHO AA8 cells to Ag-np induced DNA 
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damage (9.3 μm). Collectively, the data imply an essential role played by DNA-PKcs in 
DNA repair upon Ag-np exposure. 
To investigate whether the Ag-np induced DNA damage could be recovered, Ag-np 
containing media were removed 48 hours post treatment and following which cells were 
incubated with fresh media without Ag-np for another 48 hours (Figure 3.3B). Our data 
showed that the DNA damage was repaired (0.9 μm) in IMR-90 cells following 48 hours of 
recovery. DNA damage was persisted in both MO59K cells (3.6 μm, p <0.01) and MO59J 
cells (3.2 μm, p <0.05). In CHO AA8 cells, the DNA damage was enhanced significantly 
after recovery (10.4 μm, p <0.01) meanwhile we observed that the DNA damage remained 
high in CHO V33 cells (18.8 μm, p <0.01). Similarly, IMR-90 cells pre-treated with NU7026 
showed recovery from DNA damage (1.3 μm) whilst DNA damage was enhanced in both 






















Figure 3.3: Induction of DNA damage in Ag-np treated cells. DNA damage as measured 
by the Comet assay in different cell types following 48 hours treatment with Ag-np (100 
μg/ml) and NU7026 (10 µM). (A) Representative of SYBR Green-stained comets prepared 
from control (i) and Ag-np treated (ii) MO59K cells. Magnification=20×. (B) Mean tail 
moment (μm) represents the damage distribution in the attached cells. Mean ± standard error 
of three sets of independent experiments is shown. * Denotes p <0.05 and ** denotes p <0.01 

















3.2.4. DNA-PKcs deficiency or inhibition increases Ag-np induced genome instability. 
The activities of repair pathways and their coordination with other cell functions are 
regulated by a DNA damage-signalling network. Dysregulation of this network would 
significantly impair the coordinated effort to repair DNA damage thus can contribute to 
genomic instability (Shen, 2011). In the present study, we show that the DNA repair was 
compromised when functional DNA-PKcs was lacking in the cells. To examine whether Ag-
np induce genome instability when the repair network is dysregulated in the absence of 
functional DNA-PKcs, we used micronuclei induction, a chromosome instability marker, to 
assess if loss or inhibition of DNA-PKcs renders cells more susceptible to Ag-np induced 
genomic instability. Micronuclei in the resulting binucleated cells were scored following 
exposure to Ag-np. Representative images of binucleated cells with and without micronuclei 
are shown Figure 3.4Ai, ii respectively.    
As shown in Figure 3.4B, the percentage of micronuclei in IMR-90 cells was 
increased from 1.4 to 2.7% after Ag-np treatment. There is no significant increase in the 
percentage of micronuclei in IMR-90 cells pre-treated with NU7026 followed by Ag-np 
treatment (2.9%) indicating the fact that normal cells were able to safeguard the stability of 
genome even without functional DNA-PKcs. In Ag-np treated MO59K cells, there was 2.4-
fold increase in percentage of micronuclei from 1.3 to 3.1% (p <0.05). MO59K cells pre-
treated with NU7026 showed 4.2-fold after Ag-np exposure, compared with that of the 
control group, which is a higher increase in micronuclei percentage (5.4%) compared to Ag-
np treatment alone. In agreement with comet data, there was no increase in micronuclei 
percentage in MO59J cells without (3.5%) and with Ag-np treatment (3.2%). The loss of 
DNA-PKcs sensitised CHO V33 cells to Ag-np and resulted in higher increase in micronuclei 
percentage from 4.7 to 8.1% compared to CHO AA8 cells from 1.3 to 1.6% micronuclei. 
CHO AA8 cells pre-treated with NU7026 are more susceptible to genome instability with 
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higher percentage of micronuclei (3.8%, p <0.05) after Ag-np exposure compared to Ag-np 
treatment alone. The results observed in CHO V33 cells, NU7026 pre-treated MO59K cells 
and CHO AA8 cells following Ag-np treatment imply that both Chinese hamster cells and 
human brain cancer cells are sensitised to Ag-np induced genome instability when they lack 
functional DNA-PKcs. 
              
 
    
 
Figure 3.4: Induction of micronuclei in cells following Ag-np treatment. Micronuclei as 
measured in different cell types following 48 hour-treatment with Ag-np (100 μg/ml) and 
NU7026 (10 µM). (A) Representative image of binucleated MO59K cells without (Ai) and 
with micronuclei (Aii). White arrow (Aii) indicates the micronucleus formed among the 
binucleated cells. Cells and nuclei were stained with acridine orange (30 μg/ml). 
Magnification=60×. (B) Data from CBMN show chromosomal aberrations. The data 
represent 1000 binucleated cells. Mean ± standard error of three sets of independent 






3.2.5. Ag-np induced DNA DSBs in mammalian cells. 
Earlier studies have shown that metallic nanoparticles can induce DNA damage either 
directly through physical assault (Ahamed et al., 2008, AshaRani et al., 2008b, Asharani et al., 
2009) or indirectly by triggering the production of  oxidative stress (Asharani et al., 2009) or 
both. Studies have also indicated that DNA damage and repair proteins responsible for DSBs 
were shown to be up-regulated in response to Ag-np treatment (Jiao and Tingting, 2009). Our 
results reveal that total DNA damage is greater in Ag-np treated DNA-PKcs deficient or 
inhibited cells than DNA-PKcs proficient cells or normal mammalian cells. Therefore, we 
looked at DSBs in the cells since DNA-PKcs plays pivotal role in DSB repair in mammalian 
cells. As previously reported, DSBs can induce phosphorylation of histone H2AX at serine 
139 (Rogakou et al., 1998, Rogakou et al., 1999). The phosphorylated form of histone H2AX 
is termed γ-H2AX and it is considered as an excellent marker for DSBs since γ-H2AX is one 
of the first proteins foci form at the site  of DSBs upon induction (Rogakou et al., 1998, 
Rogakou et al., 1999). Immunofluorescence based γ-H2AX foci assay and western blot 
analysis had been carried out to assay DSBs. The results showed that multiple γ-H2AX foci 
were induced indicating the presence of DSBs.  Our data demonstrate that there was an 
increase in the number of γ-H2AX foci in the nuclei of treated cells (Figure 3.5Aii) 
compared to untreated control cells (Figure 3.5Ai). In IMR-90 cells, number of γ-H2AX foci 
increased after 48 hour-treatment but decreased following 48 hours of recovery in fresh 
medium. Similarly, in IMR-90 cells pre-treated with NU7026, highest number of foci were 
observed at 24 hour post treatment and decreased thereafter. This implies that normal human 
cells are capable of repairing DSBs even when DNA-PKcs activity was chemically inhibited 
(Figure 3.5B). In contrast, there was time dependent increase in γ-H2AX foci in MO59K 
cells and CHO AA8 cells. The number of foci has persisted or further increased significantly 
after 48 hours of recovery indicating persistence of DSBs. In addition, higher number of foci 
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detected in MO59K cells and CHO AA8 cells infers higher susceptibility of these cells to Ag-
np induced DSBs compared with IMR-90 cells. Interestingly, significantly low number of γ-
H2AX foci was observed in MO59J cells and CHO V33 cells which is not in line with our 
hypothesis that more DSBs are expected to be produced in cells lacking functional DNA-
PKcs (Figure 3.5B). γ-H2AX protein level as measured by Western blotting are in agreement 
with observations deduced from the foci assay (Figure 3.5C).  Histone H2AX became 
phosphorylated (γ-H2AX) in IMR-90 cells and the level of phosphorylation was highest at 48 
hours post treatment and decreased after 48 hours of recovery. Similar observation was made 
for in NU7026 pre-treated IMR-90 cells (Figure 3.5C). Both MO59K cells and CHO AA8 
cells showed time dependent increase in γ-H2AX protein and the protein level was greatly 
enhanced after 48 hours of recovery. γ-H2AX was not detected in MO59J cells. The protein 





























       
 
 
Figure 3.5: Induction of DNA double strand breaks in response to Ag-np treatment.  (A) 
Representative of immunofluorescence images of γ-H2AX foci without (Ai) and with (Aii) 
100 μg/ml Ag-np treatment in MO59K cells, detected with anti-γ-H2AX antibodies. Nuclei 
were stained with DAPI (blue) and γ-H2AX was stained green with FITC. 
Magnification=60×. (B) Represents mean no. of γ-H2AX induced in various cell types of 
three sets of independent experiments; * Denotes p <0.05 as obtained using Student’s t -test. 
(C) Western blots analysis of γ-H2AX following Ag-np treatment. Whole cells were 
trypsinised and lysed. Equal amounts of proteins were loaded and separated using 12% SDS-
PAGE, transferred to nitrocellulose membrane and immunoreacted with antibodies against 






3.2.6. Ag-np induced DSBs trigger the activation of DNA-PKcs and ATM. 
As explained above, Ag-np induce DSBs in treated mammalian cells. Since DNA-
PKcs mediates NHEJ repair pathway, which is the primary DSB repair pathway in 
mammalian cells, we examined whether DNA-PKcs expression and activation (in term of 
phosphorylation) will be triggered under the influence of Ag-np. We have also included 
investigation of ATM, a key signal transducer in the DNA damage response in order to 
understand further the DNA damage potential of Ag-np in our model. Western blot analysis 
revealed that IMR-90 cells treated with Ag-np show neither up-regulation nor increase in 
phosphorylation of DNA-PKcs (p-DNA-PKcs). There was no significant difference in the 
expression level of this protein in IMR-90 cells pre-treated with NU7026 followed by Ag-np 
treatment as verified by densitometry. There was 2.2-fold increase in phosphorylated ATM 
(p-ATM) in Ag-np treated IMR-90 cells and 2.3-fold increase in NU7026 pre-treated IMR-90 
cells after Ag-np exposure (Figures 3.6A, D). As shown in Figures 3.6B, E, Ag-np treated 
MO59K cells showed activation and up-regulation of DNA-PKcs and ATM. There was 1.7-
fold increment in p-DNA-PKcs and 4.3-fold increase in p-ATM. DNA-PKcs was not detected 
in MO59J cells. Similar results were obtained for CHO AA8 cells following treatment with 
Ag-np; p-DNA-PKcs increased by 3.3-fold and p-ATM by 4.4-fold. DNA-PKcs remained 
undetected in CHO V33 (Figures 3.6C, F). These data suggest the induction of DNA damage 
in all the tested mammalian cell types. It is possible that similar repair mechanisms are 
initiated in human glioblastoma cells and Chinese hamster cells in response to Ag-np 
exposure. Higher levels of activated DNA-PKcs and ATM were detected in MO59K and 
CHO AA8 cells compared to normal human cells. This is in agreement with our above 
observations in which more DSBs were shown to be induced in MO59K and CHO AA8 cells 
and therefore higher amount of the DNA repair proteins were activated to repair the DSBs 
induced compared to IMR-90 cells. 
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We analysed the levels of p-ATM in MO59J cells and CHO V33 cells in comparison 
with MO59K cells and CHO AA8 cells, respectively. Results show that p-ATM level 
remained low in both treated and untreated MO59J cells and CHO V33 cells (Figures 3.6B, 
C, E, F). The low level of ATM in MO59J cells and CHO V33 cells can be correlated to the 




































      
 
      
 
      
 
Figure 3.6: Ag-np upregulated and activated DNA-PKcs and ATM in mammalian cells. 
Western blot analysis of DNA-PKcs and ATM following 48 hour Ag-np treatment (100 








(C) CHO AA8 cells and CHO V33 cells. (D–F) Fold change for protein levels were obtained 
by densitometry analysis of X-ray films using Kodak molecular imaging software and 




3.2.7. DNA-PKcs deficiency or inhibition induces greater G2/M arrest and cell death in 
Ag-np treated cells. 
DNA damage to cells causes cell cycle arrest. Cells with irreversible damage might 
undergo apoptosis, giving rise to accumulation of cells in sub-G1phase (Canman et al., 1994, 
Boonstra and Post, 2004). We show here that Ag-np induce significant DNA damage and 
genome instability in cells lacking functional DNA-PKcs (Figures 3.3 and 3.4). To examine 
whether the extensive DNA damage induced in DNA-PKcs deficient or inhibited cells will 
perturb the cell cycle progression, cell cycle analysis was performed. We have previously 
shown that Ag-np induced G2/M arrest in cells (AshaRani et al., 2008b). Cell cycle profiles 
of DNA-PKcs deficient or DNA-PKcs inhibited cells were compared with respective DNA-
PKcs proficient cells.  
As shown in Figure 3.7A, there was no phase shift in IMR-90 cells with and without 
NU7026 pre-treatment at increasing doses. MO59K cells exhibited a dose-dependent increase 
in S and G2/M phase up to 60 μg/ml (1.7-fold, p <0.05), above which the value remained 
constant, with increase in sub-G1 populations at 60 μg/ml (8.5%) and 100 μg/ml (10.8%) 
compared to untreated control cells. Data showed no marked changes in cell cycle profile of 
MO59J cells for all doses. Cell populations arrested at S and G2/M in MO59K cells pre-
treated with NU7026 were significant only at 100 μg/ml (6.6-fold, p <0.01). It is also 
noteworthy that NU7026 pre-treated MO59K cells showed dose-dependent increase in sub- 
G1 population and were significant at 60 μg/ml (~30%, p <0.01) and 100 μg/ml (~33%, p 
<0.01) as compared to Ag-np treated MO59K cells alone (Figure 3.7B). There was 1.5-fold 
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increase in G2/M in CHO AA8 cells at 20 μg/ml and 60 μg/ml and only 1.3-fold at100 μg/ml 
compared to untreated cells. Percentage of cells in sub-G1 population increased slightly with 
increasing dose which is not statistically significant. There is 2.2- and 2.4-fold increase in 
G2/M in CHO V33 cells at 60 and 100 μg/ml (p <0.05), respectively compared with 
untreated control. Minimal increase in sub-G1 populations detected in CHO V33 cells. In 
CHO AA8 cells pre-treated with NU7026, there was 1.5-fold increase in cell population at 
G2/M phase at 60 μg/ml and this fold increase remained at 100 μg/ml of Ag-np treatment 
(Figure 3.7C).  
The data obtained in this study demonstrate two major scenarios following 
nanoparticle treatment in mammalian cells when DNA-PKcs is absent or inhibited. The 
efficacy of DNA repair was compromised and more cells were either arrested at S or G2/M 
phase to enable the repair of Ag-np induced DNA damage as shown in CHO V33 cells and in 
NU7026 treated CHO AA8 cells. Lack of functional DNA-PKcs following NU7026 in 
MO59K cells might have caused elevated DNA damage which was beyond repair thereby 
resulting in cell death. The cell cycle analysis has indirectly implied the importance of DNA-


















Figure 3.7: Cell cycle analysis by flow-cytometry. Cell cycle histograms for (A) IMR-90 
cells, (B) MO59K cells and MO59J cells, and (C) CHO AA8 cells and CHO V33 cells after 
48 hours exposure to Ag-np (20, 60 and 100 µg/ml) and NU7026 (10 μM) as measured by 
propidium iodide staining. Markers were set at regions of interest (sub-G1, G1, S, and G2/M), 
and the percentage of cells (events) under each area was generated using Microsoft excel. 
Mean ± standard error of three sets of independent experiments is shown. * Denotes p <0.05 









DNA damage and repair dynamics following Ag-np treatment are not well understood. 
Thorough investigation of these mechanisms could shed light on the mechanisms of toxicity 
as well as potential therapeutic applications of nanoparticles. Here, we demonstrate for the 
first time that Ag-np with average size of 20 nm and negative zeta potential (−0.309±0.13 
mV) are able to trigger DNA repair pathway particularly NHEJ repair pathway. Deficiency or 
inhibition of NHEJ repair pathway sensitised cells to Ag-np. The combined effect of small 
size and negative surface charges on Ag-np are believed to be the main contributors to our 
observed results. Ag-np of 20 nm can easily penetrate cell (Asharani et al., 2009). Toxicity of 
nanoparticles could have been enhanced with their negative zeta potential as previously 
shown in our laboratory that Ag-BSA and Ag-PVA bearing negative surface charges show a 
high affinity for the cell membrane and, as a consequence, are captured by cells with higher 
efficiency (Wilhelm et al., 2003, Patil et al., 2007, Asharani et al., 2010). Possibly, through 
electrostatic interaction with positively charged cell surface receptors or nuclear import 
receptors, negatively charged Ag-np further entered the nucleus generating stress to the 
genomic material. 
Deficiency or pharmacological inhibition of DNA-PKcs has increased sensitivity to 
Ag-np induced genotoxicity and cytotoxicity. DNA-PKcs plays a direct role in DSBs repair 
by acting as a key component of NHEJ and defects in kinase activity result in radio- and 
chemosensitivity (Allalunis-Turner et al., 1993, Bentle et al., 2007). The NHEJ repair 
mechanism was assumingly impaired in the absence or functional loss of DNA-PKcs (Burma 
and Chen, 2004). We speculate that the repair capacity for Ag-np induced DNA damage was 
compromised which resulted in extensive DNA damage and contributed to genomic 
instability of cells. Since one implication of DNA damage is cell cycle arrest (Pellegata et al., 
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1996), the transient delay at G2/M phase of cell cycle and decrease in cell viability of DNA-
PKcs deficient or inhibited cells could have been due to extensive DNA damage. 
In this study, differential susceptibility to Ag-np was observed in MO59J cells and 
CHO V33 cells despite the fact that both cell types are deficient in DNA-PKcs. CHO V33 
cells are highly susceptible to Ag-np as demonstrated by the data obtained in cell viability 
assay, Comet assay, CBMN assay and cell cycle analysis. In contrast, MO59J cells displayed 
significant resistance to Ag-np as a deviation from our hypothesis that DNA-PKcs deficiency 
rendered cells more susceptible to Ag-np. Prolonged absence of DNA-PKcs in MO59J cells 
might have caused inadequate regulation of p53. The cell death stimulus imbalance, i.e., 
increased levels of anti-apoptotic Bcl-2 and decreased expression of pro-apoptotic Bcl-2 
members (Bak and Bax), could have contributed to the higher resistance in MO59J cells 
(Chen et al., 2005). Another possibility for remarkable resistance of MO59J cells against Ag-
np cytotoxicity maybe that these cells are unable to quickly liberate toxic Ag+ from the 
accumulated Ag-np but rather store Ag-np in non-toxic form, as such accumulation of Ag-np 
was observed in a recent study (Luther et al., 2011). In addition, this observation can also be 
considered as a form of cancer cell adaptation (Di Nicolantonio et al., 2005). We speculate 
that resistance genes are up-regulated under unfavourable condition to facilitate cancer cell 
survival by conferring protection to MO59J cells against Ag-np in both cellular and 
macromolecular aspect, causing M059J cells to become less susceptible to Ag-np. Since 
CHO V33 cells are stable and immortalised hamster cells deficient in DNA-PKcs, the 
adaptive mechanism in cancer cells is unlikely to be triggered in the CHO V33 cells and 
hence it is plausible that these cells are more susceptible to Ag-np. 
Persistence or enhancement of DNA damage was observed in DNA-PKcs deficient or 
inhibited cells. On the contrary, efficient recovery of DNA damage was evident in normal 
human cells. Human cancer cells and immortalised rodent cells may express receptors, 
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ligands, or functional group such as sulphate on cell surface which are not expressed in 
normal human cells (Moghimi et al., 2005). These surface moieties can either facilitate the 
uptake of Ag-np into intracellular region or they may have higher affinity for Ag-np which 
allows intake of greater amount of Ag-np into the cells. Moreover, Ag-np are metallic 
nanomaterials. Longer time frame is needed to expel these nanoparticles from cells via 
exocytosis (Asharani et al., 2009) which suggests that short-term recovery (48 hours) is 
insufficient to remove Ag-np from cells. This could have resulted in the persistence or 
enhancement of DNA damage in human glioblastoma cells and Chinese hamster cells. The 
lack of certain surface molecules in normal human cells may render them less susceptible for 
Ag-np uptake and binding (Moghimi et al., 2005). In addition, alternative repair mechanisms 
such as HR can be triggered at the same time (Takata et al., 1998) to safeguard the genome 
when NHEJ is inhibited in normal cells to faithfully maintain the genome to counteract 
potentially mutagenic and cytotoxic insults (Lindahl and Wood, 1999). This could be another 
reason for efficient recovery in normal cells. 
DSBs activate an array of responses which lead to damage repair and continuation of 
cellular life (Hopfner et al., 2002). In mammalian cells, DSBs initiate the generation γ-H2AX 
foci, which function as essential indicators for recognition and repair of DSBs (Kinner et al., 
2008). We show in this study that Ag-np induce DSBs as indicated by the presence of γ-
H2AX foci. DNA damage response is presumably initiated (Sánchez-Pérez, 2006) to trigger 
NHEJ repair pathway as evidenced by DNA-PKcs phosphorylation (serine 2056) and overall 
increase in their expression level. Activation of NHEJ repair pathway is a crucial defence 
mechanism evolved to combat the potential deleterious consequences of DNA damage for 
maintaining genomic integrity. However, lack of proper NHEJ repair in DNA-PKcs deficient 
or inhibited cells results in cell death or survival of cells with mis-repaired DNA, which may 
then lead to tumourigenesis. Under these circumstances it may be advantageous for cells with 
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severely damaged DNA to convert into lethal events, promoting cell death instead of 
transformation (Sánchez-Pérez, 2006). 
We have observed a lower level of γ-H2AX protein in MO59J cells and CHO V33 
cells compared to MO59K cells and CHO AA8 cells respectively, despite higher amount of 
DNA damage observed in particular in Ag-np treated CHO V33 cells. On the contrary, γ-
H2AX level increased in both IMR-90 cells treated with Ag-np alone and with NU7026 and 
Ag-np. It was previously reported that DNA-PKcs and ATM can complement each other in 
H2AX phosphorylation (Quanz et al., 2009, Shrivastav et al., 2009). When DNA-PKcs 
activity was inhibited by NU7026 in IMR-90 cells, ATM was presumably activated to 
phosphorylate H2AX as an effort to trigger DNA repair machinery. These opposing results in 
human glioblastoma cells and Chinese hamster cells could be explained due to the dominant 
role played by DNA-PKcs in regulating H2AX phosphorylation in response to DNA damage 
(Reitsema et al., 2005, Mukherjee et al., 2006, An et al., 2010) due to the reduced level of 
ATM in both MO59J cells and CHO V33 cells (Kühne et al., 2003, Peng et al., 2005), which 
has made H2AX phosphorylation unattainable. Based on this observation, we speculate that 
the DSBs are induced albeit under detected due to the fact that H2AX is not phosphorylated 
efficiently when DNA-PKcs is lacking in MO59J cells and CHO V33 cells (An et al., 2010).  
ATM activation as evidenced by phosphorylation at serine 1981 and increase in their 
expression level was also noted in DNA-PKcs proficient cells after Ag-np treatment. 
Although some studies have shown that ATM might be involved in single-strand breaks 
repair (Nur-E-Kamal et al., 2003) and HR (Morrison et al., 2000), it also plays a vital role as 
transducer in general damage-signalling and DSB repair (Riballo et al., 1999, Zhou and 
Elledge, 2000). This explains the activation of ATM in normal human cells, DNA-PKcs 
proficient human glioblastoma cells and Chinese hamster cells in response to DNA damage 
induced by Ag- np. Interestingly, we found no change in p-ATM level in Ag-np treated 
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DNA-PKcs deficient cells though greater total DNA damage observed. Previous studies 
correlated the reduced ATM level in these cells to the truncating mutations in both ATM 
alleles (Tsuchida et al., 2002) and p53 (Anderson and Allalunis-Turner, 2000). Peng et al. 
(Peng et al., 2005) also reported that DNA-PKcs deficiencies could have consequences in 
processes connected to the network of damage response pathways controlled by ATM that 
have not been recognised previously which causes down-regulation of ATM.  
Based on the data obtained in the present study, it can be concluded that DNA-PKcs 
deficiency or inhibition impairs NHEJ repair pathway, renders cells to higher susceptibility to 
Ag-np induced DNA damage and genome instability. DNA-PKcs is an essential component 
of DNA DSB repair that serves as defence mechanism in cells in response to Ag-np and lack 
of functional DNA-PKcs sensitise cells to Ag-np induced genotoxicity and cytotoxicity. 
Clearly, further studies are required to understand the molecular interplay and physiological 











4. DNA-dependent protein kinase alters the anti-cancer properties of silver 
nanoparticles in human cancer cells through JNK and telomerase pathway  
4.1. Background 
The application of nanoparticles in biomedical research and clinical practice is a 
rapidly developing area of nanotechnology which has boosted the emergence of 
nanomedicine. Active manipulation of nanoparticles in tumour imaging, profiling of cancer 
biomarkers, targeted drug delivery and as novel anticancer drugs facilitate important 
advances in detection, diagnosis, and treatment of human cancers (Smith et al., 2008, Jain, 
2009).  Ag-np stood up among other nanoparticles due to their strong biocidal effects on 
microorganisms (Spadaro et al., 1974). It is widely accepted that Ag-np are cytotoxic and 
genotoxic and may lead to cellular apoptosis. Studies reported that Ag-np possess 
antineoplastic activity and can kill cancer cells in a manner similar to chemotherapeutics 
(AshaRani et al., 2008b, Asharani et al., 2009, Sriram et al., 2010). However, the underlying 
molecular mechanism(s) of antineoplastic properties of Ag-np is not well understood.  
Human glioblastomas are highly susceptible to and do not recover from oxidative 
stress induced damage resulted from Ag-np treatment (AshaRani et al., 2008b). Cytotoxicity 
study using modified Ag-np revealed that only naked Ag-np affect the viability of human 
lung adenocarcinoma epithelial cells (Ilknur et al., 2010). The viability of human glioma cells 
and human hepatocellular carcinoma cells was greatly reduced by protein conjugated silver 
sulphide nanocrystals (Wang et al., 2010). Our laboratory has previously reported that Ag-np 
act through intracellular calcium transients and the chromosomal aberrations induced are 
believed to be responsible for cytoskeleton deformations leading to inhibition of cancer cell 
proliferation (Asharani et al., 2009). These evidences suggest that Ag-np may be a cost-
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effective alternative in the treatment of cancer (You et al., 2012). On the other hand, breast 
cancer is the number five leading cause of death worldwide and it affects men and women 
differentially (World Health Organization, WHO, 2008). Conventional chemotherapies for 
breast cancer block oestrogen/oestradiol from binding to and processed by oestrogen receptor 
on breast cancer cells. Of the more than one million global cases of breast cancer diagnosed 
each year, approximately 15% are characterised as triple-negative, lacking the oestrogen, 
progesterone, and Her2/neu receptors. Therefore, traditional therapies targeting oestrogen 
binding are inefficient against the triple-negative breast cancer cells (Tate et al., 2012).  
Studies have shown that DNA-PKcs functions beyond DNA repair. Compared with 
wild-type, DNA-PKcs-deficient cell lines were highly sensitive to heat-induced apoptosis 
(Hendrickson et al., 1991), suggesting a role for DNA-PK in anti-apoptotic responses 
(Hendrickson et al., 1991, Peterson et al., 1995, Muller et al., 1998). DNA-PKcs is also 
involved in telomeres capping to prevent chromosome end-to-end fusion (Gilley et al., 2001), 
telomere length maintenance through functional interaction with enzyme telomerase (Espejel 
et al., 2002) and other pathways of genome surveillance (Bekker-Jensen et al., 2006). These 
manifold functions of DNA-PKcs are closely associated with an increasing number of protein 
interaction partners and phosphorylation targets (Burma and Chen, 2004, Dip and Naegeli, 
2005). 
As shown in Chapter 3, DNA-PKcs appears to safeguard the genome stability from 
harmful effects of Ag-np in mammalian cells. DNA-PKcs could also confer resistance to 
cancer cell towards genotoxin through association with other cellular factors (Shintani et al., 
2003, Hosoi et al., 2004, Um et al., 2004). In this study, we investigate the anticancer activity 
of Ag-np alongside with DNA-PKcs inhibition in order to understand the cellular defensive 
mechanism(s) associated with DNA-PKcs activation which act in orchestrate manner to 




4.2.1. Ag-np alter morphology, impair migration, induce cell death, reduce proliferative 
potential and c-Myc expression in human brain and breast cancer cells.  
Anticancer properties of Ag-np depend on the shape, size, capping agent and 
concentration of silver used during Ag-np synthesis as well as the model system investigated 
(Franco-Molina et al., 2010, Sriram et al., 2010).  In this study, we first tested the effects of 
Ag-np in two human breast cancer cells, MDA-MB-231 and MCF-7, and two human brain 
cancer cells, U251 and M059K. The effects of Ag-np on these cells were compared with 
normal human lung fibroblasts, IMR-90 cells. 
 Exposure to Ag-np for 48 hours resulted in altered cell shape in cancer cells compared 
to their respective controls. Ag-np treated cells appeared to be clustered with a few cellular 
extensions and cell spreading patterns were restricted as compared to control cells. This could 
be due to disturbances in cytoskeletal functions as a consequence of Ag-np treatment 
(AshaRani et al., 2008b). More floating and rounded cells which suggest dying cells were 
observed in the human breast and brain cancer cells. In contrast, there were minimal changes 







Figure 4.1: Morphological appearance of cells treated with Ag-np. Ag-np treatment 
significantly changes the morphology of human cancer cells. Morphology of normal cells 
remains unaffected. IMR-90, MDA-MB-231, MCF-7, U251 and MO59K cells following 48 
hour-treatment of Ag-np at 200 µg/ml. 
 
 
Ag-np significantly inhibited cell migration in all of the human cancer cells 
investigated in relative to control cells in scratch wound-healing assay (Figure 4.2). The 
closure of the wound was delayed in Ag-np treated MDA-MB-231 cells. Ag-np had widened 
the wound induced in MCF-7 cells, U251 cells and MO59K cells and the density of cells 
surrounding the wound decreased. Such Ag-np induced effects on migration was not 
observed in normal human cells as the closure of scratch wound in IMR-90 cells was 









   
 
Figure 4.2: Scratch wound-healing assay to determine cell migration. Migration of human breast cancer and brain cancer cells was impeded 
following Ag-np treatment. IMR-90, MDA-MB-231, MCF-7, U251 and MO59K cells following 48 hour-treatment of Ag-np at 200 µg/ml.   
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Cell cycle analysis revealed that Ag-np induces apoptotic cell death in cancer cells 
while normal human cells remained unaffected. As shown in Figure 4.3, there was 
significant increase in sub-G1 population in MDA-MB-231 (from 3.4% to 49.2%, 14.5-fold, 
p <0.001), MCF-7 (from 6% to 51%, 8.75-fold, p <0.01), U251 (from 3% to 29%, 11-fold) 
and M059K (from 5% to 39%, 7.7-fold).  
 
 
Figure 4.3: Ag-np treatment results in massive cell death in human brain and breast 
cancer cells. Cell cycle histograms of different cells exposed to Ag-np as measured by 
propidium iodide staining. IMR-90, MDA-MB-231, MCF-7, U251 and MO59K cells 
following 48 hour-treatment of Ag-np at 200 µg/ml. Mean ± standard error of three sets of 




 In parallel with our findings in cell cycle analysis, trypan blue exclusion assay showed 
significantly reduced proliferative potential of the human cancer cells following Ag-np 
treatment (Figure 4.4). The 48 hour-treatment with Ag-np decreased the viable proliferative 
MDA-MB-231 cells by 57%, MCF-7 cells by 68% (p <0.05), U251 cells by 42% and 




Figure 4.4: Ag-np treatment decreases proliferative potential of human brain and 
breast cancer cells. Cell viability as determined by trypan blue exclusion assay. IMR-90, 
MDA-MB-231, MCF-7, U251 and MO59K cells following 48 hour-treatment of Ag-np at 
200 µg/ml. Mean ± standard error of three sets of independent experiments are shown.* 
Denotes p <0.05. 
 
 
A prominent c-Myc overexpression drives hyperproliferation, DNA hypomethylation, 
tumour formation and human malignancy (He et al., 1998, Chen et al., 2001, Buchholz et al., 
2006, McNeil et al., 2006). Therefore, we checked whether Ag-np decrease the maglinancy 
of cancer cells by down-regulating expression of c-Myc.  Analysis of c-Myc expression 
through western blotting demonstrated that there was 1.7-fold increase in c-Myc level in 
IMR-90 cells upon Ag-np exposure. The Ag-np treated human cancer cells showed 
consistency which there was reduction in c-Myc expression. Ag-np treated MDA-MB-231 
cells and MCF-7 cells exhibited 0.5-fold and 0.2-fold reduction in c-Myc expression 
respectively. Ag-np treatment had down-regulated c-Myc level in U251 cells by 0.3-fold and 









          
Figure 4.5: Ag-np treatment restrains proliferation of human brain and breast cancer 
cells potentially through down-regulating c-Myc. Changes in expression level of c-Myc 
protein in IMR-90, MDA-MB-231, MCF-7, U251 and MO59K cells following 48 hour-
treatment of Ag-np at 200 µg/ml. Fold change for protein levels were obtained by 
densitometry analysis of X-ray films using Kodak molecular imaging software and 
normalised against actin levels to represent accurate values for proteins which deviated from 
the control. Mean ± standard error of three sets of independent experiments are shown. * 















4.2.2. Inhibition of DNA-PKcs increases cell death in Ag-np treated cells. 
In Chapter 3, we have reported that human glioblastoma cells were more sensitive to 
Ag-np treatment compared to normal human cells and DNA-PKcs initiated repair of DNA 
damages induced by Ag-np in human glioblastoma cells. To understand the signalling 
cascade responsible for the anticancer effect of Ag-np in this study, we first validated the 
importance of DNA-PKcs in governing the survival of Ag-np treated other human cancer 
cells. We have used specific pharmacological inhibitor, NU7026, which specifically inhibit 
DNA-PKcs activity  (Veuger et al., 2003). Cells were pre-treated with NU7026 (10 µM) for 1 
hour prior to incubation with Ag-np and luminescence based cell viability assay was 
performed after 48 hour-treatment. In normal cells, treatment with Ag-np reduced cell 
viability by 9% (p <0.05) and cells pre-treated with NU7026 showed even greater decrease 
by 34.6% (p <0.01). As reported earlier, cancer cells are more sensitive to Ag-np treatment 
(AshaRani et al., 2008b).  Treatment with Ag lead to 74.8% (p <0.001), 23.8% (p <0.001), 
32.3% (p <0.001) and 44% (p <0.001) reduction in survival in MDA-MB-231, MCF-7, ,U251 
and M059K cells respectively as compared to their untreated control. Cancer cells pre-treated 
with NU7026, however, showed further reduction in cell viability. There was 82.4% (p 
<0.001), 36.9% (p <0.001), 50.3% (p <0.001) and 63.2% (p <0.001) of cell death in MDA-
MB-231, MCF-7, U251 and M059K cells compared to their untreated controls (Figure 4.6). 
This was associated with reduction of clonogenicity in all tested cell types (Figure 4.7). The 
growth inhibition effect was more pronounced in brain cancer cell types as compared to 
breast cancer cells following Ag-np treatment. Inhibition of DNA-PKcs in all tested cell types 
treated with Ag-np results in more significant growth inhibition compared with Ag-np treated 





Figure 4.6: Inhibition of DNA-PKcs increases cell death in Ag-np treated cells. Cell survival following 48 hour-treatment with Ag-np (200 
µg/ml) and NU7026 (10 µM). For combination treatment, cells were pre-treated with NU7026 for 1 hour. Ag-np were then added to the cells and 
further incubated for 48 hours. The percentage cell viability was normalised against the untreated control (0 µg/ml). The values represent the 
mean ± standard error of three sets of independent experiments; * Denotes p <0.05, ** denotes p <0.01 and *** denotes p <0.001 as obtained 





Figure 4.7: Inhibition of DNA-PKcs induces growth inhibition in Ag-np treated brain 
and breast cancer cells. Colony formation capacity of cells treated with 14 days of Ag-np 
(200 µg/ml) and NU7026 (10 µM). Cells were pre-treated with NU7026 for 1 hour. Ag-np 
were then added to the cells and further incubated for 14 days for combination treatment. The 
cells were then allowed to grow for another 14 days in media without treatment and stained 












4.2.3. Ag-np treatment produces DNA damage in human brain and breast cancer cells. 
Comet assay under alkaline condition (pH13) was used to determine the DNA damage 
induced by Ag-np. As displayed in Figure 4.8, IMR-90 cells are less susceptible to Ag-np as 
data show minimal increase in DNA damage (from 0.8 µm to 1.5 µm) after 48 hour-treatment. 
The tail moment in MDA-MB-231 cells increased from 0.8 µm to 2.8 µm (p <0.05) after 
treated with Ag-np. MCF-7 and U251 cells are most susceptible to Ag-np induced DNA 
damage as both showed highest increase in tail moment. Upon exposure, the tail moment in 
MCF-7 cells increased significantly from 1.1 µm to 8.3 µm (p <0.05). There was also 
significant increase in tail moment in U251 cells which tail moment increased from 1.4 µm to 
8.7 µm (p <0.05). In MO59K cells, the DNA damage induced was significant as well from 
0.9 µm to 3.3 µm (p <0.05). 
 
 
Figure 4.8: Ag-np treatment induces DNA damage in human cells. DNA damage as 
measured by the Comet assay in different cell types following 48 hour-treatment with Ag-np 
at 200 µg/ml. Mean tail moment (µm) represents the damage distribution in the attached cells. 
Mean ± standard error of three sets of independent experiments are shown. * Denotes p <0.05 
as obtained using Student’s t-test. 
 
As previously reported, DSBs can induce phosphorylation of histone H2AX, termed 
γ-H2AX and behave as excellent marker for DSBs (Rogakou et al., 1998, Rogakou et al., 
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1999). In our study, western blot analysis had been carried out to assess DSBs in the Ag-np 
treated human normal cells and cancer cells (Figure 4.9). The results showed γ-H2AX had 
been activated in MDA-MB-231 cells by 2.98-fold after treated with Ag-np for 48 hours. 
MCF-7 and U251 cells showed comparable fold increase in activated γ-H2AX protein level 
which was 2.52-fold and 2.44-fold respectively. MO59K cells expressed highest level of γ-
H2AX protein after 48 hours incubation with Ag-np. The protein was activated by 5.24-fold.  
There was no activation of γ-H2AX in IMR-90 cells after exposed to Ag-np.  In short, Ag-np 
treatment induced more prominent DNA damage in human breast cancer cells and brain 
cancer cells than the normal human cells. DSBs are one of the most lethal DNA damages 
(Rich et al., 2000, Pilch et al., 2003). The resulted DSBs as indicated by the up-regulation of 
γ-H2AX, has contributed partially if not totally to genotoxic stress and triggered physiologic 
response to DNA damage in the cells.  
         
Figure 4.9: Increase in phosphorylation of H2AX (γ-H2AX) upon DNA damage 
induction in Ag-np treated cells. Protein expression of γ-H2AX following 48-hour 
treatment with Ag-np at 200 µg/ml for IMR-90, MDA-MB-231, MCF-7, U251 and MO59K 
cells respectively. Fold change for protein levels were obtained by densitometry analysis of 
X-ray films using Kodak molecular imaging software and normalised against actin levels to 
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represent accurate values for proteins which deviated from the control. Mean ± standard error 




4.2.4. Ag-np exposure activates DNA-PKcs and JNK pathway in human brain and 
breast cancer cells. 
In response to DSBs signals, activation of DNA-PKcs facilitates recruitment of 
downstream DNA repair factors for repair of the resulting DNA damage (Khanna and 
Jackson, 2001). Meanwhile, JNKs have been reported to regulate DNA repair following 
genotoxic stress and a rapid and preferential activation of this pathway was observed upon 
DNA damage induction (Devary et al., 1991).  We have shown in figure 4.8 and 4.9 that Ag-
np exposure produces DNA damage to human cancer cells. To understand the physiological 
response underneath, we examined the activation status of DNA-PKcs and JNK pathway.  
As shown in figure 4.10, in IMR-90 cells, there was meagre increase in p-DNA-PKcs 
level at 1.1-fold after 48-hour treatment with Ag-np. In contrasts, all four human cancer cell 
types showed significant activation of DNA-PKcs, i.e. p-DNA-PKcs. U251 cells showed 
highest level of p-DNA-PKcs level of 11.0-fold. This was followed by the 2.2-fold activation 
in MDA-MB-231 cells. The p-DNA-PKcs level in Ag-np treated MO59K cells was increased 
by 1.6-fold and by 1.6-fold in MCF-7 cells. The densitometry analysis revealed that basal 
DNA-PKcs was minimally down-regulated in IMR-90, MCF-7, U251 and MO59K cells after 
treatment with Ag-np. Meanwhile, basal DNA-PKcs expression increased slightly in Ag-np 
treated MDA-MB-231cells. 
 To test for JNK pathway activation, the protein expression of main components of 
JNK pathway: phosphorylated JNK1 (p-JNK1), basal JNK1 and c-Jun was analysed. There 
was a 1.9-fold increase in p-JNK1 level in MDA-MB-231 cells after being exposed to Ag-np. 
The MCF-7 cells showed activation of the same protein by 2.8-fold, which was the highest 
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among all of the human cancer cells lines tested. U251 and MO59K cells showed 
comparatively lower level of p-JNK1, at 1.2-fold and 1.3-fold, respectively. There was no 
activation of JNK pathway in treated IMR-90 cells, as p-JNK1 level was decreased by 0.2-
fold (Figure 4.11). Basal JNK1 protein expression was examined as well (Figure 4.11). 
IMR-90 cells exhibited slight increase in basal JNK1 level by 1.2-fold after Ag-np treatment. 
MCF-7 and MO59K cells showed significant down-regulation of basal JNK1 expression by 
0.5 and 0.9-fold, respectively. In MDA-MB-231 and U251 cells, meagre down-regulation of 
JNK1 was observed by 0.1 and 0.2-fold, respectively. C-Jun, the direct downstream target of 
JNK1 in JNK pathway was examined as well (Figure 4.11). There was slight increase (1.1-
fold) in c-Jun level in Ag-np treated IMR-90 cells. In agreement with activation of JNK1, i.e. 
p-JNK1, c-Jun expression was significantly up-regulated by ~4-fold, 2.1-fold, 1.9-fold and 
3.6-fold in MDA-MB-231, MCF-7, U251 and MO59K cells respectively. Our data suggest 
DNA-PKcs and JNK stress response pathway were promptly activated in human cancer cells 
following Ag-np induced DNA damage. Interplay between DNA-PKcs and JNK might be 











          
 
Figure 4.10: DNA damages induced in Ag-np treated cells activate DNA-PKcs. Protein 
expression of p-DNA-PKcs and DNA-PKcs following 48 hour-treatment with Ag-np at 200 
µg/ml for IMR-90, MDA-MB-231, MCF-7, U251 and MO59K cells. Fold change for protein 
levels were obtained by densitometry analysis of X-ray films using Kodak molecular imaging 
software and normalised against actin levels to represent accurate values for proteins which 









        
 
   
Figure 4.11: DNA damage induced in Ag-np treated cells activate JNK pathway. Protein 
expression of p-JNK1, JNK1 and c-Jun following 48 hour-treatment with Ag-np at 200 µg/ml 
for IMR-90, MDA-MB-231, MCF-7, U251 and MO59K cells. Fold change for protein levels 
were obtained by densitometry analysis of X-ray films using Kodak molecular imaging 
software and normalised against actin levels to represent accurate values for proteins which 





4.2.5. JNK1 was insufficiently activated after DNA-PKcs inhibition in Ag-np treated 
human cancer cells. 
DNA-PKcs was reported to positively regulate JNK pathway activation (Fritz and 
Kaina, 2006).  In order to understand the interplay between DNA-PKcs and JNK1 activation 
upon Ag-np induced genotoxic stress, we inhibited DNA-PKcs activity with NU7026 for 1 
hour prior to Ag-np treatment and determined the status of JNK pathway activation. Western 
blot analysis was carried out to determine the changes in expression level of these proteins in 
the presence of DNA-PKcs inhibitor (Figure 4.12). Densitometry analysis revealed, as 
expected, DNA-PKcs were activated in form of p-DNA-PKcs in Ag-np treated MDA-MB-
231, MCF-7, U251 and MO59K cells. P-DNA-PKcs remained low in IMR-90 cells with 
either Ag-np alone or with combination treatment.  
Two main scenarios were observed of how activation of JNK1 (i.e. p-JNK1) changes 
upon inhibition of DNA-PKcs activity. We have compared the level of activation of these 
proteins in cells treated with Ag-np alone versus combination treatment. Firstly, the p-JNK1 
level was increased from 2.3-fold to 3.4-fold in MBA-MB-231 cells. Secondly, p-JNK1 level 
was decreased in MCF-7, U251 and MO59K cells in combination treatment. P-JNK1 level 
was decreased from 1.6-fold to 1.5-fold in MCF-7 cells, from 1.2-fold to 0.9-fold in U251 
cells and from 1.6-fold to 0.3-fold in MO59K cells. Basal DNA-PKcs and basal JNK1 
expression was also examined for control purpose. Thus, we concluded that DNA-PKcs 
tightly regulates phosphorylation/ activation of JNK1 in MCF-7, U251 and MO59K cells but 















Figure 4.12: JNK1 was insufficiently activated after DNA-PKcs inhibition in Ag-np treated human cancer cells. Changes in expression 
level of p-DNA-PKcs, basal DNA-PKcs, p-JNK1, and basal JNK1 in untreated cells and cells treated with Ag-np (200 µg/ml) and NU7026 (10 
µM) after 48 hours. Densitometry analysis determines fold change in protein levels. Mean ± standard error of three sets of independent 
experiments are shown. 
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4.2.6. Ag-np cause telomere loss in human brain and breast cancer cells. 
Telomeres cap and protect the chromosome ends (Blackburn, 1991). Due to their 
location at the chromosomes, these structures resembled as fragile sites in the genome and are 
readily exposed to molecular attack from various DNA-damaging agents (Alvarez et al., 1993, 
Sfeir et al., 2009). To gain thorough understanding on Ag-np induced genotoxicity, we 
monitored changes in telomere length, if any, following Ag-np treatment using TRF assay. 
All cell lines in this study were treated with Ag-np over a span of 4 days and telomere length 
was then measured.  Four days treatment with Ag-np showed detectable change in telomere 
length. Telomere length was decreased by 19% in MDA-MB-231, which marked the highest 
reduction in telomere length among four cancer cell types. This was followed by 12% 
reduction in U251 cells, 6% in MCF-7 cells and 3% in MO59K cells. No detectable change 
was observed in IMR-90 cells (Figure 4.13A-C).    
  TRF2, a member of shelterin complex, coats the length of all human telomeres and 
can remodel telomeric DNA into t-loops (Broccoli et al., 1995, Bilaud et al., 1997). It was 
reported that the protection of human telomeres crucially depends on TRF2 (Guiducci et al., 
2001, Kim et al., 2001). To understand how TRF2 was affected by Ag-np treatment, we 
checked expression of this protein. Cells were incubated with Ag-np for 4 days with same 
doses used for TRF assay and harvested for western blotting.  TRF2 were down-regulated in 
all the cancer cells, implying disruption of shelterin complex by Ag-np. Down-regulation of 
TRF2 in IMR-90 cells was negligible (Figure 4.14). We also observed down-regulated 
hTERT, the catalytic component of enzyme telomerase in Ag-np treated human cancer cells 
used in the study (Figure 4.14).  
 
 





Figure 4.13: Ag-np cause telomere loss in human brain and breast cancer cells.  (A) Telomere restriction fragment analysis for telomere 
length measurement in IMR-90, MDA-MB-231, MCF-7, U251 and MO59K cells following 4 days treatment with 200 µg/ml of Ag-np. TRF blot 
shown is a representative from two independent experiments. (B) Average telomere length (kbp) of untreated control and Ag-np treated cells. (C) 








Figure 4.14:  Loss of shelterin complex integrity and reduction of telomerase expression 
in Ag-np treated human brain and breast cancer cells. Changes in expression level of 
TRF2 and hTERT in untreated cells, cells treated with Ag-np (200 µg/ml) and NU7026 (10 










4.2.7. Ag-np induced DNA damage is not telomere-specific. 
In order to examine whether the DNA damaging effect of Ag-np is telomere specific, 
immunofluorescence based telomere dysfunction induced foci (TIF) assay was carried out. 
This assay usually relies on simultaneous detection of telomere associated proteins 
(antibodies against TRF1 or TRF2) and DNA damage (antibody against a DNA damage 
marker) (Takai et al., 2003). However, instead of antibodies against telomeric proteins, we 
used telomeric PNA probe which bind directly to telomeres in combination with an antibody 
against a DNA damage marker, γ-H2AX (immuno-FISH). We have shown in Chapter 3 that 
Ag-np induces primarily DSBs in mammalian cells as indicated by the presence of γ-H2AX 
foci in the nucleus. The dysfunction or uncapped telomeres can be recognised as DSBs by 
mammalian cells (Takai et al., 2003, d'Adda di Fagagna et al., 2004, Shay and Wright, 2004, 
Longhese, 2008, Jackson and Bartek, 2009). Hence, we used γ-H2AX foci as an indicator for 
DNA damage in this study. Co-localisation of γ-H2AX foci and telomeres implies the 
induction of dysfunction telomeres in our study.  Our findings showed γ-H2AX foci co-
localised with but not exclusively at telomeres suggest Ag-np do not specifically target 
telomeres (Figure 4.15A). There was minor increase in average number of TIFs in MDA-
MB-231 cells and MCF-7 cells after 48 hours incubation with Ag-np. The TIFs number 
increased significantly in Ag-np treated U251 cells (p <0.01) and MO59K cells (p <0.05) 
(Figure 4.15D). Overall, the TIFs induced by Ag-np in human cancer cells were low and γ-
H2AX foci appeared at telomeres as well as other areas of the genome. Hence, we concluded 
that the effect of Ag-np to the genome is not telomere specific.  
The presence of co-localised p-DNA-PKcs and γ-H2AX foci is an ideal estimation for 
DNA damage and repair response in cells exposed to DNA damaging agent such as ionising 
radiation (Asaithamby et al., 2008, Asaithamby and Chen, 2011). Our results showed p-
DNA-PKcs and γ-H2AX foci appeared throughout the nucleus. The co-localised foci 
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indicated the recruitment of DNA repair machinery to the DSBs sites (Figure 4.15B).  The 
quantification of staining in figure 4.15B showed that the average number of co-localised p-
DNA-PKcs and γ-H2AX foci increased significantly in all the four cancer cell types 
investigated (Figure 4.15E).   
In addition to its role in NHEJ repair pathway, DNA-PKcs is also essential in capping 
of telomeres (Gilley et al., 2001) and in some cases maintenance of telomere length (Espejel 
et al., 2002). To explore role of DNA-PKcs in Ag-np damaged telomeres, TIF assay was 
performed to check for DNA-PKcs activation at telomeres. Our data suggest Ag-np triggered 
recruitment of p-DNA-PKcs to telomeres (Figure 4.15C and 4.15F) in human breast and 
brain cancer cells implying the potential recruitment/activation of DNA repair machinery to 























                
Figure 4.15: Ag-np induced DNA damage is not telomere-specific and recruitment of 
activated DNA-PKcs to telomeres upon Ag-np treatment. (A) Cells were immunoreacted 
with anti-γ-H2AX antibody and anti-FITC followed by Telo-FISH hybridisation with 
telomere-specific PNA probe. Representative immunofluorescence microscopic single-plan 
images showing Ag-np induced DNA damage signals by γ-H2AX (green) were merged with 
telomere signals (red) within the same cells to demonstrate the TIF (yellow). DNA was 
counterstained with DAPI (blue). (B) Immunofluorescence microscopy of γ-H2AX and p-
DNA-PKcs (red) DNA-damage foci after Ag-np exposure. The merged images show co-






anti-p-DNA-PKcs antibody and anti-FITC followed by Telo-FISH hybridisation with PNA 
probe after treatment with Ag-np. Ag-np induced p-DNA-PKcs foci (green) were merged 
with telomere signals (red) within the same cells to demonstrate the TIF (yellow). White 
arrowheads indicate TIFs/Co-localised foci. Representative images are taken in U251 cells, 
(D) Quantification of staining shown in A. The average number of TIF is shown. (E) 
Quantification of staining shown in B. The average number of co-localised γ-H2AX and p-
DNA-PKcs foci is shown. (F) Quantification of staining shown in C. The average number of 
TIF is shown. Magnification = 60X. All cells were treated with Ag-np for 48 hours. Doses of 
Ag-np used are 200 µg/ml. The values represent the mean ± standard error of three sets of 
independent experiments.* Denotes p <0.05 and ** denotes p <0.01 as obtained using 
Student’s t-test.  
 
 
4.2.8. DNA-PKcs inhibition substantiates the damaging effect of Ag-np at telomeres in 
human cancer cells. 
To determine whether DNA-PKcs inhibition will enhance the damaging effect of Ag-
np on telomeres, we inhibited DNA-PKcs activity with NU7026. In order to study the long 
term effects of Ag-np and DNA-PKcs inhibition, the cells were treated with Ag-np for 14 
days beyond which viable cells number were too low to carry out TRF. For this purpose, dose 
of Ag-np used were standardised at 100 µg/ml for all cell types. We observed no change in 
telomere length in IMR-90 cells treated with both NU7026 and Ag-np. However, in cancer 
cells, combination of NU7026 and Ag-np treatment further reduced the telomere length in 
MDA-MB-231, MCF-7, U251 and MO59K cells. In MDA-MB-231 cells, the relative 
telomere length was decreased from 95% to 88% from Ag-np alone treatment to combination 
treatment. In MCF-7 cells, relative telomere length was decreased from 94% to 82%. The 
relative telomere length reduced from 90% to 85% in U251 cells and from 99% to 85% in 
MO59K cells (Figure 4.16A-C). Our observations suggest that absence of functional DNA-
PKcs augmented the telomere damaging effect of Ag-np, resulting in further reduction of 
telomere length in human breast and brain cancer cells, which eventually contributing to 








           
  
Figure 4.16: DNA-PKcs inhibition substantiates the damaging effect of Ag-np at 
telomeres in human cancer cells. (A) TRF analysis for telomere length measurement in 
cells following 14 days treatment with Ag-np at 100 µg/ml and NU7026 at 10 µM. TRF blot 
shown is a representative from two independent experiments. (B) Average telomere length 
(kbp) of Ag-np and NU7026 treated cells. (C) Changes in telomere length are expressed as 
percentage with respect to its untreated controls. Graph shows mean ± standard error from 







One of the most challenging problems of existing chemotherapeutics is high 
cytotoxicity and lack of specificity. We show in this study that Ag-np selectively exert 
anticancer effects as human breast and brain cancer cells were highly susceptible to Ag-np 
compared to normal human cells.  Ag-np altered the human cancer cells’ morphology 
implying disturbance to the cytoskeletal function of human cancer cells. Impaired migration 
of human cancer cells by Ag-np suggests that cancer cells have lost the ability to metastasise.  
The reduced proliferative potential of human breast cancer cells and brain cancer cells was 
evidenced by the decrease in viable cancer cells and the increase in apoptotic cell death. C-
Myc is over expressed in more than 80% of human cancer cells (Henriksson and Lüscher, 
1996, Nesbit et al., 1999, Schlagbauer-Wadl et al., 1999) and c-Myc overexpression is often 
associated with hyperproliferation and predispose cells to malignant transformation (Chen et 
al., 2001). In line these observation, we found that decrease expression of c-Myc in human 
cancer cell lines and series of studies have shown that reduction in c-Myc inhibits tumour 
cells growth both in vivo and in vitro (Russo et al., 2003, Wang et al., 2005). Hence, the 
altered morphology, impaired migration, reduced proliferative potential and malignancy in 
human breast cancer cells and brain cancer cells highlight that Ag-np possess anticancer 
properties.     
DNA-PKcs is often involved in DNA DSBs repair and maintenance of genomic 
integrity (Kurimasa et al., 1999). In addition, several studies have revealed in recent years 
that DNA-PKcs could confer resistance to cancer cells towards genotoxic agents through 
association with other cellular factors (Shintani et al., 2003, Hosoi et al., 2004, Um et al., 
2004). From our data, we found that inhibition of DNA-PKcs with specific pharmacological 
inhibitor, NU7026 further decreased the survival of Ag-np treated human cancer cells.  As 
described in Chapter 3, the presence of DNA-PKcs triggers NHEJ repair pathway upon DNA 
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damage induced by Ag-np while in cells lacking functional DNA-PKcs there were greater 
cell death. Hence, the presence of DNA-PKcs is believed to reduce genotoxicity and 
cytotoxicity of Ag-np in cells. In addition, we suspect that greater cell death observed upon 
DNA-PKcs inhibition in Ag-np treated cancer cells is not limited to impairment of DNA 
repair based on our observation due to the multifaceted roles played by DNA-PKcs in the 
complex cellular signalling network.  
Our findings indicated that Ag-np induced significant DNA damage in the human 
breast cancer cells and brain cancer cells. Particularly, the increased  γ-H2AX protein level 
implied DSBs were induced in these cells. These DNA damages from Ag-np treatment 
resulted in massive genotoxic stress to the human cancer cells which may trigger signalling 
pathways that mediate either the protection or killing of affected cells. As can be seen from 
the data presented in this thesis, DNA-PKcs and JNK pathway were concurrently activated by 
the resulted genotoxic stress. Activation of the JNK stress response pathway was indicated by 
phosphorylation of JNK1 and increased expression of c-Jun. Previous study has also shown 
that involvement of JNK pathway in Ag-np mediated toxicity studies (Hsin et al., 2008) and 
JNK activation and its signalling pathway are associated with triggers cell cycle arrest and 
DNA repair (Verheij et al., 1996, Podar et al., 2007). The JNK signalling pathway in 
response to genotoxic stress is thought to be largely a compensatory and protective response 
that positively regulates genes involved in cellular protective functions, such as glutathione-
S-transferase, quinine reductase, and MTIIA (Litz-Jackson et al., 1992, Pinkus et al., 
1996).The prolonged activation of JNK pathway, however, promote apoptosis (Verheij et al., 
1996, Podar et al., 2007). Therefore, we speculate that simultaneous activation of DNA-PKcs 
and JNK pathway is likely be one of the defensive signalling events that allow the DNA 
repair to take place and prevent the cancer cells from undergoing apoptosis.  
 128 
 
It was reported that DNA-PKcs participate in the damage signalling pathway by 
targeting various proteins (Anderson and Carter, 1996, Karmana et al., 1997, Park et al., 1999, 
Smith and Jackson, 1999). We speculate that one such target could be protein kinases such as 
JNK1. To investigate the regulation between DNA-PKcs and JNK1, we inhibited DNA-PKcs 
activity and exposed cells to Ag-np treatment. Results showed that JNK1 was not entirely 
activated in DNA-PKcs inhibited MCF-7, U251 and MO59K cells upon Ag-np treatment as 
evidenced by down-regulation of p-JNK1, indicating tight regulation of JNK1 
phosphorylation by DNA-PKcs.  Fritz and Kaina (Fritz and Kaina, 2006) reported that JNK1 
protein associated with DNA-PKcs and was efficiently phosphorylated by DNA-PKcs (Fritz 
and Kaina, 2006). Our results are in line with this finding, suggesting that DNA-PKcs plays 
an important role in controlling JNK activity and this regulation is required to mediate DNA 
damage and repair in human brain cancer and breast cells in response to Ag-np induced 
genotoxic stress. With DNA-PKcs inhibition, JNK pathway was insufficiently activated and 
therefore DNA damage and repair response were not properly triggered to repair the resulted 
DNA damages from Ag-np. These observations serve as explanation of further reduction in 
cancer cell survival in DNA-PKcs inhibited MCF-7, U251 and MO59K cells treated with Ag-
np. Unlike the other human cancer cell lines, there was excessive phosphorylation of JNK1 in 
MDA-MB-231 cells with combination treatment. This suggests phosphorylation of JNK1 is 
independent of DNA-PKcs in this particular cell type. The persistent JNK1 activation in these 
cells might be an indication of significant genotoxic stress resulted from excessive DNA 
damage induced by Ag-np when DNA-PKcs has become non-functional in the presence of 
NU7026. Hence, JNK1 mediated apoptosis, instead of DNA repair in these cells. This 
observation served as an explanation for enhanced cell death in MDA-MB-231 cells in 
combination treatment.  Further investigations are required to determine whether this 
observation is a result from the triple negative status of MDA-MB-231 cells.  
 129 
 
Telomeres are referred as fragile sites of the genome (Sfeir et al., 2009) and we have 
previously shown cells with short telomeres are more sensitive to DNA damaging agents 
(Newman et al., 2008, Gurung et al., 2010). In our current study, Ag-np selectively exerts 
toxicity on human breast and brain cancer cells rather than normal human cells. Thus, we 
sought to determine if this selectivity is due to the specific targeting effect of Ag-np on 
telomeres of human cancer cells. From our observation, for the first time, we found that Ag-
np alters telomere maintenance in human cancer cells and not in normal cells as evidenced by 
down-regulation of TRF2 and telomere shortening. As shelterin complex is known to confer 
protective effects on telomeres (de Lange, 2005), the loss of shelterin complex integrity upon 
Ag-np treatment potentially exposes telomeres further to Ag-np or other DNA damaging 
agents in the cellular environment resulting in telomere attrition as observed in our study. 
Down-regulation of hTERT was also observed further demonstrated the effects of Ag-np on 
telomere maintenance. In addition, studies have shown that functional interaction between 
telomerase and DNA-PKcs activities is involved in telomere length maintenance (Espejel et 
al., 2002). We suspect that this functional interaction was abrogated in Ag-np treated human 
cancer cells with down-regulation of hTERT. It is possible that the activation of JNK 
pathway in Ag-np treated cancer cells might contribute to down- regulated expression of 
telomerase and leading to cell apoptosis as study reported DNA damaging agents such as 
arsenics and monomethylarsonic acid induced apoptosis mediated by reduction of hTERT 
expression via JNK activation (Shen et al., 2008). Thus, the loss of shelterin complex 
integrity and hTERT expression contribute to telomere attrition in Ag-np treated human 
cancer cells. Eventually, the exposed telomeres lead to rapid DNA damage response which 
can ultimately induce senescence and/or apoptosis in the human breast and brain cancer cells. 
As previously reported, TIF are novel markers for telomere dysfunction (Takai et al., 
2003). Dysfunctional or uncapped telomeres can be recognised as DSBs and became 
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associated with DNA damage response factors such as γ-H2AX, Rad17 and ATM (Takai et 
al., 2003). TIF assay revealed Ag-np induced dysfunctional telomeres as evidenced by the 
accumulation of γ-H2AX foci at the telomeres. Furthermore, Ag-np preferentially induced 
telomere dysfunction in human cancer cells in our study as significantly higher number of 
TIF were induced in these cells compared to the normal cells and thus might contribute 
partially to the selective toxicity of Ag-np on human cancer cells but not normal cells. These 
observations can be attributed to the preferential uptake and longer retention of Ag-np in 
human cancer cells than normal human cells as we discussed in our previous publications 
(Asharani et al., 2009), allowing Ag-np to have sufficient time to damage telomeres in the 
human cancer cells. We also concluded that the DNA damaging effect of Ag-np is not 
telomere specific as γ-H2AX foci appeared throughout the nucleus and present not 
exclusively at the telomeres. Moreover, the measurement of co-localised p-DNA-PKcs and γ-
H2AX foci revealed significant DNA damage repair responses were triggered in Ag-np 
treated cells cancer cells. These observations again support our conclusion that Ag-np do not 
specifically target telomeres but induce DNA damage throughout the nucleus as low level of 
damage induced at telomeres is insufficient to ignite massive DNA damage and repair 
response in the cells.     
 DNA-PKcs has been shown to play a critical role in capping of mammalian telomeres 
as abrogation of DNA-PKcs activity causes end-to-end chromosomal fusion (Bailey et al., 
2001, Gilley et al., 2001). It has been reported that Ku70/80 heterodimer interacts with TRF1 
or TRF2 to assist the loading of DNA-PKcs to telomeres, regulates telomere length and 
facilitates NHEJ repair of induced DSBs at telomeres (Song et al., 2000, Doherty and Jackson, 
2001). Recruitment of activated DNA-PKcs to telomeres upon Ag-np treatment in this study 
revealed the activation of DNA repair machinery at damaged telomeres. Once telomere 
length becomes critically shortened by Ag-np, the formation of a T-loop is prevented  
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(Espejel et al., 2002). The chromosome end is unsequestered and detected as damaged DNA 
as evidenced by co-localised γ-H2AX foci with telomeres and processed as such by the DNA 
repair machinery as we proved the recruitment of p-DNA-PKcs to the damaged telomeres. 
These observations could also be related to the consequences of TRF2 down-regulation in 
Ag-np treated cancer cells as studies reported that TRF2-depleted telomeres are perceived as 
DNA damage sites and trigger DNA repair responses (van Steensel et al., 1998, Karlseder et 
al., 1999). We have inhibited DNA-PKcs activity in the cell lines tested in our study in order 
to gain thorough understanding of how DNA-PKcs is involved in telomere length regulation 
in Ag-np treated cells. Inhibition of DNA-PKcs in Ag-np treated MDA-MB-231, MCF-7, 
U251 and MO59K cells showed a faster rate of telomere loss compared to cells treated with 
Ag-np only, which suggests clearly involvement of DNA-PKcs in telomere length 
maintenance in Ag-np treated human cancer cells. Hence, DNA-PKcs inhibition potentiates 
the telomere damaging effect of Ag-np in the cancer cells.  
In short, we demonstrate that Ag-np selectively exerts toxicity in human cancer cells 
but meagre effect on normal human cells.  Activation of DNA-PKcs reduces the toxicity of 
Ag-np in human cancer cells by triggering the activation of JNK pathway and telomeres 
length maintenance. Collectively, these data suggest pharmacological inhibition of DNA-
PKcs can act as a potent target in cancer cells to enhance the anticancer effect of Ag-np. The 




CHAPTER 5  
 
5. Ataxia telangiectasia mutated inhibition sensitises human brain cancer 
cells to cytotoxicity of silver nanoparticles 
5.1. Background 
Mammalian cells are constantly exposed to endogenous and exogenous agents which 
can potentially result in lethal and mutagenic genomic lesions. As a result, cells have 
developed an intrinsic network of DNA-damage response pathways to sense and repair 
damaged DNA at a timely and efficient manner. Loss of function of critical DNA damage 
sensors, transducers and effectors from these pathways can enhance sensitivity of the cells to 
DNA damaging agents (Kennedy and D'Andrea, 2006).  
The ATM kinase is a tumour suppressor and key regulator of biological responses to 
DNA damage. ATM is promptly activated through autophosphorylation in mammalian cells 
in response to genotoxic agents that induce DSBs. Normal human tissues contain 
nonphosphorylated, inactive form of ATM. In sharp contrast, nuclear staining showed an 
aberrant constitutive activation of ATM was observed in embryonal carcinomas, teratomas 
and pre-invasive carcinoma. The ATM autoactivation provides further evidence for 
constitutive activation of the DNA damage machinery during cancer development (Bartkova 
et al., 2005).  
The first evidence that ATM may be an attractive target for chemotherapy was that 
cells from A-T patients were delicately sensitive to ionising radiation (Savitsky et al., 1995). 
Further evidences proposed that specific inhibition of ATM function in combination with 
current anticancer therapeutics may result in enhanced cancer cell killing. Caffeine and 
LY294002 (known inhibitors of ATM) could increase cellular sensitivity to radiation and 
chemotherapeutic drugs (Sarkaria et al., 1999, Sabisz and Skladanowski, 2008). The lack of 
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specificity and potency of caffeine and LY294002 as they broadly inhibit the kinase activity 
of all other PI-3 kinases makes them unsuitable clinical agents.  KU-55933, a highly specific 
ATP competitive inhibitor of ATM (Hickson et al., 2004) can efficiently sensitise tumour 
cells to radiation and DSB-inducing chemotherapeutic agents (Bolderson et al., 2009). An 
improved analogue of KU-55933, named KU-60019, with Ki and IC50 values half of those of 
KU-55933, is 10-fold more effective than KU-55933 at blocking ATM-mediated DNA 
damage responses events in human glioma cells (Golding et al., 2009).  
Mechanisms commonly utilised by tumours to bypass early neoplastic checkpoints 
determine chemotherapeutic response. These mechanisms generate tumour-specific 
vulnerabilities as well which can be exploited with targeted therapies. In cells with wild-type 
ATM, p53 proteins accumulate and subsequently increase in their activity, in response to 
DNA damage. Loss-of-function mutation in p53 often leads to the development of cancer. 
The characterization of the biochemical pathways by which p53 alteration triggers 
tumourigenesis is the foundation for the design of novel therapeutic approaches (Fulci et al., 
1998). Therefore, evaluation of the combined status of ATM and p53 can help to predict the 
clinical response to genotoxic chemotherapies. 
We have previously shown in chapter 3 that ATM was activated in Ag-np treated 
human cancer cells. In this study, we were interested in testing the hypothesis that targeting 
ATM kinase activity in cancer cells carrying endogenous TP53 mutation could sensitise the 
cancer cells to Ag-np. We have employed two cell types; 1) MRC-5 cells are human foetal 
lung fibroblasts express wild-type p53 and 2) U251 cells are human glioma cells carry a 
missense mutation at TP53 gene, which results in expression of a functionally altered p53 
protein (Brázdová et al., 2009). This mutation reduces the ability of mutant p53 proteins for 
sequence-specific DNA binding; however geometry-specific DNA binding is retained (Ma 
and Levine, 2007). The ATM kinase activity of these two cell lines has been 
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pharmacologically inhibited using KU-60019 and coupled with Ag-np treatment in order to 
provide a useful model for evaluating the effectiveness of this combinatorial approach in 
killing human brain cancer cells.  The roles of activated ATM in cancer cells in response to 
Ag-np treatment were also elucidated. 
 
5.2. Results 
5.2.1. Recruitment of activated ATM and γ-H2AX to DSB sites in human brain cancer 
cells following Ag-np treatment. 
To determine whether the missense mutation at TP53 gene in U251 cells will affect 
the basal expression of p53 which might potentially determine the cellular response following 
Ag-np treatment, western blot was carried out to test this hypothesis. Our results showed that 
TP53 mutation does not affect p53 expression in U251 cells. No obvious change in 
expression of p53 following Ag-np treatment (1.1-fold) and the expression was down-
regulated after ATM inhibition to 0.6-fold compared with untreated control. In Ag-np treated 
MRC-5 cells, expression of p53 was up-regulated by 1.2-fold and down-regulated to 0.8-fold 
following ATM suppression.       
The early cellular response for DSBs is characterised by rapid formation of nuclear 
foci at sites of DSBs which indicate aggregates of recruited DNA damage response proteins. 
γ-H2AX has been reported to play an important role in anchoring DNA damage response 
proteins to the DSBs. The recruited chromatin-bound ATM to DSBs sites was reported to be 
autophosphorylated and activated, and subsequently retreated with kinetics similar to that of 
DSB repair (Andegeko et al., 2001, Uziel et al., 2003). To determine involvement of ATM in 
initial DNA damage signalling in response to Ag-np induced DNA damage, we checked the 
activation status of p-ATM with γ-H2AX foci and their co-localisation in cells following Ag-
np treatment.  
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Our data showed there was 1.4-fold (p <0.05) and 2.4-fold increase in γ-H2AX 
activation level in MRC-5 and U251 cells respectively, suggesting the induction of DSBs in 
the cells by Ag-np.  Activation of ATM protein (p-ATM) in both MRC-5 and U251 cells at 
2.9-fold and 2.1-fold, respectively were also detected, suggesting initiation of DNA repair 
responses (Figure 5.1B). To further understand the importance of γ-H2AX and p-ATM 
activation, co-localisation assay for γ-H2AX with p-ATM was carried out.  We found that the 
number of MRC-5 cells with ≥ 2 co-localised p-ATM and γ-H2AX foci increased from 2 to 9 
cells following treatment with Ag-np. After treatment with Ag-np, the number of U251 cells 
with ≥ 2 co-localised foci was increased to 20 (p <0.01) compared with 7 cells in the 




























       
Figure 5.1: Recruitment of activated ATM and γ-H2AX to DSB sites in human brain 
cancer cells following Ag-np treatment. (A, B) Protein expression of p53, p-ATM and γ-
H2AX following 48 hour-treatment with Ag-np (200 µg/ml) and KU-60019 (10 µM). Fold 
change for protein levels were obtained by densitometry analysis of X-ray films using Kodak 
molecular imaging software and normalised against actin levels to represent accurate values 
for proteins which deviated from the control. Mean ± standard error of two sets of 
independent experiments are shown. (C) Immunofluorescence microscopy of γ-H2AX  and 
p-ATM (red) DNA-damage foci after Ag-np exposure. The merged images show co-
localisation of γ-H2AX and p-ATM in yellow. White arrowheads indicate co-localised foci. 
The number of cells with ≥ 2 co-localised γ-H2AX and p-ATM foci is shown. Magnification 
= 60X. The values represent the mean ± standard error of three sets of independent 




5.2.2. Inhibition of ATM substantiates DNA damaging effect of Ag-np in human brain 
cancer cells.  
The ATM kinase manages DNA repair by activating enzymes that fix the damaged 
DNA. Efficient repair of broken DNA strands is utmost essential to maintain the stability of 
the genome. To verify whether the ATM inhibition sensitises cancer cells to Ag-np through 
impaired DNA repair machinery, we used KU-60019 which specifically inhibits ATM kinase 
activity (Golding et al., 2009). Comet assay was carried out 48 hours post treatment to 
quantitate the total DNA damage in ATM inhibited Ag-np treated cells. Our experimental 
data showed that MRC-5 normal cells were less sensitive to genotoxicity of Ag-np as no 
marked increase in DNA damage observed following Ag-np treatment (Figure 5.2A). ATM 
inhibition in the normal cells did not sensitise them further towards Ag-np induced DNA 
damage (Figure 5.2A). On the contrary, U251 cells were more sensitive to Ag-np treatment 
compared to normal cells. According to our comet data, the tail moment increased from 1.4 
µm to 8.2 µm in U251 cells treated with Ag-np (Figure 5.2B). The DNA damage was much 
higher in Ag-np treated U251 cells when ATM kinase activity was inhibited with KU-60019, 
which we observed tail moment of 12.8 µm (p <0.01) compared to treated U251 cells without 
inhibition (Figure 5.2B). These findings indicate ATM inhibition effectively sensitises 















Figure 5.2: Inhibition of ATM substantiates DNA damaging effect of Ag-np in human 
brain cancer cells.  DNA damage as measured by the Comet assay in (A) MRC-5 cells and 
(B) U251 cells following 48 hour-treatment with Ag-np (200 µg/ml) and KU-60019 (10 µM). 
Cells were pre-treated with KU-60019 for 1 hour prior to incubation with Ag-np. Mean tail 
moment (µm) represents the damage distribution in the attached cells. Mean ± standard error 












5.2.3. Inhibition of ATM increases cell death in Ag-np treated human cells. 
ATM has an important role in maintaining genome integrity. It has been proposed that 
pharmacological inhibition of ATM might promote cellular radiosensitisation and 
chemosensitisation. To determine whether ATM inhibition sensitise cells to Ag-np, cells 
were pre-treated with KU-60019 (10 µM) for 1 hour prior to incubation with Ag-np (200 
µg/ml) and trypan blue exclusion assay was performed after 48 hour treatment to determine 
the cell survival. In MRC-5 cells, Ag-np treatment decreased their survival by 4%   (p <0.05) 
and ATM inhibition resulted in additional 24% reduction in cell survival, when compared to 
untreated cells (Figure 5.3A). The U251 cells are more sensitive to Ag-np and combination 
treatment compared with MRC-5 cells.  There was 20% (p <0.05) reduction in survival in 
U251 cells following treatment with Ag-np as compared to untreated control. Pre-treatment 
with KU-60019 had further decreased the viability of Ag-np treated U251 cells by 44% (p 










          
      
Figure 5.3: Inhibition of ATM increases cell death in Ag-np treated human cells. Cell 
survival of (A) MRC-5 cells and (B) U251 cells following 48 hour-treatment with Ag-np 
(200 µg/ml) and KU-60019 (10 µM). For combination treatment, cells were pre-treated with 
KU-60019 for 1 hour. Ag-np (200 µg/ml) were then added to the cells and further incubated 
for 48 hours. The percentage cell survival  was normalised against the untreated control (0 
µg/ml). The values represent the mean ± standard error of three sets of independent 














5.2.4. Suppression of ATM inhibits growth of Ag-np treated brain cancer cells.  
Neoplastic transformation occurs via a series of genetic and epigenetic alterations 
render the transformed cells with anchorage-independent growth capability. The ability of 
cancer cells to form a colony is an important step for the cancer cells to successfully 
metastasise to secondary organ (Aapro et al., 1987, Liotta and Stetler-Stevenson, 1991, Nair 
et al., 2004).  To determine whether ATM inhibition will affect the ability of cancer cells to 
form colonies, U251 cells were treated with both KU-60019 (10 µM) and Ag-np at 200 µg/ml. 
After 14 days treatment, the cancer cells were cultured in fresh media without treatment for 2 
weeks. Our results showed that the number of colonies formed after Ag-np treatment was 
comparatively fewer than untreated control. However, ATM inhibited-Ag-np treated U251 
cells produced the lowest number of colonies, suggesting that lack of functional ATM kinase 
activity inhibits further the colony formation ability of Ag-np treated brain cancer cells 




Figure 5.4: Suppression of ATM inhibits growth of Ag-np treated brain cancer cells. 
Colony formation capacity of U251 cells treated with 14 days of Ag-np (200 µg/ml) and KU-
60019 (10 µM). Cells were pre-treated with KU-60019 for 1 hour. Ag-np were then added to 
the cells and further incubated for 14 days for combination treatment. The cells were then 
allowed to grow for another 14 days in media without treatment and stained with crystal 





5.2.5. Inhibition of ATM forbids cell cycle arrest in TP53 mutated U251 cells, leading to 
greater cell death. 
To determine whether the ATM inhibition will alter cell cycle profile of Ag-np treated 
cells, cells stained with propidium iodide were subjected to FACS analysis. Increase in sub-
G1, S and G2/M population were observed only in U251 cells (Figure 5.5B). In U251 cells 
treated with Ag-np, there was 5% increase in sub-G1,  20% decrease in G1, 7.5% (p <0.05) 
increase in cells arrested at S phase and 7% (p <0.05) increase at G2/M phase compared to 
untreated U251 control cells (Figure 5.5B). In contrast, there was only 2% increase in sub-
G1 population in Ag-np treated normal cells compared to untreated control. A 4% increase in 
S-phase cell population was also observed in MRC-5 cells following Ag-np treatment 
(Figure 5.5A). In the combination treatment, inhibition of ATM kinase activity further 
sensitised U251 cells to Ag-np treatment. There was 22% (p <0.05) increase in sub-G1 cell 
population in ATM inhibited, Ag-np treated U251 cells compared to untreated control and 
17% increase in U251 cell death compared to those treated with Ag-np only (Figure 5.5B). 
Meagre, non-significant increase in MCR-5 cell death observed following combination 
treatment (Figure 5.5A). Our finding from cell cycle analysis is also in agreement with cell 
survival assay that ATM inhibition sensitises human cells to Ag-np with more pronounce 





   
 
Figure 5.5: Cell cycle analysis by flow-cytometry. Cell cycle histograms for (A) MRC-5 
cells and (B) U251 cells after 48 hour-exposure to Ag-np (200 µg/ml) and KU-60019 (10 μM)  
and combination of Ag-np and KU-60019, as measured by propidium iodide staining. 
Markers were set at regions of interest (sub-G1, G1, S, and G2/M), and the percentage of 
cells (events) under each area was generated using Microsoft excel. The values represent the 
mean ± standard error of three sets of independent experiments. * Denotes p <0.05 as 













We have shown that suppression of ATM activity promoted a protective phenotype in 
TP53 wild-type MRC-5 cells while sensitises TP53 mutated U251 cells to Ag-np. Both ATM 
and p53 play major roles in overall genomic repair, therefore, determining cell fate following 
Ag-np treatment.  
To support the importance of ATM in regulating DNA repair and subsequently cell 
survival and growth in Ag-np treated cells, we investigated the physical involvement of ATM 
in DNA damage response following Ag-np treatment. We observed that ATM became 
activated through autophosphorylation at serine 1981 in both MRC-5 and U251 cells after 
treatment with Ag-np for 48 hours. In the same treatment, γ-H2AX was also activated with 
greater fold increase in U251 cells than MRC-5 cells. The protein expression data were 
supported by higher number of Ag-np treated U251 cells with co-localised p-ATM and γ-
H2AX foci than MRC-5 cells.  It was reported previously that γ-H2AX has important role in 
effective DSB-dependent activation of ATM-related damage responses (Kobayashi et al., 
2009). Moreover, γ-H2AX might serve as a docking site for the DNA damage/repair proteins 
such as MRE11/NBS1/RAD50, MDC1 and BRCA1 to nuclear and promote DSB repair and 
genome stability (Kobayashi et al., 2009). Thus, our results imply that Ag-np treatment 
promoted activation of ATM and γ-H2AX. Subsequently, γ-H2AX concentrates activated 
ATM proteins in the vicinity of DNA lesions to facilitate further DNA repair. Additionally, 
U251 cells which lacks functional ATM activity displayed enhanced γ-H2AX activation after 
treated with Ag-np suggest a dramatically delayed repair kinetics which in turn results in 
enhanced DNA damage in the cells. On the contrary, the MRC-5 cells repair DNA damage 
efficiently even in the absence of functional ATM as no accumulation of γ-H2AX protein 
after ATM inhibition which is consistent with the low level of DNA damage observed.    
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From our data, ATM inhibition further sensitised U251 cells to Ag-np cytotoxicity 
and genotoxicity. The significant higher DNA damage in ATM inhibited U251 cells treated 
with Ag-np correlates with the observed increases in cell death that ATM suppression and 
mutant p53 reduced efficiency of DNA repair in U251 cells, lead to massive cellular 
apoptosis. Clearly, these evidences indicate in the absence of functional p53, availability of 
ATM signalling is the predominant requirement for U251 cell survival in response to 
genotoxic stress produced by Ag-np. The presence of functional p53 is accounted for the 
protective response in normal cells. p53 protein mediates DNA repair response in the 
presence of ATM protein. Efficient DNA repair machinery is further supported by the low 
level total DNA damage in Ag-np treated MRC-5 cells. ATM inhibition in MRC-5 cells did 
not result in further DNA damage possibly due to the activation of alternative repair 
machinery such as DNA-PKcs to promptly repair the DNA damage which we have shown in 
chapters 3 and 4. Suppression of ATM activity resulted in moderately low cell death (20%) in 
MRC-5 cells following treatment of Ag-np as opposed to 66% cell death in U251 cells might 
indicate the presence of efficient alternative repair machinery to maintain genome stability of 
MRC-5 cells when functional ATM is absent. Therefore, massive cell death is prevented in 
the normal cells. Our data suggest the presence of functional ATM and p53 are essential to 
facilitate survival signals in normal and cancer cells in response to Ag-np induced 
genotoxicity.  
To gain understanding in ATM regulation on p53 which could be manipulated to kill 
U251 cells selectively, we checked the cell cycle profiles of Ag-np treated U251 cells without 
and with ATM kinase inhibitor. The profiles were also compared with MRC-5 cells. Previous 
study reported that p53 phosphorylation, stability and execution, in part, are regulated by 
ATM protein (Keramaris et al., 2003). Another report showed that p53 protein levels are not 
induced by ionising radiation in thymus of ATM-deficient mice (Barlow et al., 1997). ATM 
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can promote either G1/S arrest in cells in a p53-dependent manner or S/G2 cell cycle arrest 
independent of p53 following exposure to DNA damaging agents (Reinhardt et al., 2007). In 
our study, we observed a significant S/G2 arrest in Ag-np treated U251 cells, which is 
correlated with their mutated p53 status. To maintain genome stability, ATM induces cell 
cycle arrest independent of p53 to ensure the DNA repair is carried out in these cells. When 
ATM kinase activity was inhibited in U251 cells, ATM was unable to facilitate cell cycle 
arrest thus DNA damages accumulate. Eventually, these cells died as evidenced through 
significant increase in sub-G1 population. Theoretically, the functional wild-type ATM and 
p53 in MRC-5 cells can mediate DNA repair either through G1/S or S/G2 arrest in response 
to genotoxic stress. However, we observed no significant increase in cells arrested at 
particular phase of cell cycle in MRC-5 cells either treated with only Ag-np or in 
combination. This is possibly due to low level of DNA damage induced or efficient and rapid 
DNA repair.           
Our findings imply that the potential efficacy of ATM inhibitors as chemosensitising 
agents for Ag-np is largely dependent on the p53 status in the target cancer cells. Though 
TP53 mutation does not affect p53 expression in brain cancer cells, it does affect its normal 
functionality and leads to overall aberrant response to genotoxic stress from Ag-np, which 
can be exploited to our advantage in designing more effective combination therapy for cancer. 
The selective inhibition of ATM kinase activity will likely have an impact in human brain 
cancer cells with TP53 mutation. Though our study is limited to one cancer cell type, the data 
suggest combination therapy of Ag-np and ATM inhibitor may selectively kill tumour cells 






CHAPTER 6  
6. Conclusion 
6.1. Final remarks 
DNA-damaging agents have been used as cancer chemotherapeutic agents for more 
than a decade now. However, the efficiency of these anticancer drugs is often limited by 
dose-limiting toxicities as well as the development of drug resistance. Thus, attacking these 
vulnerabilities by treatment with combinations of drugs seems an inevitable strategy. In our 
study, Ag-np as a potent DNA damaging agent results in DNA repair response in human 
cancer cells which might partially limits its’ efficacy. Thus, combination therapy of Ag-np 
and DNA repair factors inhibition was proposed. 
Firstly, we found that Ag-np induced more prominent dose-dependent decrease in cell 
viability in DNA-PKcs deficient or inhibited cells. The deficiency or inhibition of DNA-PKcs 
renders the cells with higher susceptibility to Ag-np-induced DNA damage and genome 
instability which in turn contributed to greater cell cycle arrest/cell death. These findings 
support the fact that DNA-PKcs is involved in the repair of Ag-np-induced DNA damage and 
NHEJ repair pathway and DNA-PKcs particularly is activated to safeguard the genome upon 
Ag-np exposure. 
Secondly, at selected doses of Ag-np, DNA-PKcs inhibition causes JNK pathway to 
be inadequately activated, abrogating the signalling events necessary to facilitate DNA repair 
in cancer cells. Further investigation on genotoxic potential of Ag-np indicated that Ag-np 
also reduces telomerase expression, disrupts shelterin complex located at the telomeres and 
results in telomere attrition in human cancer cells.  Activation of DNA-PKcs at telomeres 
signifies the importance of DNA repair machinery at damaged telomeres. However, the 
genotoxic effect of Ag-np is not limited to telomeres but the entire genome. Furthermore, 
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inhibition of DNA-PKcs substantiates the damaging effect of Ag-np at telomeres in human 
cancer cells. In line with these observations, inhibition of DNA-PKcs activity sensitises the 
cancer cells towards cytotoxicity of Ag-np. Thus, presence of DNA-PKcs reduces the toxic 
effects of Ag-np in human cancer cells by triggering the activation of JNK pathway and 
telomeres length maintenance. Targeting DNA-PKcs in Ag-np treated cancer cells will 
enhance therapeutic performance of Ag-np in these cells.    
Lastly, suppression of ATM activity in U251 cells with mutant p53 diminished the 
ability of these cells to arrest at S/G2 phase, leading to significant higher DNA damage due to 
inefficient DNA repair and eventually massive cell death. ATM inhibition has minor effect 
on Ag-np treated MRC-5 cells, presumably due to the presence of functional p53. Hence, we 
showed the regulation of ATM on p53 is one of the most important cell fate determinants in 
U251 and MRC-5 cells following Ag-np treatment. The absence of both functional ATM and 
p53 sensitise cancer cells to Ag-np toxicity.  All in all, our study implicates the potential of 
targeting DNA repair proteins along with Ag-np treatment in improving therapeutic response 
in cancer management. 
 
 
6.2. Future work 
In this study, we presented preliminary signalling events mediated by DNA-PKcs and 
ATM as cellular defence mechanisms to counteract toxicity of Ag-np. Further investigations 
are necessary to complete the interactome with regards to DNA damage and repair responses 
of Ag-np in order to boost the efficacy of Ag-np for cancer treatment.  
We provided evidence using cancer cell model that apart from its primary role in 
NHEJ, DNA-PKcs was also found regulating JNK pathway activation which we hypothesised 
as one of the essential signalling events in DNA repair responses in Ag-np treatment. It was 
reported that the activated JNKs were translocated to nucleus and phosphorylated scores of 
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target proteins in response to cellular genotoxic stress. Thus, it will be interesting to 
determine the interacting partners or signalling proteins which mediate the translocation of 
JNK to nucleus in response to activation of DNA-PKcs and complete downstream proteins 
that were phosphorylated by or interacted with JNK in order to facilitate the DNA repair 
responses.     
In our study, we showed that recruitment of activated DNA-PKcs to telomeres and 
DNA-PKcs activity is required to maintain telomere length in cancer cells exposed to Ag-np. 
Since the t-loop of telomeres are protected by shelterin complex, it is essential to determine 
whether DNA-PKcs works with members of shelterin complex or other uncharacterised 
telomeric proteins to carry out this protective function. Since the binding of Ku70/80 of 
DNA-PK to TRF1 and TRF2 is essential for bridging the DNA-PKcs to telomeres (Hsu et al., 
2000, Song et al., 2000, Walker et al., 2001b), it is crucial to investigate whether the down-
regulated TRF2 in our study is responsible for low number of co-localised p-DNA-PKcs to 
dysfunctional telomeres in response to genotoxic stress produced by Ag-np.   
Additionally, it was shown TRF2 inhibited autophosphorylation of ATM on serine 
1981 to prevent mammalian telomeres from activating DNA damage checkpoints (Karlseder 
et al., 2004). The observed down-regulation of TRF2 upon Ag-np treatment in our study 
might facilitate activation of ATM kinase to initiate DNA damage response possibly at 
damaged telomeres. Thus, it is necessary to elucidate the potential interplay between TRF2 
and ATM and roles of activated ATM at damaged/dysfunction telomeres upon Ag-np 
treatment. 
Though through our work, we observed higher sensitivity of human cancer cells 
towards Ag-np compared to normal cells, it is undeniable that Ag-np treatment does result in 
genotoxicity and cytotoxicity in normal cells though at lower edge and the long term side 
effects should not be underestimated. Therefore, the specific targeting ability of Ag-np for 
 151 
 
cancer cells should be enhanced through nano-engineering to generate functionalised Ag-np. 
The surface manipulation on Ag-np can be readily achieved via careful selection of capping 
agents which bind to and uptake by surface channels or receptors exclusively expressed by 
the cancer cells, and hence eliminating potential non-specific binding and uptake of Ag-np to 
the normal cells.    
The anti-tumourigenic activity of Ag-np can also be evaluated in vivo. Human breast 
and brain cancer cells used in this study will be injected to nude or SCID mouse for 
development of human tumours. Appropriate concentration of Ag-np will be injected 
intravenously at over a period of time at particular interval to treat the tumours formed from 
injected cancer cells. This will be served as verification for in vitro data we have produced.       
This work can be further extended to understand how various host environments 
affect the uptake and subsequent fate of Ag-np. When Ag-np enter a biological environment, 
their surface will be surrounded by a “corona” of macromolecules in biological fluid, leads to 
an in vivo response. The majority of the identified biological macromolecules surrounding 
nanoparticles are proteins, though recently reported the presence of some lipids.  The 
composition of the corona defines the biological identity of Ag-np and contributes to the 
biological fate of these particles. Knowledge of rates, affinities, and stoichiometries of 
macromolecules association with, and dissociation from, nanoparticles is important for 
understanding the nature of the particle surface seen by the functional machinery of 
cells. Thus, investigation on protein corona formation is an important addition to our existing 
understanding in determination of possible toxicity of Ag-np and the development of silver 
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